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ABSTRACT 
THE EFFECT OF SIX WEEKS OF ORAL ECHINACEA SUPPLEMENTATION ON 
ERYTHROPOIESIS, NITRIC OXIDE PRODUCTION,  
AND EXERCISE PERFORMANCE 
by Tyler David Martin 
December 2011 
 The purpose of the present study was to investigate the effect of six weeks of oral 
Echinacea supplementation on serum erythropoietin (EPO) and erythropoietic status, 
plasma nitric oxide [NO], submaximal endurance exercise performance, and maximal 
oxygen uptake (V˙ O2max). Twenty-four males (mean ± SE): age = 25.2 ± 1.4 yr, height = 
178.1 ± 1.4 cm, mass = 78.1 ± 1.6 kg, percent body fat = 12.7 ± 0.9 %, V˙ O2 max = 52.9 ± 
0.9 mL·kg-1·min-1 were randomly grouped using a matched-pair, double-blind design and 
self-administered 8,000 mg·d-1 (5 × 400 mg × 4 times·d-1) of either Echinacea purpurea 
(ECH) (n=12) or placebo (PLA) (n=12) for 42 consecutive days. Blood samples were 
collected and analyzed for EPO, red blood cells (RBCs), hemoglobin (Hb), hematocrit 
(Hct), mean corpuscular volume (MCV), mean corpuscular hemoglobin concentration 
(MCHC), nitrite, and total nitrite (nitrite/nitrate) concentrations.  Graded exercise tests 
were performed on a treadmill to assess submaximal exercise performance and maximal 
oxygen uptake (V˙ O2max). Separate 2 × 4 (Group × Time) factorial ANOVA with repeated 
measures were used to determine statistical differences with significance set at p ≤ .05. 
There were no statistically significant (p > .05) interaction, group or time effects 
observed for EPO, erythropoietic status markers, nitrite, nitrate, nitrite/nitrate, 
submaximal V˙ O2, submaximal heart rate (HR), or V˙ O2max. The present study indicates 
 iii 
that six weeks of oral ECH supplementation in apparently healthy, recreationally active, 
males with above average fitness status (V˙ O2max = 52.9 ± 0.9 mL·kg-1·min-1), does not 
enhance EPO, erythropoietic status, [NO], or endurance exercise performance. These 
findings are in contrast with previous reports of Echinacea supplementation and any 
explanation for these differences, including the role that training and/or physical fitness 
level of participants, is unclear and speculative. 
Key Words: erythropoietin, red blood cells, maximal oxygen uptake (V˙ O2max), 
physiology, aerobic training, endurance, herbal supplements, sport nutrition  
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CHAPTER I 
INTRODUCTION 
Cardiorespiratory endurance represents the human body’s ability to efficiently 
and effectively uptake, transport and utilize oxygen in the working muscles of the body to 
sustain continuous, large-muscle group physical activity (Powers & Howley, 2009; 
Wuest & Bucher, 2009). The maximum rate at which the human body can consume and 
use oxygen will determine the physical work capacity of an individual (Brooks, Fahey, 
White, & Baldwin, 2000). The capacity for an individual’s maximal oxygen consumption 
(V˙ O2max) is influenced by the efficiency of the cardiorespiratory system to distribute 
oxygen and nutrients to the working tissues (Brooks et al., 2000; Wuest & Bucher, 2009). 
Oxygen (O2) is a major substance required for chemical reactions in the cells of the body 
including the chemical reactions that use O2 and nutrients to provide energy for the cells 
(Guyton & Hall, 2000; Sherwood, 2007). Thus, performance of sustained physical 
activity can be greatly reduced when oxygen cannot be sufficiently supplied to the 
working cells of the body. In contrast, enhancing the capacity to consume and utilize 
oxygen will increase the amount of physical work that an individual can perform until the 
onset of fatigue (Brooks et al., 2000; Wuest & Bucher, 2009). 
Echinacea is a purple coneflower plant indigenous to North America. It is 
commonly used as an herbal supplement and has traditionally been considered a 
nonspecific immunostimulant (Goel et al., 2002a, 2002b; Whitehead, Martin, Scheett, & 
Webster, 2007). Echinacea supplementation has been shown to improve oxygen carrying 
capacity in equine models (O’Neill, McKee, & Clarke, 2002). Enhanced oxygen transport 
to the cells is considered to improve the parameters of exercise performance. The oxygen 
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transport capacity is influenced by the size and concentration of red blood cells (RBCs), 
the concentration of hemoglobin (Hb), and hematocrit (Hct) (O’Neill et al. 2002; 
Whitehead et al., 2007). The major function of RBCs is to transport hemoglobin, which 
has the primary function of combining loosely and reversibly with oxygen. Oxygen will 
combine with hemoglobin as it diffuses into the pulmonary blood from the alveolar tissue 
in the lungs. Hemoglobin carries oxygen from the lungs to the tissue capillaries where the 
oxygen is readily released for use by the cells (Guyton & Hall, 2000). The process by 
which RBCs are produced, known as erythropoiesis, is stimulated by the circulating 
hormone, erythropoietin (EPO), that is primarily produced in the kidneys (Guyton & 
Hall, 2000; Hillman & Finch, 1971). The process of erythropoiesis has been shown to be 
enhanced in animal models as a result of Echinacea supplementation based on the 
increased hemoglobin levels and number of red blood cells (O’Neill, et al, 2002; 
Whitehead et al., 2007). 
A study by Whitehead, Martin, Scheett, and Webster (2007) showed that 
Echinacea supplementation in humans increased serum EPO. The increased EPO was not 
accompanied with significant alterations to RBC counts, hemoglobin levels or 
hematocrit. However, there were nonsignificant increases in the erythropoietic status 
data, such as percentage change in RBC, Hct, Hb, and mean corpuscular volume (MCV), 
which may indicate that the process of erythropoiesis was initiated (Whitehead et al., 
2007). The increase in serum EPO observed in the study by Whitehead et al. (2007) is 
similar to the previously reported increase in EPO induced by hypoxic conditions through 
a live-high, train-low protocol (Chapman, Stray-Gundersen, & Levine, 1998; Whitehead 
et al., 2007). Although the stimuli used to stimulate an increase in EPO production are 
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different, the increases in serum EPO observed from these investigations are similar in 
magnitude and time of response (Ashenden et al., 2000; Chapman et al., 1998; Wehrlin, 
Zuest, Hallén, & Marti, 2006; Whitehead et al., 2007). Erythropoietin production is 
closely linked to tissue oxygen demand (Fliser & Bahlmann, 2008). Generally, there is an 
increase in EPO production to increase erythrocyte production in response to hypoxic 
conditions (Guyton & Hall, 2000). Maximum EPO production will be reached after 1-3 
days of hypoxic exposure followed by a gradual decline in EPO production 
approximately one week after the maximum peak to a level that will maintain the 
required number of RBCs for adequate tissue oxygenation (Berglund, 1992; Guyton & 
Hall, 2000; Whitehead et al., 2007). The Echinacea supplementation study by Whitehead 
et al. (2007) did not have a hypoxic stimulus, but they did observe a similar EPO 
response to that of hypoxic stimulation. It can be observed from the altitude-induced 
hypoxia investigations, that serum EPO levels peak 2-3 days after exposure to hypoxic 
conditions compared to serum EPO levels peaking at approximately day 14 in the 
Echinacea supplementation study. This time span allows approximately 25 days 
undergoing erythropoiesis under hypoxic conditions compared to only 14 days in the 
Echinacea protocol (Berglund B, 1992; Chapman et al., 1998; Stray-Gundersen, 
Chapman, & Levine, 2001; Whitehead et al., 2007). Therefore, an Echinacea 
investigation utilizing an extended data collection period approximately two weeks 
beyond the original four week supplementation period may provide further insight into 
the potential initiation of erythropoiesis. This would allow for further observation of the 
erythropoietic status indices that showed a nonsignificant increase over the duration of 
the final 14 days of the previously reported investigation. 
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Erythropoiesis stimulated by an increase in the concentration of erythropoietin 
will result in erythrocythemia and this will improve the oxygen transport capacity to the 
tissues (Gledhill, 1985; Guyton & Hall, 2000). Research has shown that induced 
erythrocythemia can increase the maximal oxygen consumption (V˙ O2max) with an 
improved oxygen transport capacity and ultimately improving aerobic performance 
(Buick, Gledhill, Froese, Spriet, & Myers, 1980; Gledhill, 1982; Gledhill, 1985). 
Research has also shown that induced erythrocythemia can enhance running economy 
(RE) and aerobic performance times, possibly due to an increase in oxygen delivery to 
the working muscles (Brien & Simon, 1987; Williams, Wesseldine, Somma, & Schuster, 
1981). Running economy has been defined as the cost of energy during submaximal 
running which is typically evaluated by measuring steady-state oxygen consumption     
(V˙ O2) (Saunders, Pyne, Telford, & Hawley, 2004). In regards to Echinacea 
supplementation in humans; oral administration of this herbal supplement for one month 
has shown a nonsignificant increase in maximal oxygen consumption (V˙ O2max) in 
untrained subjects (Szołomicki, Samochowiec, Wójcicki, & Droździk, 2000). As 
mentioned previously, Echinacea supplementation in the equine model resulted in an 
increase in the size and number of red blood cells, hemoglobin, and hematocrit (O’Neill 
et al., 2002). Additionally, the study by Whitehead et al. (2007) evaluated Echinacea 
supplementation in humans and showed significant increases in serum EPO, and showed 
nonsignificant improvements in erythropoietic status.  
Red blood cells develop from the pluripotential hematopoietic stem cells located 
within the bone marrow. As the stem cells reproduce, they will differentiate to form a 
committed stem cell lineage to a particular line of peripheral blood cells including 
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erythrocytes (Guyton & Hall, 2000). Commitment to the erythroid lineage induces 
erythropoiesis (Perry & Soreq, 2002). Colony forming unit-erythrocyte (CFU-E) 
represents a committed stem cell that will produce erythrocytes (Guyton & Hall, 2000). 
Development of erythrocytes from the hematopoietic stem cells is controlled by several 
growth inducers including EPO, granulocyte-macrophage colony stimulating factor (GM-
CSF) and interleukin-3 (IL-3) (Berdel, Danhauser-Riedl, Steinhauser, & Winton, 1989; 
Guyton & Hall, 2000; Sieff, 1987). Circulating erythropoietin is considered the principal 
stimulator of red blood cell production from the bone marrow. The production of RBCs is 
regulated within narrow limits in the circulatory system to ensure that an adequate 
amount of red blood cells are available to provide sufficient oxygen transport to the 
tissues. Contrastly, over-production of red blood cells may cause the blood flow to be 
impeded due to elevated blood viscosity (Guyton & Hall, 2000). The most essential 
regulator of the production of red blood cells is tissue oxygenation. Conditions that cause 
the reduction in the quantity of oxygen transported to the tissues are typically associated 
with an increase in EPO secretion from the kidneys into circulation resulting in the 
stimulation of red blood cell production (Guyton & Hall, 2000). This mechanism for 
RBC production has been observed in conditions that can reduce the transport of oxygen 
to the tissues such as various lung diseases, prolonged cardiac failure, anemia, and high 
altitude conditions (Guyton & Hall, 2000). However, in healthy individuals there is 
evidence to suggest that other mechanisms other than EPO production that may stimulate 
RBC production in healthy individuals (Cavill, 2002; Guyton & Hall, 2000). Echinacea 
supplementation in healthy human subjects has been observed to elicit elevated serum 
EPO levels similar to that observed in hypoxic conditions without a hypoxic stimulus 
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(Ashenden et al., 2000; Berglund, 1992; Chapman et al., 1998; Stray-Gundersen et al., 
2001; Wehrlin et al., 2006; Whitehead et al., 2007). Therefore, the control of EPO 
production in healthy individuals may have alternative mechanisms other than decreased 
tissue oxygenation (Cavill, 2002). 
Echinacea has been shown to stimulate macrophage activity (Burger, Torres, 
Warren, Caldwell, & Hughes, 1997; Goel et al., 2002a, 2002b; Mishima et al., 2004; 
Rininger, Kickner, Chigurupati, McLean, & Franck, 2000; Roesler et al., 1991; Stimpel, 
Proksch, Wagner, & Lohmann-Matthes, 1984) which can stimulate the production of 
cytokines in vitro (Burger et al., 1997). Additionally, Echinacea has been shown to 
enhance the activity of natural killer T cell function that can result in the stimulation of 
GM-CSF and erythroid progenitor growth factor IL-3 (Bickel, Wahl, Mergenhagen, & 
Pluznik, 1988; Cuturi et al., 1989; Davignon et al., 1988; Fitzpatrick & Kelso, 1995; 
Mishima et al., 2004; Oster, Lindemann, Mertelsmann, & Herrmann, 1989). Echinacea 
supplementation in humans demonstrated a significant increase in serum IL-3 which 
paralleled the observed increased in EPO (Whitehead et al., 2007). Therefore, T-cell 
activity may have been initiated because activated T-cells are known to stimulate IL-3 
secretion (Davignon et al., 1988; Fitzpatrick & Kelso, 1995). Erythropoietin acts 
synergistically with several erythroid growth factors including GM-CSF and erythroid 
progenitor growth factor IL-3 to activate the maturation and proliferation of erythroid 
progenitor cells (Fisher, 2003). Echinacea supplementation in humans may stimulate the 
production of EPO through the activation of macrophages and T-cells, which can 
stimulate the secretion of erythroid growth inducers such as IL-3 (Whitehead et al., 
2007). 
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Prostaglandin E2 (PGE2) has been shown to stimulate erythropoietin production 
(Boer, Drayer, Rui, & Vellenga, 2002; Fisher, Radtke, Jubiz, Nelson, & Burdowski, 
1980; Gross, Brookins, Fink, & Fisher, 1976; Jelkmann, Kurtz, Förstermann, 
Pfeilschifter, & Bauer, 1985; Kurtz, Jelkmann, Pfeilschifter, & Bauer, 1985; Ortega, 
Dukes, Ma, Shore, & Malekzadeh, 1984). Echinacea has been shown to stimulate 
macrophage activity, and macrophages have been reported to secrete a wide variety of 
biologically active compounds including cytokines, prostanoids, nitric oxide (NO) and 
oxygen radicals (Busam, Schulze-Specking, & Decker, 1991; Decker, 1990; Dieter et al., 
1999; Duyster, Schwende, Fitzke, Hidaka, & Dieter, 1993; Gallaird, Mulsch, Klein, & 
Decker, 1992; Grewe, Gausling, Gyufko, Hoffmann, & Decker, 1994). Echinacea 
supplementation in humans demonstrated a nonsignificant peak in the percent change of 
PGE2 preceding the significant increase in serum EPO levels (Whitehead et al., 2007). 
Furthermore, PGE2 is known to increase the production of granulocyte-macrophage 
colony-stimulating factor (GM-CSF) (Emond, Fortier, Murphy, & Lambert, 1998). The 
GM-CSF is considered an erythroid progenitor growth inducer and the production is 
known to be stimulated by activated T-cells (Bickel et al., 1988; Cuturi et al., 1989; 
Davignon et al., 1988; Fitzpatrick & Kelso, 1995; Oster et al., 1989) which are known to 
be activated by Echinacea (Currier & Miller, 2001; Mishima et al., 2004). Echinacea 
supplementation in humans has demonstrated a nonsignificant increase in GM-CSF over 
the course of 28 days (Whitehead et al., 2007). The trend of these data indicates a 
possible continuation in the rising values beyond the 28 day period.               
Research has provided evidence for nitric oxide (NO) production in human 
macrophages (Panaro, Brandonisio, Acquafredda, Sisto, & Mitolo, 2003). Nitric oxide, 
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commonly referred to as endothelial derived relaxing factor (EDRF), is produced by 
many cells in the body including the vascular endothelium, where it  plays an important 
role in blood flow by causing local arteriolar vasodilation through the relaxation of local 
arterial walls (Guyton & Hall, 2000; Klabunde, 2005; Sherwood, 2007). Echinacea has 
been shown to stimulate nitric oxide production in alveolar macrophages in the murine 
model (Goel et al., 2002a, 2002b) and research has shown that enhanced aerobic capacity 
can be associated with an increased nitric oxide production (Maxwell et al., 2001). 
Additionally, EPO has been identified as having important endothelial and vascular 
effects, including the activation of endothelial nitric oxide synthase (eNOS) (Beleslin-
Cokic et al., 2004; d’Uscio et al., 2007; Fliser & Bahlmann, 2008). Based on the 
aforementioned research in combination with the significant increase in serum EPO 
levels demonstrated with Echinacea supplementation in untrained males (Whitehead et 
al., 2007), a proposed nonhematological response to the elevated EPO concentration 
could be physiological changes such as more efficient use of oxygen in the muscles as 
localized blood flow improves from enhanced nitric oxide production (Gore, Clark, & 
Saunders, 2007).  
Very limited research has been performed with the use of oral Echinacea 
supplementation in animal models and human subjects evaluating hematological 
parameters and exercise performance. Whitehead et al. (2007) demonstrated that four 
weeks of oral supplementation with Echinacea in untrained males resulted in a significant 
increase in serum EPO; however, these results were only accompanied by nonsignificant 
increases in erythropoietic status markers. Nonetheless, the nonsignificant increases in 
RBC concentration, Hct, Hb, and MCV towards the conclusion of the investigation may 
9 
 
indicate that the process of erythropoiesis was initiated. Therefore, this present study is 
designed to investigate the effects of six weeks of oral Echinacea supplementation on 
erythropoietin, erythropoietic status measures (RBC, Hb, Hct, MCV, and MCHC), 
submaximal exercise performance, and maximal exercise capacity. Additionally, the 
study will investigate whether the proposed Echinacea-induced increase in serum EPO 
observed by Whitehead et al. (2007) is associated with an increased plasma concentration 
of nitric oxide to explain potential alternative mechanisms for enhanced oxygen transport 
and delivery. 
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CHAPTER II 
REVIEW OF RELATED LITERATURE  
Enhancing the ability to efficiently and effectively uptake, transport and utilize  
oxygen in the working muscles of the body will increase the amount of physical work 
that an individual can perform until the onset of fatigue (Brooks et al., 2000, Powers & 
Howley, 2009; Wuest & Bucher, 2009). It is well known that an increase in the oxygen 
carrying capacity can improve aerobic capacity which in turn can enhance aerobic 
exercise performance and reduce the adverse effects of various diseased states caused by 
a decrease in oxygen carrying capacity. There is conclusive evidence that an increase in 
serum erythropoietin (EPO) levels can result in an increase in red blood cell (RBC) 
production which will enhance the oxygen carrying capacity of the body (Fliser & 
Bahlmann, 2008; Guyton & Hall, 2000). Echinacea, an herbal supplement, has 
traditionally been considered a nonspecific stimulant of the immune system (Goel et al., 
2002a, 2002b, Whitehead et al., 2007); however, there is evidence to suggest that it may 
also enhance measures of erythropoiesis, oxygen carrying capacity and the parameters of 
endurance exercise performance. Recent research indicated that Echinacea 
supplementation in horses increased measures of erythropoietic status (O’Neill et al., 
2002) and its supplementation in humans also demonstrated a significant increase in 
serum EPO levels (Whitehead et al., 2007). The following review of literature will focus 
on the Echinacea literature by examining the effect of Echinacea on erythroid growth 
factors and erythropoietic status, Echinacea-induced EPO production, Echinacea-induced 
activation of macrophages and nitric oxide, and the plausible alternative actions of 
Echinacea-induced EPO production. However, prior to reviewing the Echinacea literature 
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a comprehensive background on the composition of human blood, oxygen transport and 
delivery, erythropoiesis, alternative actions of EPO, and nitric oxide will be presented. 
Human Blood 
Composition of Human Blood  
Blood is a liquid connective tissue in the human body that represents about 8% of 
the total weight (Marieb & Hoehn, 2010; Sherwood, 2007; Tortora, 2005). The average 
volume of blood in healthy adult males is 5-6 liters (about 1.5 gallons) and 4-5 liters 
(about 1.2 gallons) in healthy adult females. Whole blood consists of blood plasma and 
formed elements (Marieb & Hoehn, 2010; Tortora, 2005). Blood plasma is a nonliving 
fluid matrix consisting of approximately 90% water that contains dissolved substances 
(Marieb & Hoehn, 2010; Sherwood, 2007). Dissolved solutes in plasma represent about 
8% by weight of the plasma volume and include the plasma proteins albumin (60%); the 
globulins (36%) including α-globulins, β-globulin, γ-globulin; fibrinogen (4%) (Marieb 
& Hoehn, 2010); electrolytes, nutrients, hormones, respiratory gases, and waste products 
such as urea, uric acid, creatinine, ammonia, and bilirubin (Marieb & Hoehn, 2010; 
Sherwood, 2007; Tortora, 2005). The formed elements of blood consist of the blood cells 
and cell fragments, which are collectively referred to as blood cells (Marieb & Hoehn, 
2010; Sherwood, 2007; Tortora, 2005). There are three types of specialized blood cellular 
elements, erythrocytes (red blood cells), leukocytes (white blood cells), and thrombocytes 
(platelets) that are suspended within the blood plasma (Sherwood, 2007). Erythrocytes 
and leukocytes are whole blood cells, which function to transport oxygen and protect the 
body, respectively, whereas platelets are cell fragments which help stop bleeding (Marieb 
& Hoehn, 2010; Sherwood, 2007; Tortora, 2005). 
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 Hematocrit. Typically, red blood cells (RBCs) represent 99% of the formed 
elements, whereas the white blood cells (WBCs) and platelets represent less than 1% of 
the total blood volume (Marieb & Hoehn, 2010; Sherwood, 2007; Tortora, 2005). 
Hematocrit, packed cell volume or blood fraction, represents the percentage of red blood 
cells in the total volume of blood (Marieb & Hoehn, 2010; Sherwood, 2007). The average 
hematocrit value for healthy adult males is approximately 45%; in healthy adult females 
it is approximately 42% (Sherwood, 2007). Blood plasma represents the remaining blood 
volume (Marieb & Hoehn, 2010; Sherwood, 2007; Tortora, 2005) which corresponds to 
approximately 58% in healthy adult females and approximately 55% in healthy adult 
males (Sherwood, 2007). 
 Function of blood. Human blood serves three primary functions revolving around 
the transportation of substances, the regulation of substances in the blood, and protecting 
the body. Blood transports and delivers oxygen (O2), nutrients, and hormones to the cells 
of the body; transports heat and a variety of waste products for elimination from the body 
at particular sites, such as carbon dioxide (CO2) elimination in the lungs (Marieb & 
Hoehn, 2010; Tortora, 2005). Secondly, blood performs regulatory functions such as 
regulating adequate fluid volume in the circulatory system to maintain efficient blood 
circulation throughout the body; regulating body temperature by absorbing and 
distributing heat throughout the body as well as to the skin where excess heat can be 
dissipated; the maintenance of pH through buffers (Marieb & Hoehn, 2010; Tortora, 
2005). Lastly, blood serves to protect the body from excessive blood loss from the 
cardiovascular system when a blood vessel is damaged. Platelets and plasma proteins 
circulating in the blood provide the ability to form a clot at the damaged site. Blood can 
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also protect the body by preventing infection and disease through the white blood cells, 
antibodies, and complement proteins that can defend the body against disease (Marieb & 
Hoehn, 2010; Tortora, 2005). 
Oxygen Transport and Delivery 
Gas Exchange   
The primary function of respiration is to maintain blood-gas homeostasis by 
obtaining oxygen (O2) from the external environment to be used by the cells of the body 
and to eliminate the carbon dioxide (CO2) that is produced by the cells (Powers & 
Howley, 2009; Sherwood, 2007). Respiration can be broken down into two components: 
pulmonary respiration and cellular respiration. Pulmonary respiration refers to the 
exchange of O2 and CO2 between the atmosphere and the air sacs, alveoli, of the lungs as 
a result of ventilation and diffusion (Powers & Howley, 2009; Sherwood, 2007). Oxygen 
is exchanged between the air in the alveoli into the blood of the pulmonary capillaries 
and carbon dioxide in the opposite direction, through the process of diffusion (Guyton & 
Hall, 2000; Sherwood, 2007). The rate of respiratory diffusion of the respiratory gases, 
oxygen (O2), nitrogen (N2), and carbon dioxide (CO2), is directly proportional to the 
partial pressure of each gas within the gas mixture (Guyton & Hall, 2000). Cellular 
respiration refers to the O2 utilization and the CO2 production by the tissues as 
intracellular metabolic processes are performed to create energy from foodstuffs (Powers 
& Howley, 2009; Sherwood, 2007). 
 According to Dalton’s Law of Partial Pressures, the total pressure exerted by a gas 
mixture is the sum of the pressures exerted by each gas in the mixture independently. The 
pressure that a specific gas in the gas mixture exerts independently is referred to as the 
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partial pressure (Powers & Howley, 2009; Marieb & Hoehn, 2010; Whitehead, 2006). 
The pressure exerted by the weight of the gases contained in the atmosphere on the 
earth’s surface is referred to the atmospheric or barometric pressure (Powers & Howley, 
2009; Sherwood, 2007). At sea level, and an atmospheric pressure of 760 mmHg the 
composition of air is 20.93% oxygen, 79.04% nitrogen, and 0.03% carbon dioxide. The 
partial pressure of each of these gases can be calculated by multiplying the fractional 
composition of each gas by the total atmospheric pressure. Therefore, the sea level partial 
pressure of oxygen (PO2) is 159 mmHg, the partial pressure of nitrogen (PN2) is 600.7 
mmHg, and the partial pressure of carbon dioxide (PCO2) is .228 mmHg (Powers & 
Howley, 2009, Whitehead, 2006). In the human body, water (H2O) is always present, 
including within the respiratory system (Brooks et al., 2000). The partial pressure of 
water vapor (PH2O) is dependent on body temperature (Brooks et al., 2000). With an 
average body temperature of 37 °C, the PH2O is 47 mmHg (Brooks et al., 2000; Guyton & 
Hall, 2000). Therefore, the humidification of the inspired air within the respiratory 
passages dilutes the gas concentrations resulting in a PO2 of about 150 mmHg and a 
PCO2 of about 0.2 mmHg (Brooks et al., 2000; Guyton & Hall, 2000). Additionally, 
alveolar air composition is slightly different than that of atmospheric air as a result of the 
alveolar air being only partially replaced by atmospheric air with each breath, oxygen 
being continually absorbed into the pulmonary blood, carbon dioxide continuously 
diffusing into the alveoli from the pulmonary capillaries, and the relatively dry 
atmospheric air is humidified as it travels through the respiratory system to the alveoli 
(Guyton & Hall, 2000). Therefore, the alveolar PO2 is about 105 mmHg and the PCO2 is 
about 40 mmHg (Brooks et al., 2000). Contrastly, the PO2 and PCO2 of the blood leaving 
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the tissues and entering the lung are about 40 mmHg and 46 mmHg respectively (Marieb 
& Hoehn, 2010; Powers & Howley, 2009). This creates a partial pressure difference 
across the blood-gas interface that provides a driving force for the elimination of CO2 out 
of the blood and diffusing into the alveolus, and O2 diffusing from the alveolus into the 
blood (Power & Howley, 2009). The blood that leaves the lungs and enters the tissue 
capillaries will have a PO2 of approximately 95 mmHg and a PCO2 of approximately 40 
mmHg (Powers & Howley, 2009). Within the body tissues, the PO2 is generally less than 
40 mmHg and the PCO2 is generally more than 45 mmHg, providing partial pressure 
gradients that promote the exchange of O2 and CO2 across systemic capillary membranes 
in the body tissues (Marieb & Hoehn, 2010). 
Oxygen Transport 
The ventilation rate of the body is regulated by the demand for the uptake of O2 
and the removal of CO2 (Sherwood, 2007). The process of ventilation works to maintain 
an alveolar PO2 of 105 mmHg (Brooks et al., 2000) compared to the blood leaving the 
tissues and entering the lungs having a PO2 of about 46 mmHg (Marieb & Hoehn, 2010; 
Powers & Howley, 2009). The difference in the alveolar PO2 and the PO2 of the 
deoxygenated pulmonary capillaries entering the lung provides a gradient promoting the 
exchange of O2 across the respiratory membrane into the pulmonary blood leaving the 
heart (Marieb & Hoehn, 2010). The blood leaving the lungs is about 96-98% saturated 
with oxygen, as some alveoli are not ventilated with each breath (Brooks et al., 2000). 
Oxygen diffusing into the pulmonary blood will primarily bind with hemoglobin in the 
red blood cells (RBCs) (Guyton & Hall, 2000). Red blood cells serve as the primary 
transporter of oxygen throughout the circulatory system, as it distributes the oxygen to 
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the tissue capillaries where the O2 can be released to be used by the cells (Guyton & Hall, 
2000; Marieb & Hoehn, 2010). Red blood cells transport approximately 97% of the total 
amount of oxygen in the blood, with the remaining 3% dissolved in the plasma (Guyton 
et al., 2000). 
 Red blood cells. The major function of red blood cells is to transport oxygen from 
the lungs to the tissues (Guyton & Hall, 2000; Whitehead, 2006). Humans have about 5 
million red blood cells per microliter of blood; more specifically, the average adult male 
has approximately 5.4 million red blood cells ·μL-1 and the average adult female has 
approximately 4.8 million·μL-1 (Marieb & Hoehn, 2010; Sherwood, 2007; Tortora, 2005). 
Red blood cells are small cells that are shaped like biconcave discs having a mean 
diameter of about 7.8 μm and a thickness at the thickest point of 2.5 μm and a thickness 
in the center of 1.0 μm or less (Guyton & Hall, 2000; Whitehead, 2006). Red blood cells 
are unique in that they lack a nucleus and other organelles and they do not reproduce nor 
carry out complex metabolic activities (Tortora, 2005). They do not have mitochondria 
and generate adenosine triphosphate (ATP) anaerobically, therefore red blood cells do not 
use the oxygen they are transporting (Marieb & Hoehn, 2010; Tortora, 2005). Red blood 
cells contain a significant amount of hemoglobin, thus red blood cells are commonly 
referred to as bags of hemoglobin (Marieb & Hoehn, 2010; Tortora, 2005). The unique 
biconcave disc-shape of red blood cells provides a greater surface area for the diffusion 
of O2 across the membrane compared to a spherical shape and the thinness of the cell 
provides the ability for O2 to rapidly diffuse into the cell (Sherwood, 2007). Furthermore, 
the membrane of the red blood cell is flexible due to the network of proteins that are 
attached to the cytoplasmic structure of the plasma membrane (Marieb & Hoehn, 2010). 
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Spectrin is the most influential of the network proteins, as it creates a deformable net 
providing a flexible feature for the red blood cell (Marieb & Hoehn, 2010; Sherwood, 
2007). As a result, red blood cells can change shape and deform in order to squeeze into 
very narrow tissue capillaries without rupturing to deliver the O2 to the tissues (Guyton & 
Hall, 2000; Sherwood, 2007).  
 Hemoglobin. The most important component that allows red blood cells to 
transport oxygen is hemoglobin (Sherwood, 2007). Hemoglobin, found only in red blood 
cells, is made up of a globin protein that is bound to the red heme pigment, which gives 
red blood cells their red color (Marieb & Hoehn, 2010; Tortora, 2005). Globin is 
composed of four polypeptide chains, two alpha and two beta, with each chain binding to 
a nonprotein, ring like heme group. Each heme group contains an iron (Fe2+) atom at the 
center of its ring-like structure. The iron atoms have the capability to combine reversibly 
with one oxygen molecule. Therefore, each molecule of hemoglobin has the capability of 
transporting four molecules of oxygen from the lungs to the tissues (Marieb & Hoehn, 
2010; Sherwood, 2007; Tortora, 2005).  
Hemoglobin transports approximately 97% of the total amount of O2 in the blood 
and approximately 3% is transported in the dissolved state in the water of the plasma, 
because O2 is poorly soluble in the plasma (Brooks et al., 2000; Guyton & Hall, 2000; 
Sherwood, 2007). Overall, red blood cells contain about 250 million hemoglobin 
molecules, thus each red cell can carry approximately one billion molecules of oxygen 
(Marieb & Hoehn, 2010). The process of oxygen loading occurs as the oxygen deficient 
blood leaves the tissues and circulates to the pulmonary blood; oxygen will diffuse from 
the alveolar sacs of the lungs into the pulmonary blood and then bind to the iron atoms of 
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the hemoglobin molecules located in the red blood cells (Marieb & Hoehn, 2010). As 
oxygen binds to the iron (Fe2+) of the hemoglobin molecule, the hemoglobin is referred to 
as oxyhemoglobin. In contrast, as the oxygen disassociates from the iron of the 
hemoglobin molecule in the tissues the hemoglobin becomes reduced and is referred to as 
deoxyhemoglobin (Marieb & Hoehn, 2010). 
 Red blood cells can concentrate hemoglobin in the cell fluid up to about 34 g·dL-1 
of cells. This represents the metabolic limit of the cell’s hemoglobin-forming mechanism; 
therefore the hemoglobin concentration will not increase above this value (Guyton & 
Hall, 2000; Whitehead, 2006). In addition, the hemoglobin concentration in red blood 
cells is maintained near maximum levels in normal adults. However, the hemoglobin 
concentration can fall below this near maximum value when hemoglobin formation is 
deficient. This condition will also result in the reduction in red blood cell volume because 
of the decreased amount of hemoglobin to occupy the red cell (Guyton & Hall, 2000; 
Whitehead, 2006). Under normal conditions, when the percentage of blood cells is 40-
45% (hematocrit) and the hemoglobin concentrations in the red cells are normal, the 
whole blood contains about 16 g and 14 g of hemoglobin per deciliter for men and 
women respectively (Guyton & Hall, 2000; Whitehead, 2006). A single gram of 
hemoglobin is capable of establishing a reversible combination with 1.39 milliliters of 
O2. As a result, under normal conditions, more than 21 and 19 mL of O2 can be 
transported bound to hemoglobin in each deciliter of blood for males and females 
respectively (Guyton & Hall, 2000; Whitehead, 2006). 
 Additional functions of red blood cells. Red blood cells are specialized and 
dedicated to their primary function of transporting hemoglobin (Guyton & Hall, 2000; 
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Marieb & Hoehn, 2010; Tortora, 2005). In addition to transporting oxygen, hemoglobin 
can transport about 20% of the carbon dioxide (CO2) in the blood (Marieb & Hoehn, 
2010; Sherwood, 2007). As blood flows through the tissue capillaries, CO2 can combine 
with the amino acids in the globin forming carbaminohemoglobin (Marieb & Hoehn, 
2010; Tortora, 2005). As the blood is circulated back to the lungs, CO2 is unloaded from 
the hemoglobin and the gas can diffuse into the alveoli from the pulmonary blood to be 
eliminated from the body (Marieb & Hoehn, 2010; Tortora, 2005). 
 Secondly, hemoglobin (Hb) plays a role in the pH-buffering capacity of blood by 
buffering the hydrogen ion (H+) that is generated at the tissue level from the production 
of CO2. As CO2 is continuously produced in the tissues from metabolic reactions, it will 
diffuse into the blood. Most of the CO2 entering the blood forms carbonic acid (H2CO3) 
and a portion of this acid will dissociate into a bicarbonate ion (HCO3-) and a free 
hydrogen ion (H+). The hemoglobin returning to the lungs in the reduced state can 
combine with most of the H+ generated from CO2. This serves as a buffering mechanism, 
resulting in only a slight increase in the acidity of the venous blood compared to the 
arterial blood despite the large amount of H+ generated from the carbonic acid (H2CO3) 
(Sherwood, 2007). 
 Hemoglobin also contributes to the regulation of blood flow and blood pressure 
through vasodilation. Nitric oxide (NO), a vasodilator produced by the endothelial cells 
of the blood vessels, can bind to hemoglobin in the lungs. When NO is released by 
hemoglobin in the tissues, vasodilation can occur at the local vessel walls resulting in an 
increase in blood flow of oxygenated blood to the localized tissues. (Sherwood, 2007; 
Tortora, 2005). 
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 Red blood cell indices. Complete blood count (CBC) testing and analysis can be 
utilized to evaluate the various hematological indices including red blood cell (RBC) 
count, mean corpuscular volume (MCV), red cell distribution width (RDW), hemoglobin 
concentration [Hb], hematocrit (Hct), mean corpuscular hemoglobin (MCH), and mean 
corpuscular hemoglobin concentration (MCHC) (Walters & Abelson, 1996). Red blood 
cell count (RBC), MCV and RDW are commonly used to evaluate RBC status. The RBC 
count provides a measure of the number of RBCs that are concentrated within one mm3 
of peripheral venous blood (Pagana & Pagana, 2003; Whitehead, 2006). The average 
number of RBCs is 4.7-6.1 × 106·mm-3 and 4.2-5.4 × 106·mm-3 in males and females 
respectively (Pagana & Pagana, 2003; Whitehead, 2006). Mean corpuscular volume 
(MCV) can be calculated by dividing the Hct by the RBC count. The MCV represents the 
average measurement of RBC volume (Wallach, 2007; Whitehead, 2006). The normal 
MCV value, considered to be normocytic anemia, is approximately 82-98 μm3 (Walters & 
Abelson, 1996; Whitehead, 2006). Abnormally elevated MCV values (> 95 μm3) indicate 
macrocytic anemias, on the other hand abnormally depressed MCV values (< 80μm3) 
indicate microcytic anemias (Walters & Abelson, 1996; Whitehead, 2006). The red cell 
distribution width (RDW) is a measure of the dispersion of the erythrocyte size 
distribution (Walters & Abelson, 1996). It represents the coefficient of variation of the 
distribution of red blood cell (RBC) volume, expressed as a percentage (Wallach, 2007; 
Walters & Abelson, 1996). The RDW provides information about cell size variability and 
the calculation is based on MCV and RBC (Wallach, 2007; Whitehead, 2006). 
Additionally, the hematocrit (Hct) or packed cell volume measurement represents the 
percentage of red blood cells (RBCs) in the total volume of blood (Marieb & Hoehn, 
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2010; Sherwood, 2007). Normal hematocrit (Hct) percentages range between 40-45% for 
healthy adults (Guyton & Hall, 2000). 
  Furthermore, indices from the complete blood count (CBC) can be used to 
evaluate hemoglobin status of RBCs including hemoglobin concentration [Hb], mean 
corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin concentration 
(MCHC). When the Hct is 40-45% and the hemoglobin concentrations in the red cells are 
normal, the mean hemoglobin concentration in peripheral blood is approximately 14-18 
g·dL-1 in males and 12-14 g·dL-1 in females (Guyton & Hall, 2000; Pagana & Pagana, 
2003; Whitehead, 2006). Mean corpuscular hemoglobin (MCH) represents the average 
amount of Hb within a RBC, with normal values ranging from 26-34 pg [Hb] (Wallach, 
2007). Mean corpuscular hemoglobin (MCH) is obtained by dividing the Hb 
concentration by the RBC count (Wallach, 2007; Whitehead, 2006). Mean corpuscular 
hemoglobin concentration (MCHC) represents the average concentration of Hb within the 
RBCs (Wallach, 2007; Whitehead, 2006), with normal values ranging within 33-37 g· 
dL-1 (Wallach, 2007). Mean corpuscular hemoglobin concentration (MCHC) is obtained 
by dividing Hct by the Hb concentration (Wallach, 2007; Whitehead, 2006). 
Erythropoiesis 
Red Blood Cell Production 
 Stem cell differentiation. In adults, the process of blood cell formation, 
hematopoiesis or hemopoiesis, occurs in the red bone marrow (Marieb & Hoehn, 2010; 
Tortora, 2005; Whitehead, 2006). Red bone marrow is located in bones of the axial 
skeleton, pelvic and pectoral girdles, and the proximal epiphyses of the humerus and the 
femur (Marieb & Hoehn, 2010; Tortora, 2005). From within the bone marrow, all cells in 
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the circulating blood originate from pluripotent hematopoietic stem cells, which represent 
less than 0.1% of red bone marrow cells (Guyton & Hall, 2000; Marieb & Hoehn, 2010; 
Sherwood, 2007; Tortora, 2005). These pluripotent stem cells will continuously divide 
and differentiate into peripheral blood cells, whereas a small portion of them remain in 
their original form to maintain a supply of the original cell in the marrow (Guyton & 
Hall, 2000; Sherwood, 2007; Whitehead, 2006). However, the majority of the pluripotent 
stem cells differentiate to form a committed stem cell to a specific blood cell lineage 
which include erythrocytes, granulocytes (neutrophils, eosinophils, basophils), 
monocytes, macrocytes, megakaryocytes, platelets, T-lymphocytes, and B lymphocytes 
(Guyton & Hall, 2000; Tortora, 2005; Whitehead, 2006). Commitment to a blood cell 
pathway begins with the production of myeloid stem cells, developing into erythrocytes, 
granulocytes, monocytes, macrocytes, megakaryocytes, or platelets; and lymphoid cells, 
developing into T-lymphocytes, and B lymphocytes, from the pluripotent stem cells 
(Guyton & Hall, 2000; Tortora, 2005). 
 Continually, the committed myeloid stem cells will differentiate into progenitor 
cells, known as colony-forming units (CFUs), which are committed to developing the 
mature elements of the specific blood cell lineage (Tortora, 2005). The committed stem 
cells that produce erythrocytes are the colony-forming unit-erythrocytes (CFU-E), the 
colony-forming unit-granulocytes-monocytes (CFU-GM) will produce granulocytes and 
monocytes, and colony-forming unit-megakaryocytes (CFU-M) will produce 
megakaryocytes, the source of platelets (Guyton & Hall, 2000; Tortora, 2005). As the 
colony-forming units (CFUs) of the blood cell lineages develop they will form precursor 
cells, or blasts that will undergo several cell divisions leading to the development of the 
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actual blood cell (Tortora, 2005). There are several precursor cells that lead to the formed 
elements of the blood including: proerythroblasts that develop into erythrocytes, 
megakaryoblasts that develop into platelets, eosinophilic myeloblasts that develop into 
eosinophils, basophilic myeloblasts that develop into basophils, myeloblasts that develop 
into neutrophils, and monoblasts that develop into monocytes (Tortora, 2005). On the 
other hand, committed lymphoid stem cells will differentiate into T-lymphoblasts and B-
lymphoblasts which will develop into T-lymphocytes and B-lymphocytes respectively 
(Tortora, 2005). 
Red blood cell differentiation. Erythrocyte production, erythropoiesis, is initiated 
from the myeloid stem cell as it differentiates into erythroid progenitor cells (Fisher, 
2003; Tortora, 2005). The committed erythroid progenitor cell will proliferate and 
develop into a red blood cell (RBC) through the following stages of the erythrocyte 
lineage: pluripotent stem cell, myeloid stem cell, colony-forming unit-granulocyte, 
erythroid, monocyte, megakaryocyte (CFU-GEMM), colony-forming unit-
erythroid/megakaryocyte/blast (CFU-E/MEG/B), burst-forming unit-erythroid (BFU-E), 
colony-forming unit-erythroid (CFU-E), normoblast, reticulocyte, and mature erythrocyte 
(Fisher, 2003; Guyton & Hall, 2000). More specifically, following the CFU-E stage, a 
large number of red blood cells develop into the proerythroblast, which is the first cell of 
the red blood cell lineage that can be recognized as precursors to the mature cell (Guyton 
& Hall, 2000). The proerythroblast will divide several times, eventually developing many 
mature red blood cells (Guyton & Hall, 2000). The proerythroblast will transform into the 
basophil erythroblast, which is associated with the production of large numbers of 
ribosomes (Marieb & Hoehn, 2010). The cell divides many times during these first two 
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phases; however, very little hemoglobin has been synthesized and accumulated in the cell 
(Guyton & Hall, 2000; Marieb & Hoehn, 2010). Following the basophil erythroblast 
phase, the succeeding generations of the red blood cell series include the 
polychromatophil erythroblast and orthochromatic erythroblast that will increase the 
hemoglobin concentration of the cell to about 34% and the endoplasmic reticulum is 
reabsorbed (Guyton & Hall, 2000). The cell can now be referred to as a reticulocyte and 
is associated with containing a small amount of basophilic material consisting of 
remnants of the mitochondria, ribosomes, Golgi apparatus, endoplasmic reticulum and 
some other cytoplasmic organelles. The reticulocytes will pass from the bone marrow 
through the pores of the capillary membrane into the blood capillaries (Guyton & Hall, 
2000). It takes about 1-2 days for the reticulocytes to lose the remaining basophilic 
material and become mature erythrocytes (Guyton & Hall, 2000; Marieb & Hoehn, 
2010).  
Red blood cell lifespan. Red blood cells live for only approximately 120 days due 
to the fragility and proneness to rupture that develops at the plasma membrane from the 
continuous squeezing though the pores of the capillary membranes (Guyton & Hall, 
2000; Sherwood, 2007; Tortora, 2005). As a result, old or ruptured red blood cells must 
be continuously replaced by new ones generated from the bone marrow (Sherwood, 
2007). Typically, just less than 1% of the senior RBCs are replaced by new reticulocytes 
daily (Tortora, 2005). The process of red blood cell development, from pluripotent 
hematopoietic stem cell (hemocytoblast) to reticulocyte takes approximately 15 days 
(Marieb & Hoehn, 2010). Though not fully matured, the reticulocyte enters the 
bloodstream composed of a high concentration of Hb and capable of transporting oxygen 
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(Marieb & Hoehn, 2010). As mentioned previously, it takes about 1-2 days for 
reticulocytes to develop into mature RBCs (Guyton & Hall, 2000; Marieb & Hoehn, 
2010). In healthy adults, reticulocytes account for approximately 1% of all RBCs in the 
blood (Marieb & Hoehn, 2010; Tortora, 2005). Additionally, reticulocyte count provides 
a measure of erythropoiesis (Marieb & Hoehn, 2010; Tortora, 2005). 
 Erythropoietic growth factors. There are several glycoprotein hormonal 
hemopoietic growth factors that contribute to the differentiation and proliferation of the 
lineage committed progenitor cells (Groopman, Molina, & Scadden, 1989; Sieff, 1987). 
These hormones are known as the colony-stimulating factors (CSFs), which stimulate the 
progenitor cells of the different blood cell lineages to form the distinct identifiable colony 
of the developing cell (Sieff, 1987). In addition, the CSFs affect the function of the 
mature cells and their presence regulates the initiation of increased cell production when 
required by the body (Sieff, 1987).  
 The process of erythropoiesis, originating from the primitive pluripotent stem cell 
through the differentiation and development of red cell lineage, is regulated by several 
cytokines (Fisher, 2003). The growth factors known to be involved in the regulation of 
erythropoiesis are erythropoietin (EPO) and other cytokines produced by red bone 
marrow cells, leukocytes, macrophages, fibroblasts and endothelial cells including 
granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage (GM)-CSF, 
interleukin-6 (IL-6), IL-1, IL-3, IL-4, IL-9, IL-11, insulin growth factor-1 (IGF-1) and 
stem cell factor (SCF) (Fisher, 2003; Tortora, 2005; Whitehead, 2006). Erythropoietin 
influences the mature stages of development of the erythroid progenitor cells by acting 
primarily on the colony-forming unit-erythrocytes (CFU-E), the primary target cell of 
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EPO, to stimulate these cells to proliferate and develop through the normoblast stage into 
reticulocytes and mature erythrocytes (Fisher, 2003; Gregory & Eaves, 1977; Gregory & 
Eaves, 1978; Whitehead, 2006). Additionally, EPO functions synergistically with GM-
CSF, IL-3, IL-4, IL-9, IGF-1, and SCF to initiate the proliferation and development from 
the stage of the BFU-E and CFU-E to the normoblast stage of the erythrocyte 
development (Fisher, 2003; Lin, Lim, D’Agati, & Constantini, 1996; Wu, Liu, Jaenisch, 
& Lodish, 1995; Whitehead, 2006). Therefore, it is proposed that EPO principally acts on 
apoptosis, or programmed cell death, by reducing the rate at which the erythroid 
progenitor cells die in the bone marrow (Fisher, 2003; Whitehead, 2006). The 
differentiation of the pluripotent stem cell into the myeloid stem cell and the CFU-
GEMM is stimulated by SCF, IL-1, IL-3, IL-6 and IL-11 (Fisher, 2003; Whitehead, 
2006). This leads to the CFU-GEMM producing the specific CFU for the granulocytes, 
monocytes, macrophages, megakaryocytes, eosinophils, and erythroid cell precursors 
(D’Andrea & Zon 1990; Dessypris, Gleaton, & Armstrong, 1987; Fisher, 2003; Jacobs-
Helber, Penta, Sun, Lawson, & Sawyer, 1997; Whitehead et al., 2007; Wu, Klingmüller, 
Besmer, & Lodish 1995). 
Stimulation of Erythropoiesis. The number of red blood cells in the circulatory 
system is regulated to within narrow limits to maintain a balance between red blood cell 
production and destruction (Guyton & Hall, 2000; Marieb & Hoehn, 2010; Whitehead, 
2006). This is necessary to ensure that an adequate number of red blood cells are 
available to maintain sufficient oxygen transport from the lungs to the tissues, without 
over production of the red blood cells which can lead to an impeded blood flow due to an 
increased viscosity of the blood (Guyton & Hall, 2000). Hypoxia is the term that refers to 
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the oxygen deficiency in the cells (Marieb & Hoehn, 2010; Tortora, 2005). Hypoxia will 
occur under a variety conditions when not enough oxygen enters the bloodstream such as 
when the amount of oxygen in the air is greatly decreased at high altitudes, during anemic 
states, circulatory problems that reduce blood flow to the tissues, and a variety of lung 
diseases that reduce the respiratory gas exchange in the lungs (Guyton & Hall, 2000; 
Tortora, 2005). Tissue oxygenation is the primary regulator of erythropoiesis (Guyton & 
Hall, 2000). Conditions that cause the oxygen carrying capacity of the blood to decrease 
will ordinarily increase the rate of erythropoiesis (Guyton & Hall, 2000; Tortora, 2005). 
Therefore, the control for red blood cell production is the functional ability of the red 
blood cells to deliver oxygen to the tissues in a state of demand rather than the 
concentration of red cells in the blood (Guyton & Hall, 2000). 
 Stimulation of erythropoiesis from the bone marrow is primarily controlled by 
the hormone erythropoietin (EPO), a glycoprotein with a molecular weight of 34,000 
Daltons containing 165 amino acids (Fliser & Bahlmann, 2008; Guyton & Hall, 2000; 
Marieb & Hoehn, 2010; Whitehead, 2006). Erythropoietin mainly functions to supply an 
adequate supply of red blood cell mass in response to tissue oxygen demand (Fliser & 
Bahlmann, 2008; Frank, 2002; Guyton & Hall, 2000). Hypoxic conditions will stimulate 
an increase in EPO production to enhance red blood cell production until an adequate 
oxygen carrying capacity is achieved. Without the presence of EPO during hypoxic 
conditions, there will not be an effective mechanism for adequate erythropoiesis (Guyton 
& Hall, 2000). 
The kidneys form approximately 90% of the circulating EPO, with the liver 
forming most of the remainder (Guyton & Hall, 2000; Marieb & Hoehn, 2010; 
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Whitehead, 2006). When oxygen delivery to the kidneys is reduced, certain kidney cells 
become hypoxic preventing oxygen-sensitive enzymes from degrading an intracellular 
signaling molecule called hypoxia-inducible factor (HIF). Accumulation of HIF 
stimulates the release of EPO (Marieb & Hoehn, 2010). Hypoxic conditions resulting 
from the reduction in RBCs, insufficient Hb per RBC, or reduced environmental 
availability of oxygen will stimulate the formation of EPO within minutes to hours and 
maximal production can be reached within 1-3 days (Berglund, 1992; Guyton & Hall, 
2000); however new RBCs do not appear in circulation until approximately five days 
later (Guyton & Hall, 2000; Whitehead, 2006). The quantity of reticulocytes in 
circulation provides an adequate measure of the rate of erythropoiesis (Marieb & Hoehn, 
2010; Tortora, 2005). 
Erythropoiesis time span. As mentioned previously, it takes approximately 15 
days for pluripotent hematopoietic stem cells to develop into circulating reticulocytes 
(Marieb & Hoehn, 2010) and another 1-2 days for the reticulocytes to develop into 
mature erythrocytes (Guyton & Hall, 2000; Marieb & Hoehn, 2010). It has been 
discussed that EPO influences the mature stages of development of the erythroid 
progenitor cells by acting primarily on the colony-forming unit-erythrocytes (CFU-E) to 
stimulate these cells to proliferate and develop into mature cells (Fisher, 2003; Gregory & 
Eaves, 1977; Gregory & Eaves, 1978). Therefore, it is possible that the appearance of 
new RBCs could appear about five days after the maximum EPO production (Guyton & 
Hall, 2000). Furthermore, EPO acts synergistically with GM-CSF, IL-3, IL-4, IL-9, IGF-
1, and SCF initiating the proliferation and development from the stage of the BFU-E and 
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CFU-E to the normoblast stage of the erythrocyte development (Fisher, 2003; Lin et al., 
1996; Wu, Liu, Jaenisch, & Lodish, 1995).  
Dietary requirements for the maturation of red blood cells. Erythropoiesis is not 
only controlled hormonally by the production of EPO, but the process also depends on 
adequate supplies of vitamin B12, folic acid, and iron (Guyton & Hall, 2000; Marieb & 
Hoehn, 2010). The life cycle of RBCs is a dynamic process. There is a continuing 
demand for the production of new red blood cells, with the average lifespan of the red 
cell lasting only about 120 days compared to nerve and muscle cells which may last the 
lifetime of a human (Guyton & Hall, 2000; Sherwood, 2007). Therefore, erythroid cells 
derived from the bone marrow are among the most rapidly growing and reproducing cells 
in the human body. Thus, the survival, proliferation, and maturation of the erythropoietic 
cells are greatly influenced by nutritional status (Guyton & Hall, 2000). 
Two B-complex vitamins, vitamin B12 and folic acid are essential for the final 
maturation of the red blood cell (Guyton & Hall, 2000, Marieb & Hoehn, 2010). These 
vitamins are necessary for the synthesis of deoxyribonucleic acid (DNA) because they are 
required for one of the important building blocks of DNA known as thymidine 
triphosphate (Guyton & Hall, 2000). Slight deficiencies in either vitamin B12 or folic acid 
will cause diminished DNA and reduction in cell maturation and division (Guyton & 
Hall, 2000; Marieb & Hoehn, 2010). Additionally, erythroblastic cells within the bone 
marrow will have a reduced proliferation rate and the DNA abnormalities can contribute 
to malformed structural components of the cell membrane and cytoskeleton leading to 
fragility and a shorter life than normal. Thus, deficiencies in vitamin B12 and folic acid 
can cause maturation failure in the process of RBC production (Guyton & Hall, 2000). 
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Iron metabolism. Iron (Fe2+) is a trace mineral that is essential for the synthesis of 
hemoglobin (Marieb & Hoehn, 2010). In the human body, iron exists in two forms, the 
ferrous [Fe (II)] form and the ferric [Fe (III)] form (Guyton & Hall, 2000; Whitehead, 
2006). The Fe (II) form has the ability to bind with oxygen in which the Hb can transport, 
whereas the Fe (III) form causes the formation of methemoglobin, which will not carry 
oxygen (Guyton & Hall, 2000). The cytoplasmic enzymes of the red blood cell keep the 
iron in the hemoglobin of the RBC in the ferrous form rather than the ferric form (Guyton 
& Hall, 2000). As RBCs complete their average life cycle of approximately 120 days, 
they will begin a degradation process in which the cell membrane becomes permeable to 
ions, and the ferrous iron takes on the ferric form (Guyton & Hall, 2000; Whitehead, 
2006). The body has a total of about 4-5 grams of iron, with approximately 65% in 
hemoglobin (Guyton & Hall, 2000; Marieb & Hoehn, 2010). The remainder of the iron is 
stored throughout the body, with about 4% contained in myoglobin, about 1% contained 
in various heme compounds that promote intracellular oxidation, about 0.1% is bound to 
the blood transport protein transferrin, and the majority of the stored iron is in the form of 
ferritin represented by 15-30% found in the reticuloendothelial system and the liver 
parenchymal cells (Guyton & Hall, 2000; Marieb & Hoehn, 2010). The average quantity 
of iron found in the blood serum is approximately 14-32 μmol·L-1 in men and 11-29 
μmol·L-1 in women (Whitehead, 2006). The average daily loss of iron to excretion is 
about 0.6-0.9 mg in men and 1.3-1.7 mg in women. Bleeding accounts for an additional 
loss of iron, as a result, women lose a greater amount of iron due to the menstrual cycle 
(Guyton & Hall, 2000; Marieb & Hoehn, 2010). 
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Following the absorption of iron from the small intestine, it immediately binds to 
beta globulin in the blood plasma known as apotransferrin to form the transport protein 
transferrin (Guyton & Hall, 2000; Marieb & Hoehn, 2010; Whitehead, 2006). In the 
blood plasma, iron is loosely bound to transferrin enabling the iron to be released to the 
tissue cells as well as to developing erythrocytes as needed to form hemoglobin (Guyton 
& Hall, 2000; Marieb & Hoehn, 2010). When iron levels in the blood are in excess, it can 
be stored in all cells of the body, with the majority deposited in the liver hepatocytes and 
to a lesser extent in the reticuloendothelial cells of the bone marrow (Guyton & Hall, 
2000; Whitehead, 2006). When the iron is released into the cell cytoplasm it primarily 
binds to a protein apoferritin to form ferritin. Apoferritin is a large molecule, with an 
approximate molecular weight of 460,000, and varying amounts of iron can form groups 
of iron radicals to combine with the large apoferritin molecule. Thus, it is possible that 
ferritin may be composed of only a small quantity of iron or larger amounts. Storage iron 
is the term used to describe the iron stored as ferritin (Guyton & Hall, 2000).   
Additionally, when the total amount of iron in the body is greater than the 
apoferritin storage capacity, smaller amounts of iron are stored in an extremely insoluble 
form known as hemosiderin (Guyton & Hall, 2000). When the blood plasma levels of 
iron decrease below normal levels, iron is mainly removed from ferritin because it is 
more easily removed from ferritin compared to hemosiderin. Once removed from ferritin, 
the iron is again transported in the plasma in the form of transferrin. An important feature 
of the transferrin molecule is that it can form a strong bond with receptors in the cell 
membranes of erythroblasts located in the bone marrow. This is followed by the ingestion 
of the transferrin along with the bound iron into the erythroblasts by endocytosis. Upon 
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entering the erythroblast, the transferrin can deliver the iron to the mitochondria where 
the heme is synthesized (Guyton & Hall, 2000; Whitehead, 2006). When the red blood 
cells have completed their life cycle, on average 120 days, the hemoglobin that is 
released from the destroyed cell is ingested by the cells of the monocyte-macrophage 
system (Guyton & Hall, 2000; Whitehead, 2006). In this system, the iron is in a free form 
and it will primarily be stored in the ferritin pool or it can also be used again to form new 
hemoglobin (Guyton & Hall, 2000). 
Iron marker. Iron is delivered to the cell loosely bound to transferrin where a cell 
surface transferrin receptor (TfR) enables the transferrin to enter the cell and release its 
iron (Huebers, Beguin, Pootrakul, Einspahr, & Finch, 1990; Huebers & Finch, 1987). A 
soluble form of the TfR (sTfR) circulates in the form of a complex of transferrin and its 
receptor (Beguin, 2003). The concentration of sTfR in circulation is proportional to the 
total concentration of the TfR and increases with increased cellular iron utilization and 
erythroid precursor cell proliferation (Lee, Oh, Park, Lee, Kim, 2002; R’zik & Beguin, 
2001). Therefore, serum soluble transferrin receptor (sTfR) is considered a key and 
sensitive marker used to examine erythroid mass (Gore et al., 2006; Huebers et al., 1990). 
The erythroblasts are the primary source of serum sTfR (Beguin, 2003). As a result, the 
rate of erythropoiesis can be monitored by measuring sTfR (Huebers et al., 1990). The 
average serum sTfR levels are approximately 5.0 ± 1.0 mg·L-1 in normal subjects 
(Beguin, 2003). 
Erythrocythemia.  
 Erythrocythemia, also referred to as polycythemia, is a term used to describe an 
abnormal increase in circulating red blood cells that increases hematocrit (Marieb & 
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Hoehn, 2010; Sherwood, 2007; Whitehead, 2006). The two general forms of 
polycythemia are primary and secondary (Sherwood, 2007). Primary polycythemia, also 
known as polycythemia vera, is a pathologic condition that is caused by a genetic 
abnormality or tumor like condition that occurs in the hemocytoblastic cell line within the 
bone marrow that produces the blood cells (Guyton & Hall, 2000; Sherwood, 2007). This 
condition causes the blast cells to continually produce red cells even when too many cells 
already exist in circulation (Guyton & Hall, 2000). Thus, the production of red blood 
cells proceeds at an uncontrolled and excessive rate, in which RBC counts may reach 8-
11 million cells·mm-3 and the hematocrit may reach 70-80% (Marieb & Hoehn, 2010; 
Sherwood, 2007). Primary polycythemia can elevate total blood volume up to two times 
the normal level, causing the entire vascular system to become extremely engorged with 
blood (Guyton & Hall, 2000; Marieb & Hoehn, 2010). Additionally, the viscosity of the 
blood can increase up to 5-7 times normal, resulting in impeded blood flow through many 
capillaries, elevated blood pressure, thus increased workload on the heart (Guyton & 
Hall, 2000; Sherwood, 2007). 
 Secondary polycythemia is characteristic of increased red blood cell production 
due to hypoxic conditions or an increase in EPO production (Guyton & Hall, 2000; 
Marieb & Hoehn, 2010). Tissues can become hypoxic when there is a reduced 
atmospheric pressure and lower oxygen content in the air, such as at high altitudes, or 
because of various diseases that reduce the delivery of oxygen to the tissues, resulting in 
an erythropoietin-induced mechanism to increase RBC production (Guyton & Hall, 2000; 
Marieb & Hoehn, 2010; Sherwood, 2007). Secondary polycythemia is associated with a 
rise in RBC count to approximately 6-8 million cells·mm-3, compared to normal levels 
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consisting of approximately five million cells·mm-3 (Marieb & Hoehn, 2010; Sherwood, 
2007). In contrast to primary polycythemia, secondary polycythemia functions as an 
appropriate EPO-induced mechanism to enhance the oxygen transport of the blood in 
response to insufficient oxygen delivery to the tissues (Sherwood, 2007). 
Induced erythrocythemia.  Blood doping, blood boosting, blood packing or 
induced erythrocythemia are terms used to describe the procedure of RBC infusion to 
induce an above normal Hb concentration and, as a result, increased oxygen transport 
capacity (Gledhill, Warburton, & Jamnik, 1999; Jones & Tunstall Pedoe, 1989; Powers & 
Howley, 2009; Whitehead, 2006). Generally, induced erythrocythemia is accomplished 
by withdrawing a volume of blood from an individual, separating the RBCs, storing the 
RBCs, and then reinfusion of the RBCs into the individual (Gledhill et al., 1999). The 
fundamental premise of induced erythrocythemia is to stimulate erythropoiesis after the 
withdrawal of blood and allow for the increased red cell production to occur, as the 
withdrawn RBCs are stored. After sufficient time has elapsed to allow the [Hb] to return 
to normal levels, the stored RBCs are reinfused into the individual resulting in a 
significant increase in the oxygen carrying capacity of the blood, and consequently, 
aerobic exercise performance (Gledhill et al., 1999). Induced erythrocythemia can be 
achieved by the infusion of blood from a matched donor, referred to as homologous 
transfusion, or with the reinfusion of an individual’s own stored blood, referred to as 
autologous transfusion (Gledhill et al., 1999; Jones & Tunstall Pedoe, 1989; Powers & 
Howley, 2009). Additionally, the use of recombinant human erythropoietin (rHuEPO) 
has been used in the same manner as the traditional blood doping methods in an attempt 
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to increase [Hb] resulting in an improved oxygen carrying capacity and thereby 
endurance exercise performance (Gledhill et al., 1999). 
Homologous transfusion involves the infusion of blood from a matched donor 
(Gledhill et al., 1999; Powers & Howley, 2009; Whitehead, 2006). This procedure is 
routinely used in life-threatening medical emergencies (Gledhill et al., 1999; Powers & 
Howley, 2009). However, this type of transfusion is associated with the considerable risk 
of infection and blood-type incompatibility (Gledhill, 1985; Gledhill et al., 1999; Powers 
& Howley, 2009). Autologous transfusion involves the removal of a subject’s blood, 
storing the blood, and subsequent reinfusion of the blood (Gledhill et al., 1999; Jones & 
Tunstall Pedoe, 1989; Whitehead, 2006). Upon removal, the blood is centrifuged for 
separation and the plasma is immediately reinfused into the subject while the packed 
RBCs are stored by refrigeration or frozen to be reinfused at a later date (McArdle, 
Katch, & Katch, 2001). Typically, approximately 1-4 units, or about 450-1,800 mL, of 
blood is reinfused through this procedure (Leigh-Smith, 2004; McArdle et al., 2001). It is 
important to provide at least three weeks from the time of withdrawal of blood to the time 
of RBC reinfusion to allow for the re-establishment of normal [Hb] in the subject 
(Collings, 1988; Jones & Tunstall Pedoe, 1989). An extended time period of 
approximately 8-12 weeks compared to just three weeks, would be more advantageous to 
ensure the subject regains normal [Hb] and to achieve pre-donation fitness levels due to 
detraining that may have occurred from the withdrawal of blood (Eichner, 1987; Jones & 
Tunstall Pedoe, 1989). Consequently, the primary concern with autologous blood doping 
is matching the time period necessary for a subject to generate new RBCs to reestablish 
the [Hb] with the maximum time period that the donated blood can be stored and RBC 
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viability maintained (Gledhill, 1982; Powers & Howley, 2009). Generally, three to four 
weeks are needed to replace RBCs following a 400 mL donation and five to six weeks are 
necessary for a 900 mL donation (Gledhill, 1982; Powers & Howley, 2009).  
The standard storage method for the preservation of blood is by refrigeration at 4 
°C (39.2 °F) (Gledhill, 1982; Gledhill et al., 1999; Whitehead, 2006). However, the 
maximum time blood can be stored by refrigeration is three weeks, during which time 
there is an expected loss of about 1% RBCs per day. Additional loss of RBCs occurs 
from RBCs adhering to storage containers or the RBCs steadily deteriorate while in 
storage leading to progressive membrane fragility and loss of function upon reinfusion 
(Gledhill, 1982; Jones & Tunstall Pedoe, 1989; Powers & Howley, 2009; Whitehead, 
2006). As a result of these complications, only about 60% of the RBCs maintain viability 
and are functional when reinfused (Gledhill, 1982; Gledhill et al., 1999; Powers & 
Howley, 2009). However, the limited storage time might not allow for re-establishment 
of RBCs to normal levels in the body prior to reinfusion of the stored cells (Powers & 
Howley, 2009).  
The glycerol freezing technique is another method of cold storage used to 
preserve RBCs (Gledhill, 1982; Gledhill et al., 1999; Jones & Tunstall Pedoe, 1989; 
Leigh-Smith, 2004; Whitehead, 2006). This method involves the removal of blood, then 
the blood is centrifuged and the plasma component is immediately reinfused. Glycerol is 
added to the packed RBCs which are then frozen at -80 °C in liquid nitrogen (Jones & 
Tunstall Pedoe, 1989). As a result, the ageing process of the RBCs is delayed and the 
blood can be stored up to 10 years with only a 15% RBC loss (Collings, 1988; Ghaphery, 
1995; Gledhill, 1982; Jones & Tunstall Pedoe, 1989; Powers & Howley, 2009). Prior to 
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reinfusion, the RBCs are thawed, the glycerol is removed through a series of washes of 
increasing osmolality, and then the RBCs are suspended in a saline solution to a 
hematocrit of about 50% for reinfusion (Jones & Tunstall Pedoe, 1989; Leigh-Smith, 
2004). The glycerol freezing method allows for an extended storage period of the RBCs 
to ensure that the subject has regained normal [Hb] to become normocythemic (Gledhill, 
1982; Gledhill et al., 1999; Powers & Howley, 2009).  
Typically, reinfusion of stored RBCs occurs 1-7 days before endurance 
competition to increase RBC count and [Hb] up to 8-20% above normal levels (McArdle 
et al., 2001; Robergs & Roberts, 1997; Whitehead, 2006). Furthermore, an increase in 
[RBC] can increase [Hb] from 14 g·dL-1 to 20 g·dL-1, and when the Hb is 98% saturated 
with O2 there is an added 84 mL O2·L-1 in circulation resulting in an added 1.7 L O2·min-1 
at a cardiac output of 20 L·min-1 (Robergs & Roberts, 1997). With reinfusion of 900 mL 
of glycerol freeze preserved blood after normocythemia is achieved, the [Hb] can 
increase to approximately 10% followed by a steady, gradual decrease to normal [Hb] 
levels after approximately 120 days. This provides a long-term mechanism for enhanced 
oxygen carrying capacity over several weeks (Gledhill, 1982; Gledhill et al., 1999). 
The advancement and availability of the recombinant DNA technology has 
allowed for the cloning of the gene for EPO; the hormone primarily produced by the 
kidneys that functions as a growth factor for erythrocytes (Brooks et al., 2000; Gledhill et 
al., 1999; Whitehead, 2006). This has allowed for the synthesis of recombinant human 
erythropoietin (rHuEPO) (Gledhill et al., 1999; Whitehead, 2006). Recombinant human 
EPO can be administered by injection in an effort to stimulate an increase in red blood 
cell production (Brooks et al., 2000; Whitehead, 2006). Recombinant-HuEPO has shown 
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to be effective in the treatment of anemia associated with chronic kidney failure as well 
as anemia associated with the effects of concomitantly administered chemotherapy 
(Fisher, 2003; Gledhill et al., 1999; McArdle et al., 2001; Whitehead, 2006; Winearls et 
al., 1986). It has been shown that rHuEPO administration increases RBC production as 
well as increase hematocrit by 35% in patients treated for kidney failure, with higher 
doses stimulating a greater effect (Brooks et al., 2000). By enhancing the [Hb] and thus 
the oxygen transport capacity, administration of rHuEPO can be utilized to improve 
maximal aerobic capacity (Birkeland et al., 2000; Ekblom, 1996; Rosenlöf et al., 1989; 
Russell, Gore, Ashenden, Parisotto, & Hahn, 2002; Whitehead, 2006) and endurance 
exercise performance (Ekblom, 1996; Gledhill et al., 1999).  
Induced Polycythemia and Aerobic Exercise.  
 Observations of native mountain inhabitants living at very high altitudes provided 
initial observations of erythrocythemia (Hernando Ordonez, 1952; Vellard, 1952a; 
Vellard, 1952b). Within these investigations it was noted that [Hb] were above normal in 
these mountain inhabitants (Hernando Ordonez, 1952; Vellard, 1952a; Vellard, 1952b; 
Whitehead, 2006). The early altitude observations have been instrumental in the 
advancement of altitude training to enhance endurance exercise performance. Research 
has shown that training at altitude improves endurance exercise performance at sea level 
(Bailey & Davies, 1997; Mairbaurl et al., 1986). In recent years, the method of living at 
high altitude and training at low altitude has been utilized by many endurance athletes for 
improved performance at sea level (Wehrlin et al., 2006; Wilber, 2004). The concept is 
used to stimulate an increase in RBC production and [Hb] as a result of living at 
moderate altitudes, while training near sea-level to maintain training intensity (Levine & 
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Stray-Gundersen, 1992). However, results have been variable and somewhat 
controversial (Ashenden, Gore, Dobson, & Hahn, 1999; Gore & Hopkins, 2005; Hahn et 
al., 2001; Levine & Stray-Gundersen, 1997; Levine & Stray-Gundersen, 2005; Wehrlin et 
al., 2006). 
Induced erythrocythemia has been shown to significantly improve oxygen 
transport, V˙ O2max, and endurance exercise performance (Ekblom, 1996; Gledhill et al., 
1999, Whitehead, 2006). Improvements in V˙ O2max can be influenced by changes in 
physiological variables. Blood volume, which affects cardiac output, and [Hb] are very 
important in determining V˙ O2max and endurance exercise performance (Gledhill et al., 
1999). Therefore, stimulating an increase in [Hb] from induced erythrocythemia to result 
in an increased V˙ O2max must be accompanied by several criteria. An increase in [Hb] with 
no change in blood volume will increase V˙ O2max, however, if [Hb] does not change and 
blood volume increases thus increasing cardiac output, then V˙ O2max may remain 
unchanged or possibly increase slightly (Gledhill et al., 1999). Consequently, excess 
production of RBCs could increase blood viscosity and thus decrease cardiac output 
(McArdle, Katch, and Katch, 2010). Therefore, an increase in [Hb] must not be 
accompanied by a reduction in the maximal cardiac output distribution to the working 
tissues. Furthermore, as O2 transport improves the muscles must have the oxidative 
capacity to extract and utilize the additional O2 that is available (Gledhill, 1982; 
Whitehead, 2006). 
The objective of inducing erythrocythemia is to increase the maximal aerobic 
power by enhancing the oxygen carrying capacity of the blood (Gledhill, 1982). 
Investigations inducing erythrocythemia with the use of the blood doping methods have 
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produced significant improvement in V˙ O2max and endurance exercise performance (Brien 
& Simon, 1987; Buick et al., 1980; Celsing, Svedenhag, Pihlstedt, & Ekblom, 1987; 
Robertson et al., 1982; Spriet, Gledhill, Froese, & Wilkes, 1986; Williams et al., 1981). 
Early investigations of blood doping evaluated the response to exercise following the 
removal of RBCs and subsequent reinfusion of packed RBCs (Ekblom, Goldbarg, & 
Gullbring, 1972; Ekblom, Wilson, & Astrand, 1976). Ekblom, Wilson, & Astrand (1976) 
observed a reduction in V˙ O2max following the venesection of 800 mL of blood due to the 
reduced [Hb] and thus oxygen transport capacity. Additionally, the lower [Hb] resulted in 
increased submaximal V˙ O2, heart rate (HR) and blood lactate values (Ekblom et al., 
1976). On the other hand, reinfusion of the packed RBCs about 30-35 days after 
venesection increased [Hb] above control levels resulting in an increase in V˙ O2max and a 
decrease in submaximal V˙ O2, HR and blood lactate values from pre-donation values 
(Ekblom et al., 1976).  
Ekblom, Goldbarg, & Gullbring (1972) considered a classic study in this area, 
investigated the effects of erythrocythemia on acute endurance exercise performance and 
showed that the reinfusion of 900 mL (two units) of blood after four weeks increased 
[Hb] by 13%, run time to exhaustion increased, and V˙ O2max increased by 23% (Ekblom et 
al., 1972; Whitehead, 2006). Buick, Gledhill, Froese, Spriet, and Myers (1980) produced 
the first investigation of blood doping and endurance exercise performance that used the 
freeze-preserved method for storing the RBCs following donation. They observed that 
reinfusion of 900 mL of autologous, freeze-preserved RBCs resulted in a significant 
increase of 9.3% in [Hb], 5.1% in V˙ O2max, and 34% in treadmill running time to 
exhaustion (Buick et al., 1980; Whitehead, 2006). An important aspect utilized by the 
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researchers was that the RBCs were not reinfused until after the hematological 
parameters returned to pre-donation values (Buick et al., 1980; Whitehead, 2006).  
Subsequently, the same laboratory investigated the effects of reinfusing 900 mL and 
1,350 mL of freeze-preserved autologous blood on elite runners (Spriet et al., 1986; 
Whitehead, 2006). The primary purpose of this investigation was to determine whether 
induced erythrocythemia impaired cardiovascular function. The results indicated that 900 
mL and 1,350 mL reinfusions significantly increased Hct (7.9% and 10.8%, respectively) 
and V˙ O2max (3.9% and 6.6%, respectively), and no evidence of cardiovascular 
compromise was observed (Spriet et al., 1986; Whitehead, 2006). These observations 
confirmed the findings of the previous study and showed that improvements in V˙ O2max 
are even greater when the volume of blood reinfused is increased (Spriet et al., 1986; 
Whitehead, 2006). However, the researchers pointed out that the reinfusion volume of 
1,350 mL resulted in a Hct level during exercise that approached the clinical diagnostic 
value of erythrocythemia and any reinfusion volume more than 1,350 mL should be 
avoided (Gledhill et al., 1999; Spriet et al., 1986). Further support for the significant 
improvements in aerobic exercise performance and V˙ O2max as a result of the reinfusion of 
900 mL or more of freeze-preserved autologous blood has been well documented by 
several researchers (Goforth, Campbell, Hodgson, & Sucec, 1982; Robertson et al., 1982; 
Thomson, Stone, Ginsburg, & Hamilton, 1982; Whitehead, 2006; Williams et al., 1981).  
Alternative Actions of EPO 
 Primary action. It is well documented, and previously discussed, that circulating 
erythropoietin (EPO) is primarily produced in the kidney to regulate erythropoiesis by 
maintaining an optimal red blood cell (RBC) mass relative to the oxygen demand of the 
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tissues (Fliser & Bahlmann, 2008). Hypoxia sensitive cells in the kidneys represent the 
primary mechanism that stimulates an increase production of EPO to induce 
erythropoiesis until an optimal oxygen transport capacity is reached (Guyton & Hall, 
2000). Induced stimulation of erythropoiesis through the use of sufficient environmental 
hypoxic exposure has been shown to increase maximal oxygen consumption (V˙ O2max) 
and thus endurance exercise performance (Levine & Stray-Gundersen, 1997; Levine & 
Stray-Gundersen, 2005; Stray-Gundersen et al., 2001). 
 Other factors.  Erythropoietin (EPO) synthesis has also been shown to be affected 
by other factors such as blood volume (Ehmke et al., 1995) and the renin-angiotensin 
system (Donnelly & Miller, 2001; Freudenthaler, Lucht, Schenk, Brink, & Gleiter, 2000; 
Freudenthaler, Schreeb, Körner, & Gleiter, 1999). Reduced oxygen availability will 
stimulate an increased production of EPO leading to a progressive incline in Hb mass. 
Additionally, it has been shown that there is a concurrent depression in plasma volume, 
thus reducing the blood volume alongside the hemoconcentration. These results ensure 
that the arterial oxygen content is increased to levels similar to those observed at sea level 
(Lundby, Calbert, van Hall, Saltin, & Sander, 2004) and suggests that it is more 
important to control arterial oxygen content rather than blood volume in hypoxic 
conditions (Lundby et al., 2007).  
 Lundby et al. (2007) reported that rHuEPO increased [Hb] and as a result arterial 
oxygen content, by concurrently elevating Hb mass and reducing plasma volume. These 
results maintained the total blood volume with minimal change (Lundby et al., 2007). 
The researchers speculate that the rHuEPO-induced depression in plasma volume 
provides a fast acting mechanism to increase arterial oxygen content, whereas the process 
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of erythropoiesis may respond to reduced oxygen availability situations at a slower rate 
(Lundby et al., 2007). The authors discuss that the relative depression in plasma volume 
from rHuEPO treatment accounted for almost 50% of the arterial oxygen content 
(Lundby et al., 2007). 
 A mechanism by which the plasma volume could be decreased involves the 
relation between the volume regulating hormones and the production of EPO (Lundby et 
al., 2007), where the renin-angiotensin system has been shown to be involved in the 
release of EPO in a dose-dependent method (Donnelly & Miller, 2001; Freudenthaler et 
al., 2000; Freudenthaler et al., 1999). The data from Lundby et al. (2007) suggest that an 
excess of rHuEPO initiated a negative-feedback mechanism resulting in reduced activity 
of the renin-angiotensin-aldosterone axis. This would lead to the total blood volume 
remaining relatively unchanged and provide conditions that would have the advantage of 
increasing [Hb] at a faster rate. It has been noted that restoration of oxygen transport 
capacity following acute exposure to hypoxic conditions may take weeks or months when 
relying solely on erythropoiesis to develop (Reynafarje, Lozano, & Valdivieso, 1959). As 
EPO production is stimulated following low oxygen availability situations, such as high 
altitude exposure, there will be an initial rise in serum EPO levels with maximum values 
reached in 1-3 days (Berglund, 1992; Guyton & Hall, 2000) which represents the time 
period when EPO production is greater than its consumption by the bone marrow (Gore 
et al., 2007; Grover & Bärtsch, 2001). This is followed by a gradual descent in the serum 
EPO values for approximately one week (Berglund, 1992; Guyton & Hall, 2000) which 
indicates that erythropoiesis is initiated and a greater concentration of EPO is consumed 
(Gore et al., 2007; Grover & Bärtsch, 2001). As a result, an increase in EPO levels under 
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hypoxic conditions and the decrease in plasma volume that follows may provide the fast 
acting mechanism to increase arterial oxygen content while erythropoiesis is 
progressively activated (Lundby et al., 2007). 
 EPO and the endothelium. As previously mentioned, much of the reports on EPO 
mainly regard the hormone as a hematopoietic cytokine primarily functioning to initiate 
erythropoiesis through its requirement for the survival, proliferation and differentiation of 
erythroid progenitor cells (Beleslin-Cokic et al., 2004; Fliser & Bahlmann, 2008). 
However, there is evidence indicating that EPO as well as rHuEPO and its analogues 
have vasculo-protective effects (Fliser & Bahlmann, 2008). Erythropoietin has been 
reported to be important for its endothelial and vascular effects through the activation of 
endothelial nitric oxide synthase (eNOS) (Beleslin-Cokic et al., 2004; d’Uscio et al., 
2007). 
 Erythropoietin (EPO) induces a response in numerous tissues depending on the 
level of EPO receptor (EPOR) expression (Beleslin-Cokic et al., 2004). Erythropoietin 
acts on the EPORs in erythroid progenitor cells essential for erythropoiesis and, however, 
EPOR expression and biologic response to EPO have been observed in endothelial, 
neural, muscle, cardiac, and other cell types eliciting nonhematopoietic effects of EPO 
(Anagnostou, Lee, Kessimian, Levinson, & Steiner, 1990; Anagnostou et al., 1994; 
Ammarguellat, Gogusev, & Drüeke, 1996; Morishita, Masuda, Nagao, Yasuda, & Sasaki, 
1997; Ogilvie et al., 2000; Smith, Bleyer, Little, & Sane, 2003; Wu, Lee, Gao, Liu, 
Iruela-Arispe, 1999; Yasuda et al., 1998; Yu et al., 2002). It has been noted that EPO has 
the potential to elicit beneficial effects on cardiovascular function (Smith et al., 2003). 
Parsa et al. (2003) noted cardioprotective effects of EPO by protecting cardiomyocytes 
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against ischemic injury. The beneficial effects were observed without an increase in Hct, 
demonstrating that EPO can directly protect the ischemic and infarcted heart (Parsa et al., 
2003). 
In endothelial cells, EPO has been reported to act on EPOR and increase the 
quantity of functionally active endothelial progenitor cells (EPCs) resulting in enhanced 
angiogenesis (Bahlmann et al., 2003; Heeschen et al., 2003). Endothelial and 
hematopoietic cell lineages share common progenitors, and therefore cytokines such as 
EPO that are typically thought to be specific to hematopoiesis, have demonstrated to 
affect the functioning of endothelial cells, including angiogenesis (Ribatti et al., 1999). In 
addition, direct biological effects on mature endothelial cells have been observed, as EPO 
stabilizes endothelial structures and vascular integrity (Fliser & Bahlmann, 2008). 
Recombinant EPO treatment to various endothelial cell culture mediums has initiated an 
enhanced proliferation and migration of endothelial cells as well as protects the cells 
against ischemia and apoptosis (Anagnostou et al., 1990; Carlini et al., 1999; Chong, 
Kang, & Maiese, 2002). Furthermore, human endothelial cell lineages have been shown 
to respond to rHuEPO administration by significantly enhancing their differentiation into 
vascular structures (Carlini, Reyes, Rothstein, 1995; Ribatti et al., 1999). Ribatti et al. 
(1999) noted that EPO acts as a direct angiogenic factor due to the ability to interact 
directly with the endothelial cells resulting in an angiogenic response in vitro and in vivo. 
 Endothelial progenitor cells derived from the bone marrow originate from CD34+ 
hematopoietic stem cells (Bahlmann et al., 2003). Erythropoietin has been reported as a 
strong stimulator of endothelial progenitor cell (EPC) proliferation and differentiation 
mediated in large part due to the activation of the EPOR on the EPCs (Asahara et al., 
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1999; Dzau, Gnecchi, Pachori, Morello, Melo, 2005; Heeschen et al., 2003). The role 
EPO provides as a regulator of vascular protection and formation is supported by 
previous research (Bahlmann et al. 2003; Bahlmann et al., 2004) that observed rHuEPO 
and darbepoietin alpha increase the quantity of endothelial progenitor cells (EPCs) from 
the bone marrow of humans (Fliser & Bahlmann, 2008). Endothelial progenitor cells are 
believed to have endothelial repair capabilities and promote regeneration of endothelial 
cells (Asahara et al., 1999; Dzau et al., 2005). The EPCs are important in 
neovascularization of ischemic tissues and in re-endothelialization of injured blood 
vessels (Dzau et al., 2005). Moreover, Heeschen et al. (2003) observed that serum levels 
of EPO and vascular endothelial growth factor were significantly associated with the 
number of stem and progenitor cells in the bone marrow as well as the number and 
function of circulating EPCs in peripheral blood of EPO treated mice.  
Nitric Oxide 
Endothelial cells and nitric oxide. Nitric oxide (NO) is a potent vasodilator that is 
produced by the endothelial cells from the amino acid L-arginine by the enzymatic 
reaction of endothelial NO synthase (eNOS) (d’Uscio et al., 2007; Palmer, Ashton, & 
Moncada, 1988). Nitric oxide, which has a half-life in the blood of only 6 seconds 
(Guyton & Hall, 2000), plays an important role in cardiovascular homeostasis, including 
regulation of systemic blood pressure and blood flow, endothelial repair and angiogenesis 
(Dimmeler et al., 1999). The endothelial cells lining the arterioles and small arteries 
synthesize NO to regulate the degree of relaxation or contraction of the arterial wall 
(Guyton & Hall, 2000). Endothelial regulation of vasomotor tone is largely influenced by 
NO, and decreasing NO bioavailability is recognized as contributing to the initiation and 
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progression of endothelial dysfunction in vascular disease (d’Uscio et al., 2007; Harrison, 
1994). Shear stress acting on the vascular endothelium by blood flow represents a 
recognized stimulus for the continuous production of NO (Dimmeler et al., 1999; 
Klabunde, 2005). 
EPO signaling pathway.  Research has indicated that the effect of rHuEPO on 
EPCs is partially mediated by the activation of the Akt, serine/threonine protein kinase B, 
signaling pathway (Bahlmann et al., 2003; Bahlmann et al., 2004; Fliser & Bahlmann, 
2008). Once activated, Akt can directly phosphorylate eNOS, leading to NO production. 
The vasculo-protective effects of EPO are dependent on the activation of endothelial 
nitric oxide (eNOS) in EPCs (Fliser & Bahlmann, 2008). Research has established that 
the NO production from the EPCs is required for endothelial regeneration and repair 
(Fliser & Bahlmann, 2008; Urao et al., 2006). Urao et al. (2006) evaluated whether the 
mobilization of EPCs by rHuEPO promotes the repair of injured endothelium after wire 
injury of the femoral artery in mice. Their results indicated that a 3 day treatment of 
1,000 U·kg-1 of rHuEPO increased the circulating EPCs expressing an EPOR and that the 
mobilized EPCs induced a 1.4 fold increase in reendothelialization leading to the 
inhibition of neointimal hyperplasia in an NO-dependent manner (Urau et al., 2006). In 
addition, there was an upregulation in EPOR expression in the EPO-induced 
neoendothelium. Finally, EPO induced AKT/eNOS phosphorylation and NO synthesis in 
EPCs and inhibited apoptosis on wired-injured arteries (Urao et al., 2006).  
d’Uscio et al. (2007) evaluated the role that eNOS has in the vascular protective 
effect of EPO. They used a murine model of wire-induced injury of the carotid artery to 
observe the effect of EPO on endothelial repair and arterial wall architecture. They 
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administered 1,000 U·kg-1 of rHuEPO subcutaneously and biweekly for two weeks in 
wild type and eNOS deficient mice. Initially, the injured carotid arteries showed an 
impaired endothelium-dependent relaxation to acetylcholine which was associated with 
an increased medial cross sectional area. The results showed that EPO significantly 
reduced the medial cross-sectional area and the upregulation of phosphorylated eNOS 
was stimulated which improved endothelial-dependent relaxations to acetylcholine in the 
injured carotid arteries (d’Uscio et al., 2007). Previous research observed that high 
plasma levels of EPO in experimental animals resulted in increases in vascular NO 
production and enhanced NO-mediated endothelium-dependent relaxations (Kanagy, 
Perrine, Cheung, & Walker, 2003; Ruschitzka et al., 2000; Santhanam et al., 2005; Urao 
et al., 2006). This vasculo-protective effect of EPO may be the result of an increased 
hematocrit causing an increase in shear stress on the vascular walls which is a strong 
stimulus for eNOS and nitric oxide synthase (NOS) production in endothelial cells (Berk, 
Corson, & Peterson, Tseng, 1995; Ruschitzka et al., 2000). However, d’Uscio et al. 
(2007) observed after 3 days of EPO treatment the stimulation of the phosphorylation of 
eNOS without an increase in hematocrit. This indicated that EPO has a direct stimulatory 
effect on the endothelial cells through the upregulation of phosphorylated eNOS 
independent of hematocrit (d’Uscio et al., 2007). In contrast, these vasculo-protective 
effects via activation of eNOS were not seen in EPO receptor deficient mice. 
Furthermore, the eNOS deficient mice exhibited an increase in pulmonary hypertension 
and vascular injury. Therefore, these results suggest that the vasculo-protective effects of 
EPO are critically dependent on eNOS activation (d’Uscio et al., 2007). 
49 
 
Nitric oxide synthases (NOS). Nitric oxide, a small toxic molecule, is generated 
by cystolic or membrane-bound isoenzymes, called nitric oxide synthases (NOS) (Panaro 
et al., 2003). The three recognized mammalian forms of NOS, constitutive (cNOS or 
NOS3), inducible NOS (iNOS or NOS2), and neural NOS (nNOS or NOS1), catalyze the 
production of NO by the same biochemical pathway (Klabunde, 2005; MacMicking, Xie, 
Nathan, 1997). The pathway begins with the oxidation of one molecule of L-arginine at 
the terminal guanidine nitrogen atoms to produce the intermediate Nω-OH-L-arginine, 
which is oxidized further to produce one molecule of NO and L-citrulline (MacMicking 
et al., 1997; Panaro et al., 2003). The reaction yields several co-substrates including a 
total of 1.5 molecules of nicotinamide adenine dinucleotide phosphate (NADPH) and two 
molecules of dioxygen, as well as co-factors, such as tetrahydrobiopterin (BH4), 
calmodulin (CaM), and the flavins, flavin mononucleotide (FMN) and flavin adenine 
dinucleotide (FAD) (MacMicking et al., 1997; Stuehr, 1999).  
The two distinct isoforms of NOS are the constitutive enzyme (cNOS) and the 
cytokine-inducible isoform (iNOS or NOS1), which differ with respect to their 
expression patterns, tissue distribution, method of regulation, the production levels of 
NO, and biological roles (MacMicking et al., 1997; Panaro et al., 2003). Under normal, 
basal conditions, cNOS is responsible for producing NO cloned in both endothelial 
(eNOS or NOS3) and the nervous system (nNOS or NOS1). The activity of cNOS is 
calcium (Ca2+) dependent, whereas iNOS is Ca2+ independent (Klabunde, 2005; Panaro et 
al., 2003). Endothelial NOS (eNOS) is a membrane-bound isoform cloned from 
endothelial cells which is associated with NO production to regulate vascular tone and 
platelet aggregation. Neural NOS (nNOS) is a cystolic NOS that serves as a 
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neurotransmitter in the brain and in different nerves of the peripheral nervous system; and 
its messenger ribonucleic acid (mRNA) has been identified in skeletal muscle (Bredt et 
al., 1991; Janssens, Shimouchi, Quertermous, Bloch, & Block, 1992; Klabunde, 2005; 
Nakane, Schmidt, Pollock, Förstermann, & Murad, 1993).  
Under normal, basal conditions, NO derived from cNOS is continually being 
produced in relatively small amounts for short periods, in a pulsatile manner. The 
production of NO from cNOS is Ca2+ and CaM dependent after the cNOS pathway is 
stimulated. An increased stimulation of cNOS involves a rapid increase in NO levels 
followed by a rapid decline in NO when the Ca2+ levels subside demonstrating a pulsatile 
release necessary for the physiological regulation of NO (Klabunde, 2005; Panaro et al., 
2003). Stimulation of the cNOS can be executed by two basic pathways in a Ca2+ 
dependent manner which involves the release of Ca2+ from the subsarcolemmal storage 
sites of the endothelial cell. First, blood flow generates shearing forces against the walls 
of the vascular endothelium that initiates the release of Ca2+ followed by the activation of 
cNOS and subsequent release of NO from the endothelial cell. Nitric oxide production 
through this pathway is blood flow dependent; as blood flow increases the production of 
NO will increase (Klabunde, 2005). Secondly, the stimulation of endothelial receptors for 
a variety of vasoactive substances (Klabunde, 2005), such as EPO (Fliser & Bahlmann, 
2008), acetylcholine, bradykinin, substance-P, adenosine, and others, can stimulate cNOS 
(Klabunde, 2005).  
Inducible NOS (iNOS or NOS2) represents the other isoform of endothelial NOS, 
however, in contrast to cNOS, activation of iNOS is Ca2+ independent (Klabunde, 2005; 
Panaro et al., 2003). At rest, iNOS activity is very low (Klabunde, 2005) and others have 
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reported iNOS to be absent in resting cells (Panaro et al., 2003). However, during 
inflammation, NO production by iNOS may elevate to a 1,000-fold greater level than the 
NO produced by cNOS (Klabunde, 2005). The activity of iNOS is strong during 
inflammation by cytokines such as tumor necrosis factor (TNF) and interleukins and 
other immunological or microbial stimuli, such as bacterial endotoxins including 
lipopolysaccharide (LPS) of Gram-negative bacteria (Klabunde, 2005; MacMicking et 
al., 1997; Panaro et al., 2003). Additionally, iNOS is regulated by a variety of molecules 
at transcriptional and posttranscriptional levels (MacMicking et al., 1997).  
Macrophages and nitric oxide. Inducible NOS is expressed in cells in a wide 
variety of settings, including macrophages and neutrophils participating in immune 
responses, and a variety of mammalian cells, including fibroblasts, keratinocytes, 
endothelial and vascular smooth muscle cells (Bogdan, 2000; Panaro et al., 2003; Stuehr, 
1999). Additionally, the potentially toxic molecule, NO, has been shown to elicit various 
effects including regulation of vascular tone, cell apoptosis, modulation of immune 
responses, killing of microbial pathogens, tumoricidal activity, cytotoxic and tissue 
damaging in autoimmune diseases (Bogdan, 2000; Brüne, von Knethen, & Sandau, 1998; 
Fang, 1997; MacMicking et al., 1997; Panaro et al., 2003). Moilanen et al. (1997) noted 
that NO production is involved in the maintenance of the inflammatory process and 
regulator of inflammatory cell functioning, a regulator of osteoclast function, a stimulator 
of angiogenesis, and in the activation of inflammatory transcription factor. Inducible 
NOS (iNOS) expression in macrophages is regulated by cytokines and microbial products 
mainly through transcriptional induction (MacMicking et al., 1997). Inducible NOS 
(iNOS) has been observed in macrophages in a variety of mammalian species, such as 
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human, horse, cow, goat, sheep, rat, mouse and chicken (MacMicking et al., 1997). In 
humans, iNOS is primarily documented in monocytes or macrophages from patients with 
infectious or inflammatory diseases (MacMicking et al., 1997). When NO production is 
maintained, macrophages are provided with cytostatic or cytotoxic activity against 
viruses, bacteria, fungi, protozoa, helminthes, and tumor cells (MacMicking et al., 1997). 
The production of NO from activated murine macrophages to act as a significant 
microbial mediator has been well explained. Research has accumulated in regards to the 
regulation and function of induced NO in human macrophages. Human monocytes do not 
produce large amounts of NO when activated in vitro as seen in the murine model; 
however, both iNOS expression and NO production have been documented in a variety of 
human diseases or disorders (Kröncke, Fehsel, & Kolb-Bachofen, 1998; Panaro et al., 
2003). Human monocytes and macrophages have demonstrated expression of iNOS 
mRNA after stimulation with lipopolysaccharide (LPS) and interferon-gamma (IFN-γ) 
(Reiling et al., 1994). The stimulation of iNOS and the subsequent release of NO have 
been observed in human macrophages after infection with Micobacterium avium, human 
immunodeficiency virus type-1 or L major after cross-linking of CD23 or CD69 surface 
antigens (Moilanen et al., 1997). However, some studies that use tissue staining with 
CD23 antibody did not find positively stained cells, thus suggesting the existence of 
several distinct activation mechanisms, leading to iNOS induction in human macrophages 
(Moilanen et al., 1997). Panaro et al. (2003) noted that research has demonstrated that 
regulation of iNOS induction in macrophages involves a delicate balance between host-
derived cytokines, microbial products and other factors present in the microenvironment. 
Additionally, the authors described that the most distinctive feature of iNOS expression is 
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its important regulation by activating cytokines, such as IFN-γ, TNF-α, GM-CSF, or 
inhibitory cytokines, such as transforming growth factor (TGF-β) produced by different 
T-helper subsets and interleukins 4, 10, 13 (Panaro et al., 2003). 
Nitric oxide and blood flow. Nitric oxide serves as an important signal molecule 
to the vascular endothelium to facilitate vasodilation for the regulation of blood flow and 
reducing vascular resistance (Joannides et al., 1995; Klabunde, 2005). Nitric oxide, 
synthesized from the amino-acid L-arginine through the action of NOS (Palmer et al., 
1988) is lipid soluble. Therefore, when NO is produced by vascular endothelium, it can 
rapidly diffuse into the tunica media of the vascular smooth muscle cells adjacent to the 
endothelium where it binds to the enzyme guanylyl cyclase (Ignarro, Adams, Horwitz, & 
Wood, 1986; Klabunde, 2005; Maiorana, O’Driskoll, Taylor, & Green, 2003). This 
enzyme catalyzes the conversion of guanosine triphosphate (GTP) to cyclic guanosine 
monophosphate (cGMP), which plays a role as a second messenger for signaling smooth 
muscle relaxation and vascular dilation (Furchgott & Jothianandan, 1991; Klabunde, 
2005).  
Under basal conditions, low levels of NO are continuously produced (Klabunde, 
2005; Maiorana et al., 2003) in order to influence the basal vasomotor tone in the 
peripheral and coronary circulation (Duffy, Castle, Harper, & Meredith, 1999; Lefroy, 
Crake, Uren, Davies, & Maseri, 1993; Vallance, Collier, & Moncada, 1989). The 
vasomotor tone operates with a delicate balance between the dilator and constrictor 
influences (Maiorana et al., 2003). Various methods using pharmacological and 
physiological stimuli can be used to stimulate NO bioactivity to facilitate vasomotor tone 
(Maiorana et al., 2003). Inhibitors of NO production have been used in research to 
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examine ambient NO bioactivity (Mairorana et al., 2003). Initial research in this area was 
performed by Vallance, Collier, & Moncada (1989) who infused the arginine analogue 
NG-monomethyl-L-arginine (L-NMMA) into humans to inhibit eNOS and the subsequent 
production of NO, thus causing vasoconstriction. In contrast, endothelium-dependent 
vasodilators, such as acetylcholine (ACh) can be used to promote the release of NO from 
endothelial cells, resulting in vasodilation (Maiorana et al., 2003). Additionally, L-
arginine administration, the precursor to NO, has been used in numerous studies to 
augment the production of nitric oxide to increase vasodilation. Shear stress acting on the 
vascular endothelium provides a potent physiological stimulus for NO production 
(Maiorana et al., 2003). In an attempt to normalize potentially high shear forces, the 
endothelium acts as a mechanotransducer (Hutcheson & Griffith, 1991; Rubanyi, 
Romero, & Vanhoutte, 1986) to increase the vasodilator mechanisms (Maiorana et al., 
2003).   
During exercise, shear stress forces on the vascular walls are increased.  Maiorana 
et al. (2003) noted that exercise training consisting of repeating bouts of physical activity 
involves repeated exposure to significant changes in cardiovascular hemodynamics. 
Physiologically, the body acts to increase blood flow to the working tissues delivering 
oxygen and nutrients. Blood flow to working muscles can increase as much as 50- to 100- 
fold in response to acute exercise (Andersen & Saltin, 1985; Walløe & Wesche 1988). 
Numerous mechanisms interact collectively to increase blood flow for efficient delivery 
of blood to the active muscles. The mechanical action of contraction and relaxation of 
skeletal muscle as exercise is initiated generates an immediate increase in blood flow to 
the active muscle tissue, commonly referred to as a “muscle-pump” (Laughlin, 1987). 
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The continuation of muscle activity stimulates the release of vasoactive metabolites 
(Maiorana et al., 2003), including NO (Kobzik, Reid, Bredt, & Stamler, 1994) from the 
tissue, into the interstitial fluid and act directly on terminal arterioles (Maiorana et al., 
2003).  
In addition to diffusing into the vascular smooth muscle cells upon release from 
the endothelium, NO can rapidly diffuse into the blood where it binds to Hb (Klabunde, 
2005). Nitric oxide transported via the blood bound to hemoglobin may stimulate 
vasodilation of the terminal arterioles when it is released (Gow & Stamler, 1998; Segal & 
Kurjiaka, 1995). A proposed mechanism for Hb to provide vascular regulation of blood 
flow to specific tissues via NO transport and release involves: Hemoglobin (Hb) changes 
shape upon oxygenation in the lungs allowing it to accept S-nitrohemoglobin (SNO) that 
does not attach to the iron of the Hb, then the release of oxygen from the Hb to the local 
tissues causes the Hb to change shape once again, stimulating the release of NO and 
subsequent vasodilation (Gladwin et al., 2000; Jia, C. Bonaventura, J. Bonaventura, & 
Stamler, 1996; McArdle et al., 2001). As the demand for oxygen increases and the 
amount of oxygen released from Hb is accelerated, there should be an increase in NO 
released from Hb causing a more distinct vasodilation and resultant enhanced oxygen 
delivery. Therefore, Hb plays a role in the regulation of tissue blood flow relative to 
oxygen demand (McArdle et al., 2001).  
 The local mechanisms for controlling tissue blood flow, such as the metabolites 
with vasoactive properties, stimulate vasodilation only in the very small microvessels 
because the vasodilator substances can only reach these and not the progressively larger 
vessels upstream (Guyton & Hall, 2000). The significant increases in blood flow changes 
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that occur during exercise are the result of more than the metabolic vasodilation (Segal, 
1992). Therefore, a secondary mechanism, the principle of ascending vasodilation, has 
been proposed to occur consisting of coordinated dilation beginning in the microvessels 
and transmitted proximally to the larger feed arteries as metabolic demand increases 
(Green, O’Driscoll, Blanksby, & Taylor, 1996; Segal, 1992). This proposed mechanism 
suggests that, after the onset of exercise, the endothelial cells of the terminal vessels 
release metabolic vasodilator substances that stimulate vasodilation of the local vessels, 
thus increasing blood flow velocity through the upstream larger vessels (Folkow, 
Sonnenschein, & Wright, 1971). The increase in blood flow increases shear stress on the 
endothelial cells of the upstream vessels (Koller & Kaley, 1991) because of the viscous 
drag of the blood against the vascular walls (Guyton & Hall, 2000), thus stimulating an 
increased release of NO and inducing feed artery vasodilation (Maiorana et al., 2003). 
This proposed mechanism explains the magnitude of exercise hyperemia that has been 
observed by linking the downstream metabolic vasodilation of microvessels with dilution 
of upstream larger vessels that are not in contact with the metabolic vasodilator 
substances, but respond to changes in localized hemodynamics (Maiorana et al., 2003) 
and are dependent upon an increase in NO bioactivity (Joannides et al., 1995). In 
response to prolonged aerobic exercise, indirect evidence for the role NO plays in 
exercise hyperemia in humans is provided by the increased levels of plasma nitrite (NO2-) 
(Ambring, Benthin, Petersson, Jungersten, & Wennmalm, 1994) and urinary nitrate  
(NO3-) (Bode- Böger, Böger, Schröder, & Frölich, 1994; Maiorana et al., 2003). 
 
 
57 
 
Nitric Oxide and Exercise Performance.  
In response to exercise, skeletal muscle arterioles vasodilate to enhance the 
delivery of oxygen and nutrients to the active tissues (Maxwell et al., 2001). Previous 
work investigating the role of endothelium-derived nitric oxide (EDNO) as an 
endogenous vasodilator in response to exercise has demonstrated differing results (Dyke, 
Proctor, Dietz, & Joyner, 1995; Hirai, Visneski, Kearns, Zelis, & Musch, 1994; Hussain, 
Stewart, Ludemann, & Magder, 1992; Maxwell et al., 2001; Maxwell, Schauble, 
Bernstein, & Cooke, 1998; O’Leary, Dunlap, & Glover, 1994; Persson, Gustafson, 
Wiklund, Hedqvist, & Moncada, 1990). Persson, Gustafson, Wiklund, Hedqvist, & 
Moncada (1990) observed that hyperemia in response to electrically stimulated 
contraction of rabbit tenuissimus muscle was unaffected by infusion of the NOS 
inhibitor. Also, Wilson & Kapoor (1993), showed that forearm exercise hyperemia in 
response to graded rhythmic handgripping was unaffected by the NOS inhibitor NG-
monomethyl-L-arginine (L-NMMA). In contrast, Dyke, Proctor, Dietz, & Joyner (1995) 
demonstrated a reduction in forearm muscle blood flow during repetitive handgripping 
exercises in humans with infusion of NOS blockers (L-NMMA). Similarly, Hirai, 
Visneski, Kearns, Zelis, & Musch (1994) reported that NOS inhibition in rats during 
treadmill exercise reduced blood flow and blunted vasodilation in muscles within and 
around the rat’s hindquarters suggesting that exercise hyperemia is dependent on EDNO 
release. Hussain, Stewart, Ludemann, & Magder (1992) reported that NOS blockers 
reversed vasodilation during diaphragmatic contractions in canines. Additionally, 
O’Leary, Dunlap, & Glover (1994) reported that NOS inhibition in conscious dogs 
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reduced hind limb hyperemia during low-intensity but not high-intensity exercise on the 
treadmill.  
Exercise capacity. Research supports that exercise capacity as well as exercise 
hyperemia, is dependent on the integrity of the NOS pathway (Maxwell et al., 2001). A 
number of studies have demonstrated that the restoration of EDNO activity can reverse 
the endothelial dysfunction that occurs in heart failure, resulting in enhanced blood flow 
and exercise capacity (Hambrecht et al., 2000; Hornig, Maier, & Drexler, 1996; Katz, 
Krum, Khan, & Knecht, 1996; Kubota, Imaizumi, Oyama, Ando, Takeshita, 1997; Rector 
et al., 1996). Maxwell et al. (2001) described that these measures that the researchers 
used to restore EDNO activity are also likely to enhance cardiac function in the heart, and 
this may contribute to improved exercise capacity (Maxwell et al., 2001).  
Maxwell, Schauble, Bernstein, & Cooke (1998) reported that EDNO contributes 
to exercise hyperemia and it is a determinant of aerobic capacity in exercising mice. The 
researchers observed an exercise-induced increase in blood flow to the hind limb muscles 
and an increase in post-exercise urinary nitrate (NO3-) secretion, a nitrogen oxide (NO2) 
used to assess EDNO production (Maxwell et al., 1998). The administration of the NOS 
inhibitor NG-nitro-L-arginine prevented these effects (Maxwell et al., 1998). The study 
also reported that hypercholesterolemic mice demonstrated a distinct reduction in post 
exercise urinary nitrate excretion, decreased endothelial vasodilator function, and 
decreased aerobic capacity (Maxwell et al., 1998). The investigators concluded that 
inhibition of EDNO activity distinctly inhibits exercise-induced blood flow to skeletal 
muscle thus a reduction in exercise capacity (Maxwell et al., 1998). Maxwell et al. (2001) 
reported that administration of L-arginine supplementation in hypercholesterolemic mice 
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normalizes exercise-induced EDNO activity and aerobic exercise capacity, as well as 
enhanced aerobic exercise capacity in normal mice. In hypercholesterolemic mice, the 
effect of L-arginine was likely due to its ability to restore EDNO synthesis and activity. 
In speculation, prolonged exercise may lead to NOS impairment due to a variety of 
mechanisms including L-arginine depletion in the region of NOS. This would be rate-
limiting to oxygen transport and aerobic capacity. Therefore, it is possible that L-arginine 
supplementation restores EDNO activity, thus improving aerobic exercise capacity in 
normal mice (Maxwell et al., 2001). These findings together with the findings of 
Maxwell et al. (1998) indicate that not only exercise hyperemia but also exercise capacity 
depend on the integrity of the NOS pathway (Maxwell et al., 2001). 
Echinacea 
Echinacea Science 
 Echinacea is a perennial plant native to North America (Goldhaber-Fiebert & 
Kemper, 1999). The Echinacea plant is indigenous to much of the United States, with 
locations varying by the plant species, but it is generally found in open meadows or damp 
locations such as woods, swamps, ditches, river banks and low-lying thickets (Echinacea, 
2001; Whitehead, 2006). The Echinacea plant has also been grown commercially in 
Germany since the 1930’s (Goldhaber-Fiebert & Kemper, 1999). Echinacea, from the 
Greek echinos, means hedgehog or sea-urchin because of its conical spiny seed heads 
(Goldhaber-Fiebert & Kemper, 1999). In addition, common names for Echinacea include 
purple coneflower, red sunflower, thimbleweed and Rudbeckia (Echinacea, 2001; 
Whitehead, 2006). The Echinacea plant is a member of the Asteraceae or Compositae 
family (Echinacea, 2001; Goldhaber-Fiebert & Kemper, 1999; Whitehead, 2006). There 
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are nine species of Echinacea that have been identified; the three species most often used 
medicinally being Echinacea angustifolia (narrow-leafed Purple Coneflower), Echinacea 
pallida (Pale Purple Coneflower), and Echinacea purpurea (Purple Coneflower) 
(Echinacea, 2001; Goldhaber-Fiebert & Kemper, 1999; O’Hara, Kiefer, Farrell, & 
Kemper, 1998; Whitehead, 2006). Medicinal products made from Echinacea pallida and 
Echinacea angustifolia are typically produced from the roots of these species. Whereas, 
products derived from Echinacea purpurea are most often produced from the juices of 
the fresh leaves, stems and flowers, although roots are sometimes included (Goldhaber-
Fiebert & Kemper, 1999; Schulz, Hansel, & Tyler, 1998; Whitehead, 2006). 
Description. Echinacea plants are herbaceous perennials reaching heights of 10-
60 cm (Goldhaber-Fiebert & Kemper, 1999; Whitehead, 2006). The stems of Echinacea 
angustifolia and pallida grow from a vertical taproot, whereas the stem of Echinacea 
purpurea grows from branched, fibrous roots (Goldhaber-Fiebert & Kemper, 1999; 
Whitehead, 2006). As members of the Compositae family, the flowering heads of the 
Echinacea plants are composed of a conglomeration of many tiny flowers (Goldhaber-
Fiebert & Kemper, 1999; Whitehead, 2006). The inner disc flowers of the plant end in 
spines, and are surrounded by droopy outer ray flowers that have teeth at their ends 
(Goldhaber-Fiebert & Kemper, 1999; Whitehead, 2006). The plant is characterized by 
spiny flowering seed heads that have an elevated receptacle that forms a cone-shape 
(Goldhaber-Fiebert & Kemper, 1999; Whitehead, 2006). The inner disc flowers range in 
color from green to red-brown, and the outer ray flowers are purple, pink or white 
(Goldhaber-Fiebert & Kemper, 1999; Whitehead, 2006). In addition, Echinacea plants are 
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resilient, drought resistant and grow slowly (Goldhaber-Fiebert & Kemper, 1999; 
Whitehead, 2006).  
History and Uses 
Echinacea was valued for centuries by the Native Americans of North America 
for its medicinal properties (Echinacea, 2001; O’Hara et al., 1998; Whitehead, 2006). The 
Plains Indians used the plant to treat fever and respiratory infections and the Delaware 
Indians used the plant to treat venereal disease (Goldhaber-Fiebert & Kemper, 1999; 
Tyler, 1993). It has been reported that the entire plant was mashed into a paste that was 
used topically to treat snake bites, stings, burns and swelling of the lymph glands 
(Goldhaber-Fiebert & Kemper, 1999; Whitehead, 2006). In addition, the roots of the 
plant were chewed or the juice was ingested to treat toothaches, sore gums and sore 
throats (Awang & Kindack, 1991; Whitehead, 2006). More specifically, Echinacea 
angustifolia was used therapeutically by Native Americans to remedy eye conditions, 
snake bites, insect stings, infected wounds, eczema, enlarged glands, mumps and rabies 
(Echinacea, 2001). The Native Americans also used Echinacea angustifolia as a 
painkiller for a variety of conditions from stomach aches to epilepsy (Echinacea, 2001; 
Whitehead, 2006). Native Americans introduced it to European colonists, who soon 
began to medicinally use Echinacea and send it back to the European markets 
(Goldhaber-Fiebert & Kemper, 1999; O’Hara et al., 1998; Whitehead, 2006). Later, in the 
1800’s Echinacea angustifolia was used as an all-purpose blood-purifier and an anti-
infective agent (Awang & Kindack, 1991; Whitehead, 2006). In addition, Echinacea was 
used to treat diphtheria, small pox, scarlet fever and meningitis (Goldhaber-Fiebert & 
Kemper, 1999). During the late 1800’s, Echinacea angustifolia was the most commonly 
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used plant remedy in the United States (Goldhaber-Fiebert & Kemper, 1999; Whitehead, 
2006). Echinacea use continued into the early 1900’s, where the plant was used by a 
group of physicians known as Eclectics, whose medicinal practice primarily relied on the 
use of plants and their disease healing properties (Echinacea, 2001). During this time, the 
Eclectics used Echinacea to treat a variety of kidney and urinary tract conditions, chronic 
bacterial infections, and syphilis (Wagner, 1996). Echinacea use in the United States 
during the 1920’s and into the 1930’s began to decline due to antibiotic development 
(Echinacea, 2001; Goldhaber-Fiebert & Kemper, 1999; Whitehead, 2006). Although the 
use of Echinacea was in a sharp decline, European demand for the herb grew 
significantly, and eventually became greater than the American supply (Goldhaber-
Fiebert & Kemper, 1999; Whitehead, 2006). In Germany, The Madaus Company 
imported Echinacea seeds from the United States to grow the plant commercially 
(Goldhaber-Fiebert & Kemper, 1999; Whitehead, 2006). The Madaus Company 
mistakenly received Echinacea purpurea seeds instead of the more commonly used 
Echinacea angustifolia seeds (Goldhaber-Fiebert & Kemper, 1999; Whitehead, 2006). As 
a result, Echinacea purpurea was used to make the products of The Madaus Company 
and most subsequent research on Echinacea has been performed with the Echinacea 
purpurea species (Goldhaber-Fiebert & Kemper, 1999; Whitehead, 2006). An herbal 
medicine renaissance in the 1980’s has led to renewed interests in the benefits of 
Echinacea (Echinacea, 2001). Echinacea research over the past two decades or more has 
focused on the immuno-stimulant properties (Echinacea, 2001). During this time, the 
anecdotal successes and scientific research has launched Echinacea into the top ranks of 
American herbal sales (Goldhaber-Fiebert & Kemper, 1999; Whitehead, 2006). 
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Currently, Echinacea is used predominately as a nonspecific immuno-stimulant and to 
prevent and treat upper respiratory tract infections (URTI); however the plant is also used 
as a primary or complimentary therapy to combat bacterial, viral, protozoan, and fungal 
infections and as an anti-inflammatory agent (Echinacea, 2001; Goldhaber-Fiebert & 
Kemper, 1999; Newall, Anderson, & Phillipson, 1996; Whitehead, 2006). 
Echinacea Supplementation  
 There is very limited research examining the effectiveness of Echinacea 
supplementation to enhance the measures of erythropoiesis and the parameters of 
endurance exercise performance. Whitehead et al. (2007) investigated the effects of 
Echinacea supplementation in humans on the serum concentrations of erythroid growth 
factors and measures of erythropoietic status over a four week supplementation period. 
The investigation was the first to show a significant increase in erythropoietin (EPO) that 
was attributable to four weeks of Echinacea supplementation (Whitehead et al., 2007). 
The increase in EPO from this study did not result in any significant changes in the 
measured indicators of erythropoietic status, including red blood cell (RBC) count, 
hemoglobin (Hb), and hematocrit (Hct). However, there were measurable nonsignificant 
increases in the erythropoietic status data possibly suggesting that erythropoiesis may 
have been initiated (Whitehead et al., 2007). To date, there are no studies that have 
evaluated the Echinacea-induced erythropoiesis associated with increased concentrations 
of EPO observed by Whitehead et al. (2007) for an extended time period, approximately 
six weeks (42 days). Additionally, there are no studies that have directly evaluated the 
efficacy of Echinacea supplementation in humans to increase peripheral plasma 
concentration of nitric oxide (NO). In addition to stimulating RBC production, there is 
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evidence indicating that EPO also has vasculo-protective effects (Fliser & Bahlmann, 
2008) through the activation of endothelial nitric oxide (eNOS) (Beleslin-Cokic et al., 
2004; d’Uscio et al., 2007). Based on the previously observed Echinacea-induced 
increase in serum EPO by Whitehead et al. (2007), alternative functions of EPO such as 
eNOS production may play a role in enhancing endurance exercise performance. 
Moreover, Echinacea supplementation has been shown to stimulate macrophage activity 
(Burger et al., 1997; Goel et al., 2002a, 2002b; Mishima et al., 2004; Rininger et al., 
2000; Roesler et al., 1991; Stimpel et al., 1984) and there is evidence indicating the 
production of nitric oxide in human macrophages (Panaro et al., 2003). Therefore, 
collectively, the data from several investigations provides indirect evidence that suggests 
that Echinacea supplementation may stimulate macrophage activity resulting in increased 
nitric oxide production. 
 Echinacea and maximal oxygen consumption. Szołomicki et al. (2000) 
investigated the effects of supplementation with either Echinacea or the active 
components of Eleutherococcus senticosus, contained in Taiga Wurzel preparation, on 
cellular defense and physical fitness in 50 healthy volunteers of both sexes (Szołomicki et 
al., 2000). The subjects were randomly subdivided into two groups with 35 subjects 
receiving Taiga Wurzel and 15 subjects receiving Echinacea. Twenty healthy male 
subjects were randomly selected from both groups for ergospirometric evaluation. The 
Echinacea group was supplemented three times daily for 30 days with 40 drops of 80 g of 
Echinacea purpurea fresh juice in 100 g of the final product containing 22% ethanol 
(Szołomicki et al., 2000). The results indicated that oral administration of Echinacea for 
one month in humans showed a nonsignificant 5% increase in maximal oxygen 
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consumption from the initial V˙ O2max of 35.03 ± 5.5 mL·kg-1·min-1 to a final V˙ O2max of 
36.91 ± 7.63 mL·kg-1·min-1 (Szołomicki et al., 2000). It is important to note that the 
principle aim of the study by Szołomicki, Samochowiec, Wójcicki, & Droździk (2000) 
was to evaluate the influence of active components of Eleutherococcus senticosus, 
contained in Taiga Wurzel, on cellular resistance and physical fitness and not the 
assessment of Echinacea supplementation. Moreover, the study did not involve the 
evaluation of any measures of erythropoietic status (Whitehead, 2006). 
Echinacea on Erythroid Growth Factors and Erythropoietic Status 
 Echinacea induced erythropoiesis. O’Neill, McKee, & Clarke (2002) conducted a 
study to collect new data on the efficacy of Echinacea supplementation in stimulating the 
immune system of the horse. The design of the study consisted of a double-blind, 
placebo-controlled, randomized, cross-over trial, involving eight healthy horses. For a 
period of 42 days, the horses received either 30 mL of Echinacea or placebo as a top-
dress on their normal feed. The experimental supplement used was prepared from a 
powdered extract of Echinacea angustifolia root and standardized to 4% echinacoside; in 
other words, a 1:3 powdered root extract equivalent to 3000 mg crude powdered root. 
The Echinacea powder was suspended in a USP-sucrose and USP-water solution to a 
final concentration of 1,000 mg standardized extract for each 30 mL dose (O’Neill et al., 
2002). At the conclusion of the 42 day supplemental period, there was a 14 day wash-out 
phase in which the horses did not receive any supplementation and no research sampling 
was conducted. The wash-out phase was followed by a cross-over trial for a further 42 
days. Blood sampling was collected weekly during each sampling trial period at days 0, 
7, 14, 21, 28, 35, and 42. The samples were collected each sampling day between 08.30 
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and 09.30 hours with baseline values for all blood parameters established from the Day 0 
samples. Samples were analyzed to determine the effect of Echinacea on the phagocytic 
ability of isolated neutrophils and blood profiles, including RBC, Hb, Hct, mean 
corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and mean 
corpuscular hemoglobin concentration (MCHC). It was reported that Echinacea 
supplementation showed increases over time in RBC number and in MCV, with 
concurrent increase in Hb concentration and Hct (O’Neill et al., 2002). The results 
indicated that 21 days of supplementation with Echinacea significantly increased RBC 
count and Hb as compared to the control group. The mean change over time in RBC 
count and Hb from Days 0 to 42 were significantly increased in the treatment group 
compared to the control group (O’Neill et al., 2002). These results indicate that 
Echinacea supplementation in the equine model after 21 days significantly increases the 
hematological measures of erythropoiesis status by increasing Hb levels and the number 
of erythrocytes and the effects can be observed for a minimum of 42 days. It must be 
noted that only the significant differences from the data between the treatment and 
control groups of this study were reported graphically as percent change and the actual 
values were not provided in the paper (Whitehead, 2006).  
The effects of Echinacea supplementation on RBC and Hb levels observed by 
O’Neill et al. (2002) suggests that parameters of exercise physiology and exercise 
performance may be enhanced by administration of this herbal plant. Erythropoiesis is 
stimulated by an increase in the concentration of EPO, thus resulting in erythrocythemia 
and improving the oxygen transport capacity to the tissues (Gledhill, 1985; Guyton & 
Hall, 2000). Induced erythrocythemia has been shown to increase the oxygen transport 
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capacity and ultimately improve the maximal oxygen consumption (V˙ O2max), running 
economy, and aerobic performance times (Brien & Simon, 1987; Buick et al., 1998; 
Ekblom, 1996; Gledhill, 1982; Gledhill, 1985; Williams et al., 1981).  
Echinacea and Erythropoietin. Echinacea supplementation in humans has been 
shown to increase serum EPO levels (Whitehead et al., 2007). Whitehead et al. (2007) 
conducted a study to investigate the effects of 28 days of oral Echinacea supplementation 
in humans on serum concentrations of erythroid growth factors and markers of 
erythropoietic status. The study included a randomized-match and double-blind design 
with subjects placed in either an Echinacea or placebo experimental group and 
supplemented for 28 consecutive days. Twenty-four apparently healthy, recreationally 
active male students between 18-30 years of age participated in the study. The first 12 
subjects were randomly assigned to one of the two experimental groups, and subjects 13-
24 were grouped in a balance manner based on RBC count by a reliable source outside of 
the research team. Supplementation involved self-administration of either 8,000 mg·day-1 
of Echinacea purpurea or placebo (wheat flour). The daily dosage was administered 
orally with five 400 mg capsules on four separate occasions throughout the course of 
each day (Whitehead et al., 2007). This dose and protocol was similar to those utilized in 
previous research (Berg et al., 1998; Szołomicki et al., 2000). In addition, a multivitamin 
was taken orally for 28 consecutive days. Blood samples were collected on Day 0 to 
provide a baseline for comparison with subsequent blood samples taken on Days 7, 14, 
21, and 28 during the 28 day supplementation period (Whitehead et al., 2007). Blood 
samples were collected by venipuncture and each sample was collected between 6:00 – 
9:00 a.m. after a 12 hour fast. Whole blood samples for each group were collected and 
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analyzed for RBC count, Hb, Hct, MCV, and MCHC. Serum samples were collected, 
processed, and stored for analyses of ferritin, EPO, prostaglandin E2 (PGE2), interleukin-3 
(IL-3), and granulocyte-macrophage colony stimulating factor (GM-CSF) (Whitehead et 
al., 2007). The major finding of the investigation by Whitehead et al. (2007) was a 
significant increase in serum EPO at Days 7 (44%), 14 (63%), and 21 (36%) of the 
supplementation period in the Echinacea group that was significantly greater than the 
serum EPO in the placebo group. This was the first study to report a significant increase 
in serum EPO in response to oral Echinacea supplementation in human or animal subjects 
(Whitehead et al., 2007).  
An interesting finding of the study by Whitehead et al. (2007) was that the 
significant increase in serum EPO was not accompanied with any statistically significant 
alterations in measures of erythropoietic status, including RBC counts, Hb, and Hct. 
However, there were nonsignificant increases in the erythropoietic data, such as percent 
changes in RBC count, Hct, Hb, and MCV, which suggest that erythropoiesis may have 
been initiated. Graphical depiction of the percent change of the data for these 
erythropoietic markers in this study display a spike in the Echinacea group corresponding 
to the last blood sample collected on Day 28, upon completion of the 28 day 
supplementation period. These peak levels ascend from the previous blood samples 
collected on Day 21. Numerically, the specific values for RBC count, Hb, Hct, and MCV 
from the Echinacea group increase dramatically from Day 21 to Day 28 relative to the 
previous values between Days 0, 7, 14, and 21. Red blood cell count (baseline = 4.70 × 
1012·L-1) for the Echinacea group increased from Day 21 (4.71 × 1012·L-1) to Day 28 
(4.78 × 1012·L-1). Hemoglobin values (baseline = 14.5 g·dL-1) for the Echinacea group 
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increased slightly on Day 21 (14.4 g·dL-1) to Day 28 (14.6 g·dL-1). Hematocrit (baseline 
= 41.9 %) increased from Day 21 (42.1%) to Day 28 (42.9%). Mean corpuscular volume 
(baseline = 89.1 μm3) climbed from Day 21 (89.5 μm3) to Day 28 (90.4 μm3) (Whitehead, 
et al., 2007). In comparison, the placebo group did not demonstrate any noticeable 
changes in RBC count, Hb, Hct, and MCV over the course of the study as did the 
aforementioned Echinacea group. It is important to emphasize that the data from the 
Echinacea group did not show statistical significance. Based on the data provided by the 
study, further evaluation of the markers beyond the 28 day investigation period may be 
beneficial to determine if there is a continuation of these increases in the erythropoietic 
status markers to significant levels associated with Echinacea supplementation. 
The increase in serum EPO reported from the investigation by Whitehead et al. 
(2007) is similar to the increase in serum EPO induced by hypoxic conditions through a 
live-high, train-low protocol (Chapman et al., 1998). The live-high, train-low 
investigations stimulated increased EPO production by spending 28 days living at a 
moderate altitude of 2,500 m combined with low altitude training at 1,250 m above sea 
level (Chapman et al., 1998). Chapman, Stray-Gundersen, & Levine (1998) observed a 
significant 30% increase in serum EPO in the responder group (12.5 mU·mL-1 at baseline 
to 16.2 mU·mL-1 after 14 days at altitude) and (13.7 mU·mL-1 at baseline to 15.4 
mU·mL-1 after 14 days at altitude) in the nonresponder group that returned to baseline 
values after return from altitude. Although the stimuli used to induce an increase in EPO 
production are different, the increases in serum EPO from the hypoxic investigations are 
similar in the magnitude and the time of response to the increased serum EPO observed 
in the Echinacea study (Ashenden et al., 2000; Chapman et al., 1998; Wehrlin et al., 
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2006; Whitehead et al., 2007). The production of EPO is closely associated with the 
demand of oxygen by the tissues (Fliser & Bahlmann, 2008). Lack of sufficient oxygen 
delivery to the tissues is the primary regulator of erythropoiesis (Guyton & Hall, 2000) 
and oxygen deficiency in the cells, or hypoxia, will stimulate an increase production of 
EPO to enhance RBC production (Guyton & Hall, 2000). A typical response to hypoxia 
is a gradual increase in serum EPO with maximum production reached after 1-3 days of 
exposure followed by a gradual decline approximately one week after the peak to a level 
that will maintain a sufficient number of RBCs for adequate tissue oxygenation 
(Berglund, 1992; Guyton & Hall, 2000). The Echinacea-induced EPO response observed 
by Whitehead et al. (2007) did not have the hypoxic stimulus and therefore functions 
through a different mechanism, however they did report a similar EPO response to that of 
the hypoxic stimulus utilized by altitude investigations.  
As mentioned previously, the investigation by Whitehead et al. (2007) reported 
that oral Echinacea supplementation resulted in a significant increase in serum EPO; 
however this was not accompanied by significant changes in the erythropoietic status 
measures such as RBC count, Hb, and Hct. The data did suggest that these measures may 
have been increasing upon cessation of the study and therefore erythropoiesis may have 
been initiated. This would indicate that the data collection time period might not have 
been adequate to yield significant results. Conversely, similar serum EPO values 
observed in hypoxia studies have yielded significant results in 27 days (Chapman et al., 
1998; Levine & Stray-Gundersen, 1997; Stray-Gundersen et al., 2001). It can be observed 
from the altitude-induced hypoxia investigations, that serum EPO levels reach maximum 
levels 2-3 days after exposure to hypoxic conditions, whereas the serum EPO levels 
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peaked around Day 14 of a 28 day Echinacea supplementation period. For the hypoxia 
studies spanning over 28 days, there would be approximately 25 days following the peak 
in levels in which erythropoiesis could develop and significant results may be observed 
(Berglund , 1992; Chapman et al., 1998; Stray-Gunderson et al., 2001). In contrast, the 
observed peak in Echinacea-induced serum EPO levels around Day 14 of the Echinacea 
supplementation period would allow for only 14 days to elicit any possible statistically 
detectable change in the measures of erythropoietic status (Whitehead et al., 2007). It has 
been noted that EPO acts on the mature stages of development of the erythroid progenitor 
cells to enhance the proliferation and development into mature red blood cells (Fisher, 
2003; Gregory & Eaves, 1977; Gregory & Eaves, 1978). As a result, it is possible that 
new RBCs could appear in circulation about five days after maximum EPO production 
(Guyton & Hall, 2000). The production of red blood cells from the initial stem cell stage 
will take much longer. It has been reported that it takes about 15 days for pluripotent 
hematopoietic stem cells to develop into circulating reticulocytes (Marieb & Hoehn, 
2010) and another 1-2 days for the circulating reticulocytes to develop into mature 
erythrocytes (Guyton & Hall, 2000; Marieb & Hoehn, 2010). Therefore, further 
evaluation of Echinacea supplementation utilizing an extended data collection period of 
six weeks; two more weeks beyond the four week supplementation demonstrated by 
Whitehead et al. (2007); may provide further insight to whether Echinacea-induced 
increases in EPO initiates erythropoiesis. Furthermore, this would allow for further 
observation of the measures erythropoietic status that showed a nonsignificant increase 
following the maximum increase in EPO levels about Day 14 over the course of the final 
14 days of the previously reported investigation.  
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Mechanisms of Echinacea-induced EPO Production   
Macrophages. Echinacea purpurea has been shown to stimulate macrophage 
activity (Burger et al., 1997; Goel et al., 2002a, 2002b; Mishima et al., 2004; Rininger et 
al., 2000; Roesler et al., 1991; Stimpel et al., 1984) and an increase in macrophage 
activity can stimulate the production of cytokines in vitro (Burger at al., 1997; 
Whitehead, 2006). Goel et al. (2002a) reported that alkylamides are one of the active 
constituents of the Echinacea purpurea plant that effectively stimulate alveolar 
macrophage function in healthy rats at a dose of 12 μg·kg-1·day-1. There was a significant 
increase in the phagocytic activity as well as the phagocytic index of the alveolar 
macrophages. In addition, the alveolar macrophages obtained from the rats gavaged 
orally with alkylamides produced significantly more tumor necrosis factor-alpha (TNF-α) 
and nitric oxide (NO) after an in vitro stimulation with lipopolysaccharide (LPS) than the 
control group and the other active components of Echinacea purpurea (Goel et al., 
2002a). Furthermore, Goel et al. (2002b) indicated that in vivo phagocytic activity of 
alveolar macrophages in rats was increased with increasing concentrations of Echinacea 
components. The results displayed a trend of increase in TNF-α and nitric oxide release 
by the alveolar macrophages after an in vitro stimulation with LPS. The investigation also 
demonstrated an enhanced release of cytokines in rat’s spleen macrophage in response to 
higher concentrations of Echinacea components (Goel at el., 2002b). Purified 
polysaccharides prepared from the Echinacea purpurea plant have also been shown to 
strongly activate macrophages in mice (Stimpel et al., 1984). Echinacea purpurea has 
been evaluated for its ability to stimulate the production of cytokines, such as IL-1, TNF-
α, IL-6 and IL-10, by normal human peripheral blood macrophages in vitro (Burger et al., 
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1997). The results of the investigation indicated that macrophages cultured in very low 
concentrations of Echinacea produced significantly higher levels of the cytokines 
compared to unstimulated cells (Burger et al., 1997). Moreover, it has been noted that 
Echinacea herb and root powders stimulated murine macrophage cytokine secretion as 
well as significantly enhance the viability and/or proliferation of human peripheral blood 
mononuclear cells (PBMCs) in vitro (Rininger et al., 2000). Echinacea-induced 
macrophage activation in this study was analyzed via macrophage-derived factors 
including TNF-α, IL-1α, IL-1β, IL-6, IL-10 and NO (Rininger et al., 2000).  
T-cells. The activation of natural killer T cells is known to stimulate the synthesis 
and release of GM-CSF and the erythroid progenitor growth factor IL-3 (Bickel et al., 
1988; Cuturi et al., 1989; Davignon et al., 1988; Fitzpatrick & Kelso, 1995; Oster et al., 
1989; Whitehead, 2006). Echinacea has been shown to enhance the activity of T cells 
(Mishima et al., 2004; Whitehead, 2006). Mishima et al. (2004) examined the protective 
effects of Echinacea purpurea administered to mice against radiation by evaluating 
changes in the peripheral blood cell count and peripheral blood antioxidant activity. The 
administration of Echinacea purpurea demonstrated a suppressive effect on radiation-
induced leucopenia, particularly on lymphocytes and monocytes, and resulted in a faster 
recovery of blood cell counts (Mishima et al., 2004). The radio-protective effects of 
immune activation by Echinacea purpurea was evaluated by analyzing T lymphocyte 
subsets in the peripheral blood following irradiation of the whole body of the mice 
(Mishima et al., 2004). It was noted that Echinacea purpurea activates macrophages to 
stimulate the production of IFN-γ in association with the secondary activation of T 
lymphocytes, resulting in a decrease in total immunoglobulin (IgG, IgM) production 
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(Mishima et al., 2004). The Echinacea-induced cytokines released from the macrophages 
in mouse peripheral blood activated helper T cells to proliferate. Furthermore, the 
activated macrophages in association with the secondary T lymphocyte activation 
increase the production of IFN-γ and stimulate the proliferation of cytoxic T cells and 
suppressor T cells (Mishima et al., 2004). The authors conclude that the T cell subsets 
CD 4 and CD 8 were more immunologically enhanced by Echinacea purpurea than 
helper T cells and suppressor T cells (Mishima et al., 2004; Whitehead, 2006).  
Interleukin-3 (IL-3). Echinacea supplementation in humans demonstrated a 
significant increase in serum IL-3 (Whitehead et al., 2007). Therefore, it is possible that T 
cell activity was initiated because activated T-cells are known to stimulate the secretion 
of the erythroid progenitor growth factor IL-3 secretion (Davignon et al., 1988; 
Fitzpatrick & Kelso, 1995) and Echinacea has been shown to increase the activity of T-
cells in vitro (Mishima et al., 2004). The process of erythropoiesis from the primitive 
pluripotent stem cell to the mature erythrocyte is regulated by several cytokines, 
including the erythroid progenitor growth factor IL-3 (Fisher, 2003). These erythroid 
progenitor growth factors act to generate commitment and maturation of the cells in the 
red cell lineage (Fisher, 2003). The differentiation of the pluripotent stem cell into the 
myeloid stem cell and the colony-forming unit-granulocyte, erythroid, monocyte, 
megakaryocyte (CFU-GEMM) is stimulated by growth factors including IL-3 (Fisher, 
2003). The CFU-GEMM is acted on by growth factors including GM-CSF and IL-3 to 
produce the specific colony-forming units for erythroid cell precursors (D’Andrea & Zon, 
1990; Fisher, 2003; Jacobs-Helber et al., 1997; Wu, Klingmüller, Besmer, & Lodish, 
1995).   
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Whitehead et al. (2007) reported a significant increase in serum IL-3 from 
preintervention values equal to 40% and 42% at Days 14 and 21, respectively, of a 28 day 
Echinacea supplementation period. The increase in serum IL-3 parallels the observed 
increase in serum EPO, which demonstrated a significant increase at Days 7 (44%), 14 
(63%), and 21 (36%) (Whitehead et al., 2007). The actions of the erythroid growth factor, 
IL-3, precede that of EPO, which acts on the later stages of the development of erythroid 
progenitor cells (Fisher, 2003). Erythropoietin acts primarily on the colony-forming unit-
erythrocyte (CFU-E) to cause these cells to proliferate and mature through the normoblast 
stage into reticulocytes and mature erythrocytes (Fisher, 2003; Gregory & Eaves, 1977; 
Gregory & Eaves, 1978). Erythropoietin acts synergistically with the growth factors 
including GM-CSF and IL-3 to induce the proliferation and maturation from the stage of 
burst-forming unit erythroid (BFU-E) and CFU-E to the normoblast stage of the 
erythrocyte development (Fisher, 2003; Lin et al., 1996; Wu, Liu, Jaenisch, & Lodish, 
1995). Therefore, EPO principally acts on apoptosis to reduce the rate of erythroid 
progenitor cell death in the bone marrow (Fisher, 2003). Whitehead et al. (2007) 
concluded that IL-3 might play a role in the process of Echinacea-induced EPO 
production. Echinacea has been shown to enhance the activity of T-cell function, and 
activated T-cells are known to stimulate GM-CSF and the erythroid progenitor growth 
factor IL-3 (Bickel et al., 1988; Cuturi et al., 1989; Davignon et al., 1988; Fitzpatrick & 
Kelso, 1995; Mishima et al., 2004; Oster et al., 1989). The authors suggest that the 
Echinacea supplementation might cause EPO production through the activation of 
macrophages and T-cells, which are known to stimulate the secretion of erythroid 
progenitor growth factors (Whitehead et al., 2007).  
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Prostaglandin E2 (PGE2). Research has indicated that Echinacea Purpurea 
stimulates macrophage activity (Burger et al., 1997; Goel et al., 2002a, 2002b; Mishima 
et al., 2004; Rininger et al., 2000; Roesler et al., 1991; Stimpel et al., 1984; Whitehead, 
2006). Activated macrophages are known to secrete a wide variety of biologically active 
compounds including cytokines, prostanoids, nitric oxide and oxygen radicals (Busam et 
al., 1991; Decker, 1990; Dieter et al., 1999; Duyster et al., 1993; Gallaird et al., 1992; 
Grewe et al., 1994). Furthermore, Prostaglandin E2 (PGE2) has been shown to enhance 
the production of erythropoietin (Boer et al., 2002; Fisher et al., 1980; Gross et al., 1976; 
Jelkmann et al., 1985; Kurtz, Jelkmann, Pfeilschifter, & Bauer, 1985; Ortega et al., 1984; 
Whitehead, 2006). An initial study by Gross, Brookins, Fink, & Fisher (1976), evaluated 
the erythropoietic effects of the renal prostaglandins in exhypoxic polycythemic mice and 
in isolated perfused dog kidneys. The results suggested the involvement of the renal 
PGE2 in erythropoietin production by the kidney (Gross et al., 1976). Fisher, Radtke, 
Jubiz, Nelson, & Burdowski (1980) proposed a model reporting a role of prostaglandins 
E and prostacyclin in kidney production of EPO and the activation of CFU-E by EPO. 
They further reported that prostaglandins E are involved in the mechanism of kidney 
production of EPO and the E-type prostaglandins are found to enhance the effects of EPO 
in activating CFU-E in the bone marrow (Fisher et al., 1980). A clinical trial of PGE2 to 
increase erythropoiesis in four patients with anemia of end stage renal disease reported an 
increment in peripheral BFU-E that was observed to return to baseline with cessation of 
PGE2 therapy (Ortega et al., 1984). Two of the four patients showed an increase in serum 
EPO with one of these demonstrating a significant increase in serum EPO (Ortega et al., 
1984). Kurtz, Jelkmann, Pfeilschifter, & Bauer (1985) examined the role of 
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prostaglandins in hypoxia-stimulated EPO production by cultured rat renal mesangial 
cells. The investigation demonstrated an increase in PGE2 production that accompanied 
an increase in EPO due to hypoxia (Kurtz et al., 1985). Prostaglandin E2 was also 
observed to enhance EPO production under normoxic conditions. Additionally, PGE2 was 
found to stimulate adenylate cyclase activity (Kurtz et al., 1985). The authors suggest that 
hypoxia stimulated EPO production by cultured rat renal mesangial cells is mediated by 
PGE2 (Kurtz et al., 1985). Furthermore, Jelkmann, Kurtz, Förstermann, Pfeilschifter, & 
Bauer (1985) studied whether hypoxia is a stimulus for in vitro prostaglandin synthesis in 
rat renal mesangial cell cultures which produce EPO in an oxygen-dependent manner. 
Prostaglandin E2 production was observed to be enhanced in hypoxic cell cultures 
(Jelkmann et al., 1985). The results of the investigation indicated that hypoxia is a 
stimulus for in vitro prostaglandin production (Jelkmann et al., 1985). More evidence for 
supporting the role of PGE2 to enhance EPO production was reported by Boer, Drayer, 
Rui, & Vellenga (2002). The underlying mechanism that erythroid colony formation in 
response to EPO stimulation is enhanced by costimulating the cells with PGE2 was 
further analyzed (Boer et al., 2002). The authors reported that similar studies have 
demonstrated that PGE2 enhancement of EPO-induced STAT5 transactivation is 
mediated by the cyclic adenosine monophosphate protein kinase response element 
binding protein pathway (Boer et al., 2002).  
As a result of the aforementioned literature, Whitehead et al. (2007) proposed that 
an increase in PGE2 production from Echinacea stimulated macrophages may enhance 
renal EPO production. The investigation by Whitehead et al. (2007) demonstrated that 
Echinacea supplementation in humans resulted in a peak in serum PGE2 at day 7 of a 28 
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day supplementation protocol; however, the percentage change in PGE2 was not 
significant. The peak in PGE2 preceded the significant increase in EPO observed at days 
7, 14, and 21 (Whitehead et al. 2007). As mentioned previously, Echinacea is known to 
stimulate macrophage activity (Burger et al., 1997; Goel et al., 2002a, 2002b; Mishima et 
al., 2004; Rininger et al., 2000; Roesler et al., 1991; Stimpel et al., 1984) and activated 
macrophages are known to secrete a wide variety of biologically active compounds 
including PGE2 (Busam et al., 1991; Decker, 1990; Dieter et al., 1999; Duyster et al., 
1993; Gallaird et al., 1992; Grewe et al., 1994) and PGE2 has been shown to enhance the 
production of erythropoietin (Boer et al., 2002; Fisher et al., 1980; Gross et al., 1976; 
Jelkmann et al., 1985; Kurtz et al., 1985; Ortega et al., 1984). Consequently, Whitehead 
et al. (2007) noted that it is possible that Echinacea increased PGE2 production from 
activated macrophages, which may have stimulated the significant increase in serum EPO 
(Whitehead et al., 2007).  
Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF). Granulocyte-
macrophage colony-stimulating factor (GM-CSF) is considered an erythroid progenitor 
growth inducer and the production is known to be stimulated by activated T-cells (Bickel 
et al., 1988; Cuturi et al., 1989; Davignon et al., 1988; Fitzpatrick & Kelso, 1995; Oster 
et al., 1989) which are known to be activated by Echinacea (Currier & Miller, 2001; 
Mishima et al., 2004). In addition, PGE2 is known to increase the production of 
granulocyte-macrophage colony-stimulating factor (GM-CSF) (Emond, Fortier, Murphy, 
& Lambert, 1998). Echinacea supplementation in humans demonstrated a noticeable 
nonsignificant increase in GM-CSF over the course of a 28 day supplementation period 
(Whitehead et al., 2007). The increase in GM-CSF paralleled the increase in serum IL-3 
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as well as the significant increase in serum EPO (Whitehead et al., 2007). Erythropoiesis 
is regulated by several growth factors including EPO, IL-3 and GM-CSF (Fisher, 2003) 
and EPO acts synergistically with several other growth factors including IL-3 and GM-
CSF to cause the maturation and proliferation of erythroid cell development (Fisher, 
2003). Therefore, the data provided by Whitehead et al. (2007) suggests that the 
significant increases in serum EPO and IL-3 as well as the noticeable nonsignificant 
increases in serum PGE2 and GM-CSF may support the proposed Echinacea-induced 
mechanism for enhanced serum EPO production following Echinacea supplementation. 
In addition, these data may provide supporting evidence for the noticeable nonsignificant 
erythropoietic status data that could strengthen the suggestion that erythropoiesis possibly 
was initiated during 28 days of Echinacea supplementation. 
Echinacea-induced Activation of Macrophages and Nitric Oxide 
 Nitric oxide (NO) is a potent vasodilator that plays an important role in the 
regulation of cardiovascular homeostasis, including regulation of systemic blood pressure 
and blood flow, endothelial repair and angiogenesis (Dimmeler et al., 1999). Research 
has indicated that human macrophages produce nitric oxide (Panaro et al., 2003). 
Furthermore, it has been reported that that inducible nitric oxide synthase (iNOS) is 
expressed in macrophages and neutrophils participating in immune responses, and a 
variety of other mammalian cells including endothelial and vascular smooth muscle cells 
(Bogdan, 2000; Panaro et al., 2003; Stuehr, 1999). Consequently, research has indicated 
that augmented nitric oxide production has been shown to enhance aerobic capacity and 
exercise performance (Maxwell et al., 2001).  
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As previously mentioned, Echinacea has been observed to stimulate macrophage 
activity, and macrophages have been shown to secrete a wide variety of biologically 
active compounds including cytokines, prostanoids, nitric oxide and oxygen radicals 
(Busam et al., 1991; Decker, 1990; Dieter et al., 1999; Duyster et al., 1993; Gallaird et 
al., 1992; Grewe et al., 1994). Moreover, an increase in nitric oxide production has been 
observed from Echinacea-stimulated macrophages in normal rats (Goel et al., 2002a, 
2002b). Rininger, Kickner, Chigurupati, McLean, & Franck (2000) examined the 
immunopharmacological activity of Echinacea on murine macrophages in vitro. 
Echinacea-induced macrophage activity was determined from measuring macrophage-
derived factors including TNF-α, IL-1α, IL-1β, IL-6, IL-10, and nitric oxide (Rininger et 
al., 2000). Treatment of murine RAW264.7 macrophage cells with Echinacea purpurea 
through a simulated digestive protocol resulted in the detection of immunostimulatory 
activity based on the production of TNF-α and NO as activation biomarkers (Rininger et 
al., 2000). In addition, the researchers demonstrated that the immune response was 
specific by intitiating a dose-response study that found that the Echinacea-induced 
stimulation of TNF-α and NO was dose-dependent and was statistically significant 
compared to digested placebo at doses as low as 5 μg·mL-1 for both biomarkers (Rininger 
et al., 2000). Furthermore, Echinacea-induced responses were defined and compared with 
bacterial lipopolysaccharide (LPS) (Rininger et al., 2000). Echinacea purpurea through 
simulated digestion and LPS produced time-dependent and dose-dependent induction of 
TNF-α, NO, IL-1α, IL-1β, and IL-6 with TNF-α and NO demonstrating the most 
sensitive results (Rininger et al., 2000). Based on the results the Echinacea-induced 
transient stimulation of macrophages to produce TNF-α, NO, IL-1, and IL-6 could serve 
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to enhance the immune response (Rininger et al., 2000; Roesler et al., 1991; Steinmüller 
et al., 1993). Rininger et al. (2000) noted that immunostimulatory characteristics of 
Echinacea are weaker and only temporary compared to LPS.  
Goel et al. (2002a) were the first to examine the in vivo immunomodulatory dose-
related effects of the three major components of Echinacea purpurea on alveolar and 
spleen macrophage function in healthy rats. The three components isolated and purified 
from Echinacea purpurea were alkylamides, cichoric acid, and polysaccharides (Goel et 
al., 2002a). Oral administrations of alkylamides at a dose of 12 μg·kg-1·day-1 for four 
days significantly increased the phagocytic activity as well as the phagocytic index of the 
alveolar macrophages (Goel et al., 2002a). In addition, this study evaluated the effects of 
Echinacea components on the alveolar macrophages ability to produce TNF-α and NO 
(Goel et al., 2002a). The results showed that the alveolar macrophages obtained from the 
rats gavaged with alkylamides produced a significant increase in TNF-α and NO after in 
vitro stimulation with LPS (Goel et al., 2002a). The same laboratory also evaluated the 
immunomodulatory effects of preparations of Echinacea containing its components 
alkylamides, cichoric acid, and polysaccharides at different concentrations (Goel et al., 
2002b). The results showed an increase in phagocytic activity of alveolar macrophages 
with increasing concentrations of the Echinacea components (Goel et al., 2002b). 
Following an in vitro stimulation with LPS, the effects of the Echinacea extracts on TNF-
α and NO release by the alveolar macrophages were evaluated (Goel et al., 2002b). These 
data demonstrated that stimulation with LPS produced a significant increase in the release 
of TNF-α and NO by the alveolar macrophages (Goel et al., 2002b). Increasing 
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concentrations of the three components generated a dose-related increase in NO 
production (Goel et al., 2002b). 
In addition to its phagocytic response to pathogens, alveolar macrophages have 
been shown to produce a variety of cytokines including IL-1, IL-6, TNF-α, and cytoxic 
products, such as reactive oxygen and nitrogen intermediates (Goel et al., 2002b; Sibille 
& Reynolds, 1990). Consequently, the research by et al. (2002a, 2002b) investigated the 
effects of Echinacea on alveolar macrophage function and its ability to produce TNF-α 
and NO (Goel et al., 2002b). Overall their laboratory demonstrated that oral 
administrations of Echinacea extracts to healthy rats with increasing concentrations of the 
Echinacea components resulted in an increase in the release of NO from the alveolar 
macrophages (Goel et al., 2002b). In addition, the alkylamides was the most active of the 
three Echinacea components in relation to its stimulating effect of TNF-α and NO 
production by the alveolar macrophages (Goel et al., 2002b). The release of NO by the 
alveolar macrophages is known as the leading mechanism by which alveolar 
macrophages destroy infectious agents (Ding, Nathan, & Stueher, 1988; Kaplan, 
Lancaster Jr, Basford, & Simmons, 1996). Therefore, the ability of Echinacea extracts to 
increase NO production in vivo is important (Goel et al., 2002a, 2002b). Overall, 
Echinacea has been shown to stimulate macrophage activity (Burger et al., 1997; Goel et 
al., 2002a, 2002b; Mishima et al., 2004; Rininger et al., 2000; Roesler et al., 1991; 
Stimpel et al., 1984) and activated macrophages are known to stimulate nitric oxide 
production (Panaro et al., 2003). Additionally, it has been reported that Echinacea can 
stimulate nitric oxide release by macrophages (Goel et al., 2002a, 2002b). Furthermore, 
research indicates that augmented nitric oxide production enhances aerobic capacity 
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(Maxwell et al., 2001). Thus, Echinacea supplementation in humans may increase aerobic 
capacity and exercise performance by enhancing nitric oxide production via macrophage 
stimulation. 
Echinacea-induced EPO Production and Nitric Oxide 
 Echinacea supplementation in humans has been shown to elicit a significant 
increase in serum EPO levels (Whitehead et al., 2007). Despite a previous study that 
reported Echinacea supplementation in the equine model to cause significant increases in 
RBC count and Hb as compared to a control (O’Neill et al., 2002), there was not any 
significant changes in any measured indicators of erythropoietic status, such as RBC 
count, Hb, and Hct, following Echinacea supplementation in humans (Whitehead et al., 
2007). The study by Whitehead et al. (2007) noted nonsignificant increases in the 
measured erythropoietic status data indicating that erythropoiesis may have commenced. 
In another study, Echinacea supplementation in humans produced a nonsignificant 
increase in maximal oxygen consumption (V˙ O2max) (Szołomicki et al., 2000). 
Consequently, it is plausible that Echinacea-induced EPO production may stimulate 
physiological responses independent and/or in addition to erythropoiesis. 
 In addition to playing a critical role in erythropoiesis (Beleslin-Cokic et al., 2004; 
Fliser & Bahlmann, 2008) there is evidence that suggests EPO has vasculo-protective 
effects (Fliser & Bahlmann, 2008). Research has indicated that EPO can stimulate the 
activation of endothelial nitric oxide synthase (eNOS) which is important for a variety of 
endothelial and vascular effects (Beleslin-Cokic et al., 2004; d’Uscio et al., 2007). The 
endothelial cells generate nitric oxide from the amino acid L-arginine by the enzymatic 
reaction of eNOS (d’Uscio et al., 2007; Palmer et al., 1988). Considered a potent 
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vasodilator, NO plays an important role in the regulation of systemic blood flow and 
blood pressure, endothelial repair and angiogenesis (Dimmeler et al., 1999). Furthermore, 
NO functions as an essential signal molecule to the endothelial cells lining the vascular 
walls to facilitate vasodilation for the regulation of blood flow and reducing vascular 
resistance (Joannides et al., 1995; Klabunde, 2005). Exercise induces the skeletal muscle 
arterioles to enhance the delivery of oxygen and nutrients to the working muscle tissue 
(Maxwell et al., 2001). Research has observed that exercise capacity as well as exercise 
hyperemia are dependent of the integrity of the NOS pathway (Maxwell et al., 2001). 
Furthermore, there is evidence that suggests EDNO contributes to exercise hyperemia 
and is a determinant of aerobic exercise capacity in mice (Maxwell et al., 1998). A study 
investigating L-arginine supplementation in normal mice demonstrated an enhanced 
exercise capacity (Maxwell et al., 2001). Therefore, it is conceivable that Echinacea-
induced EPO production may stimulate an increase of NO from the vascular 
endothelium, thus enhancing aerobic capacity and exercise performance. 
Summary 
Research has provided sound evidence that an increase in serum erythropoietin 
(EPO) levels can result in an increase in red blood cell (RBC) production. An increase in 
RBC production will enhance the ability to uptake, transport and utilize oxygen in the 
tissues of the body. It is well known that an increase in the oxygen carrying capacity will 
improve the aerobic capacity and thus enhance endurance exercise performance. 
Echinacea is an herbal supplement that has been used for centuries as a nonspecific 
stimulant of the immune system. Recent research has provided evidence suggesting that 
Echinacea can stimulate the production of EPO. The mechanism behind this is unclear at 
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this time; however, research has indicated that Echinacea can induce the activation of 
macrophages and T-cells which are known to stimulate the production of cytokines and 
erythroid progenitor growth factors, respectively. Echinacea supplementation in the 
equine model has demonstrated an increase in measures of erythropoietic status (O’Neill 
et al., 2002); however, Echinacea supplementation in humans did not observe these 
results despite a significant increase in serum EPO levels (Whitehead et al., 2007). There 
was, however, a nonsignificant increase in the erythropoietic data. Based on the time 
period of the data collection and the typical maturation period for RBC development, it is 
plausible that an extended data collection period totaling six weeks may provide stronger 
evidence on whether Echinacea supplementation in humans can initiate erythropoiesis 
following a significant increase in EPO production. An increase in RBC would increase 
the oxygen carrying capacity and alleviate any adverse symptoms of various 
cardiopulmonary diseases, enhance one’s cardiorespiratory health and improve one’s 
aerobic exercise capacity. 
There are other mechanisms that may contribute to an enhanced oxygen carrying 
capacity attributed to Echinacea supplementation. First, macrophages have been reported 
to stimulate the production of cytokines, including nitric oxide (NO) and Echinacea-
induced activated macrophages have elicited an increase in nitric oxide production. 
Secondly, EPO is known to play a role in processes other than erythropoiesis, such as 
cardiovascular homeostasis. Erythropoietin provides vascular and endothelial effects 
through a variety of mechanisms including the stimulation of endothelial nitric oxide 
release from the endothelial cells. Therefore, an increase in nitric oxide production 
whether from Echinacea-induced activated macrophages or as a result of elevated serum 
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EPO levels, may provide a mechanism for improved oxygen delivery to the working 
tissues. This would result in an increased aerobic capacity which would provide a means 
to reduce the adverse effects of various diseased states caused by a decrease in oxygen 
carrying capacity. Additionally, an increased aerobic capacity would enhance endurance 
exercise performance.
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CHAPTER III 
THE EFFECT OF SIX WEEKS OF ORAL ECHINACEA SUPPLEMENTATION ON 
ERYTHROPOIESIS, NITRIC OXIDE PRODUCTION,  
AND EXERCISE PERFORMANCE 
 
Introduction 
Echinacea, a purple coneflower plant of the compositae family (Asteraceae), is 
native to North America and is commonly used as an herbal supplement to enhance 
immune function (Goel et al., 2002a, 2002b). Three of the species that are predominately 
used for these purposes include Echinacea angustifolia (DC.) Hell (narrow-leaf purple 
coneflower), Echinacea pallida (Nutt.) Nutt. (pale purple coneflower), and Echinacea 
purpurea (L.) Moench (eastern purple coneflower) (Barnes et al., 2005, Rininger et al., 
2000). O’Neill et al. (2002) reported that horses supplemented with an Echinacea 
angustifolia extract, standardized to 4% echinacoside (2,000 mg·d-1), after 21 days 
demonstrated significant increases in erythropoietic status as evidenced by an increased 
hemoglobin concentration ([Hb]) and number of erythrocytes (RBC). Recently, 
Whitehead et al. (2007) investigated 28 days of oral Echinacea purpurea 
supplementation (8,000 mg·d-1) in humans and reported a significantly increased serum 
erythropoietin (EPO) concentration at days 7 (44%), 14 (63%), and 21 (36%). The 
increase in EPO was not accompanied by a significant increase in the number of RBCs or 
[Hb]; however, there were nonsignificant increases in the erythropoietic status by the end 
of the four week study (% change in RBC, hematocrit, [Hb], mean corpuscular volume), 
suggesting the initiation of erythropoiesis (Whitehead et al., 2007). 
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The Echinacea-induced increase in serum EPO reported by Whitehead et al. 
(2007) was similar in time-course and magnitude to that induced by the hypoxic 
conditions of high altitude exposure (Ashenden et al., 2000; Chapman et al., 1998; 
Wehrlin et al., 2006). Whitehead et al. (2007) indicated that Echinacea-induced serum 
EPO levels peaked at day 14 of a 28 days study, thereby allowing only 14 days during 
which to elicit any detectable change in measures of erythropoietic status. It should be 
noted that EPO acts on the mature developmental stages of the erythroid progenitor cells 
to enhance the proliferation and development into mature RBCs (Fisher, 2003; Gregory 
& Eaves, 1977; Gregory & Eaves, 1978). It is possible that new RBCs could appear in 
circulation about five days after maximum EPO production (Guyton & Hall, 2000). The 
production of RBCs from the initial stem cell stage takes much longer and has been 
reported to take about 15 days for pluripotent hematopoietic stem cells to develop into 
circulating reticulocytes (Marieb & Hoehn, 2010) with another 1-2 days for the 
circulating reticulocytes to develop into mature RBCs (Guyton & Hall, 2000; Marieb & 
Hoehn, 2010).  
In addition to the potential erythropoietic effect, Echinacea has also been shown 
to stimulate macrophage activity (Burger et al., 1997; Goel et al., 2002a, 2002b; Mishima 
et al., 2004; Rininger et al., 2000; Roesler et al., 1991; Stimpel et al., 1984). An increase 
in macrophage activity has been shown to induce secretion of a wide variety of 
biologically active compounds including cytokines, prostanoids, nitric oxide, and oxygen 
radicals (Burger at al., 1997; Busam et al., 1991; Decker, 1990; Dieter et al., 1999; 
Duyster et al., 1993; Gallaird et al., 1992; Grewe et al., 1994), one of which, 
Prostaglandin E2 (PGE2), has been shown to enhance the production of EPO (Boer et al., 
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2002; Fisher et al., 1980; Gross et al., 1976; Jelkmann et al., 1985; Kurtz et al., 1985; 
Ortega et al., 1984) and granulocyte-macrophage colony-stimulating factor (GM-CSF) 
(Emond, Fortier, Murphy, & Lambert, 1998). Echinacea has also been shown to increase 
the in vitro activity of T cells (Mishima et al., 2004). The activation of natural killer T 
cells is known to stimulate the synthesis and release of GM-CSF and the erythroid 
progenitor growth factor interleukin-3 (IL-3) (Bickel et al., 1988; Cuturi et al., 1989; 
Davignon et al., 1988; Fitzpatrick & Kelso, 1995; Oster et al., 1989). Echinacea 
supplementation for 28 days in humans demonstrated a statistically nonsignificant (p > 
0.05) increase in the percent change of PGE2 at day 7 (28%) and day 14 (46%) that 
accompanied the significant (p < 0.05) increase in serum EPO levels (Whitehead et al., 
2007). A significant increase in serum IL-3 also paralleled the increase in serum EPO. 
Additionally, there was a nonsignificant increase in GM-CSF suggesting that T cell 
activity may have been initiated and that IL-3 might play a role in Echinacea-induced 
EPO production (Whitehead et al., 2007). Erythropoietin also appears to act 
synergistically with the growth factors GM-CSF and IL-3 to induce the proliferation and 
maturation of erythroid progenitor cells (Fisher, 2003; Lin et al., 1996; Wu et al., 1995b). 
It has been suggested that Echinacea might stimulate EPO production through the 
activation of macrophages and T-cells, both known to stimulate the secretion of erythroid 
progenitor growth factors (Whitehead et al., 2007). The significant increases in serum 
EPO and IL-3, as well as the noticeable increases in serum PGE2 and GM-CSF, support 
the proposed Echinacea-induced mechanism for enhanced serum EPO production 
following supplementation.   
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Nitric oxide (NO), a potent vasodilator, plays an important role in cardiovascular 
homeostasis, including regulation of systemic blood pressure, blood flow, endothelial 
repair and angiogenesis (Dimmeler et al., 1999). Consequently, researchers have 
indicated that augmented NO production enhances aerobic capacity and exercise 
performance (Maxwell et al., 2001). Echinacea has been shown to stimulate macrophage 
activity (Burger et al., 1997; Goel et al., 2002a, 2002b; Mishima et al., 2004; Rininger et 
al., 2000; Roesler et al., 1991; Stimpel et al., 1984) which is a known stimulator of NO 
production (Panaro et al., 2003). Additionally, Echinacea has been shown to stimulate 
NO production in alveolar macrophages in the murine model (Goel et al., 2002a, 2002b). 
Thus, Echinacea supplementation in humans may increase aerobic capacity and exercise 
performance by enhancing NO production via macrophage stimulation. 
As noted previously, Echinacea supplementation in humans was shown to elicit a 
significant increase in serum EPO levels (Whitehead et al., 2007), and in part this is 
supported by earlier findings indicating a nonsignificant increase in maximal oxygen 
consumption (Szołomicki et al., 2000). It is plausible that Echinacea-induced EPO 
production may stimulate physiological responses independent and/or in addition to 
erythropoiesis. There is also evidence suggesting EPO has vasculo-protective effects 
(Fliser & Bahlmann, 2008) including the activation of endothelial nitric oxide synthase 
(eNOS) (Beleslin-Cokic et al., 2004; d’Uscio et al., 2007). Based on these findings, a 
proposed nonhematological response to the elevated EPO concentration could be 
enhanced NO production (Gore, Clark, & Saunders, 2007).  
In light of the previous findings, the purpose of this study was multifaceted and 
specifically designed to investigate the following: 1) The effect of six weeks of oral 
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Echinacea supplementation on serum EPO and erythropoietic status, 2) To determine 
whether Echinacea supplementation augmented [NO] as a result of an Echinacea-induced 
increase in EPO and/or Echinacea-induced macrophage activity, and  3) To investigate 
any alterations in submaximal endurance exercise performance and maximal oxygen 
uptake (V˙ O2max) associated with Echinacea supplementation and the potential 
mechanisms contributing to this response. 
Methods 
Participants 
Twenty-four, apparently healthy, recreationally active, low risk (American 
College of Sports Medicine [ACSM], 2010) males were recruited to participate in this 
study. Participant characteristics were as follows (mean ± SE): n = 24, age = 25.2 ± 1.4 
yr, height = 178.1 ± 1.4 cm, mass = 78.1 ± 1.6 kg, percent body fat = 12.7 ± 0.9 %,         
V˙ O2max = 52.9 ± 0.9 mL·kg-1·min-1. Criteria for being determined to be recreationally 
active consisted of participants self-reporting performing moderate to vigorous intensity 
aerobic exercise for a minimum of 3-5 d·wk-1 for at least 20-30 min·session-1 (ACSM, 
2010). During the course of the study participants were instructed to not consume any 
nutritional supplements, prescription medications, or nicotine of any form. Further 
contraindications to participation included allergies or sensitivity to wheat flour-
containing products, Echinacea-containing products, sunflowers or daisy-like flowers; 
and any indications of unstable body mass one month prior to, and during the study. 
Participants were also required to be free of any signs and/or symptoms of upper 
respiratory tract infections. All procedures were approved by the Institutional Review 
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Committees for the protection of Human Subjects in Research at Troy University and 
The University of Southern Mississippi. 
Preliminary Visits 
Each participant provided written informed consent and completed a pre-
participation health screening and risk stratification form. Participants reported to the 
laboratory on two separate occasions to become familiarized with the experimental 
protocol and to perform preliminary testing. The first familiarization visit (Fam-1) 
included measurement of height, mass and body composition (Jackson & Pollock, 1985; 
Siri, 1956). Additionally, a maximal graded exercise test was performed on a motorized 
treadmill with the measurement of expired gases to assess maximal oxygen consumption 
(V˙ O2max). The second familiarization visit (Fam-2) was scheduled seven day following 
Fam-1, in which a second maximal exercise test was performed.  
The familiarization visits were utilized for two reasons: 1) determine the V˙ O2max 
of each participant and to verify that the participants met the cardiorespiratory fitness 
levels necessary to participate in the study; ≥ 50.0 mL·kg-1·min-1 or higher and reached at 
least stage 5 of the graded exercise test 2) To familiarize participants with the protocol 
and minimize any learning effect between trials. A variance of ≤ 5% in V˙ O2max between 
Fam-1 and Fam-2 was used to determine when each participant had achieved a 
satisfactory familiarization to the protocol. If a variance of > 5% was observed between 
Fam-1 and Fam-2, an additional familiarization test was scheduled seven days later until 
two consecutive trials achieved a variance in V˙ O2max ≤ 5%. When this criterion was met, 
participants progressed to the baseline experimental trial seven days later. Results of a 
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dependent sample t test indicated no difference in V˙ O2max between the two familiarization 
trials (Fam-1: 52.3 ± 0.8; Fam-2 52.6 ± 0.9 mL·kg-1·min-1). 
Study Design   
Based on preliminary data (V˙ O2max, mass, height, age), using a matched-pair, 
double-blind design, participants were randomly assigned to either Echinacea (ECH) 
(n=12) or placebo (PLA) (n=12) experimental groups, and then supplemented for 42 days 
(Table 1). Baseline venous blood samples were obtained from all participants on day 0 
(baseline) prior to beginning supplementation and then after 14-, 28-, and 42 days of 
supplementation. Whole blood samples were collected and analyzed for red blood cell 
(RBC) count, [Hb], hematocrit (Hct), mean corpuscular volume (MCV) and mean 
corpuscular hemoglobin concentration (MCHC). Serum samples were collected, 
processed, stored at -80 ºC, and analyzed for the quantitative determination of 
erythropoietin (EPO) and plasma samples were collected, processed, stored at -80 ºC, and 
analyzed for the quantitative determination of [NO]. 
Table 1 
Descriptive Characteristics of Experimental Groups 
 
Group V˙ O2max  
(mL·kg-1·min-1) 
Mass 
(kg) 
Height  
(cm) 
Age  
(yr) 
Body fat 
(%) 
Echinacea  
(n = 12) 52.5 ± 1.3 77.7 ± 2.3 177.8 ± 2.1 25.4 ± 1.8 13.2 ± 1.1 
Placebo  
(n = 12) 53.3 ± 1.3 78.5 ± 2.3 178.4 ± 2.0 24.9 ± 2.2 12.1 ± 1.4 
 
Note. Values are mean ± standard error. 
 
Continuous, incremental graded exercise tests on a treadmill were performed to 
volitional fatigue prior to beginning the study (Fam-1 and Fam-2), prior to 
supplementation on day-0 (baseline), and every two weeks during the supplementation 
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period (day-14, -28 and -42). The graded exercise tests were used to assess the maximal 
and submaximal exercise response for each participant prior to, during, and after the 42 
day supplementation period. Expired gas concentrations and heart rate (HR) were 
analyzed continuously throughout the exercise tests. Participants were instructed to 
abstain from physical activity, alcohol, and caffeine for a minimum of 48 hours prior to 
all testing days. Physical activity and diet-recall journals were recorded for three days 
prior to baseline testing (day-0) and were referenced throughout the duration of the study 
to ensure replication of behavioral activities three days leading up to each subsequent 
testing session (day-14, -28, and -42) (Whitehead et al., 2007). 
Supplementation  
For 42 days, participants self-administered either 8,000 mg·d-1 of Echinacea 
(Echinacea Purpurea, Puritan’s Pride, Oakdale, NY) or a placebo (whole wheat flour, 
Gold Medal, General Mills, Minneapolis, MN ). The supplement was provided to the 
subjects in gelatin capsules (size 0; Torpac, Inc., Fairfield, NJ) along with a multi-
vitamin/mineral supplement (Equate, Complete Multivitamin). Each participant was 
instructed to orally ingest five, 400 mg capsules, four times each day according to the 
following supplementation schedule: 1) immediately after waking in the morning, 2) with 
lunch, 3) mid-afternoon, and 4) with the evening meal. The supplementation dosage and 
administration protocol was based on those reported previously (Berg et al., 1998; 
Szołomicki et al., 2000; Whitehead et al., 2007). A multi-vitamin/mineral was instructed 
to be taken orally by each participant immediately after waking in the morning to ensure 
that no deficiencies existed for the vitamins or minerals required for erythropoiesis 
(Guyton & Hall, 2000; Marieb & Hoehn, 2010). Each week participants were provided 
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with a known quantity of ECH or PLA and multi-vitamin/mineral. Supplements for each 
participant were separated into daily quantities in order to track adherence to the 
supplementation protocol. Additionally, a daily log was provided for participants to 
document the time and dose for each self-administration of the supplements. In order to 
document and monitor adherence to the supplementation protocol, the daily log and any 
unused capsules were returned to the investigators on a weekly basis. 
Blood Collection 
Blood samples for both groups were collected between 0500 and 0900 hours 
following an 8 hour fast. Prior to the collection, participants assumed a semi-recumbent 
position for 20 minutes to allow for stabilization of body fluid compartments. Venous 
blood was obtained via venipuncture of a superficial forearm vein using a 21 gauge 
needle and blood collection tubes (Vacutainer®, Becton-Dickinson, Franklin Lakes, NJ). 
The volume of each blood collection totaled 18 mL, with 10 mL collected into a 
nonadditive glass serum tube, 4 mL collected into a K2EDTA tube for complete blood 
count (CBC) analysis, and 4 mL collected into a K2EDTA tube for plasma collection. 
Sample Analysis 
 The 10 mL nonadditive blood collection serum tubes were allowed to clot for 60 
minutes following collection and were centrifuged for serum separation (PowerSpinTM 
LX C858 Centrifuge, UNICO, Dayton, NJ) at 1400 × g (3,500 rpm) for 15 minutes at 
room temperature (~21 ºC). One of the 4 mL K2EDTA blood collection tubes, containing 
whole blood samples, was immediately refrigerated (~1 ºC) until transported to a clinical 
laboratory. Samples were analyzed within eight hours of collection using an automated 
flow cytometer (COULTER® HmX Hematology Analyzer, Beckman Coulter, Brea, CA) 
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for RBC count, [Hb], Hct, MCV, and MCHC. The additional 4 mL K2EDTA blood 
collection tubes were centrifuged for plasma separation at 1400 × g (3,500 rpm) for 15 
minutes at room temperature within 30 minutes of collection. The separated serum and 
plasma samples were then transferred by pipette into 1.5 mL polyethylene eppendorf 
tubes for storage and immediately frozen at -80 °C for later analysis. 
Serum samples were prepared and analyzed in duplicate using enzyme-linked 
immunosorbent assay (ELISA) kits for quantitative determination of EPO concentrations 
(DEP00, R&D Systems, Minneapolis, MN). For the quantitative determination of NO 
concentrations, the plasma samples were prepared and analyzed in duplicate using a nitric 
oxide colorimetric assay kit (KGE001, R&D Systems, Minneapolis, MN).  
Analyses of the serum and plasma samples were performed using a BioTek 
µQuant microplate reader and accompanying data analysis software (Gen5TM Ver 1.08, 
BioTek® Instruments, Inc., Winooski, Vermont). Duplicate samples were prepared and 
analyzed using the same assay kit. Sensitivities (minimum detectable dose), inter-assay 
coefficients of variation, and intra-assay coefficients of variation for EPO (< 0.6 mU· 
mL-1, 6.70%, and 7.10%, respectively, DEP00, R&D Systems), nitrite (0.09-0.78 µmol· 
L-1 [mean = 0.25 µmol·L-1], 3.05%, and 6.37%, respectively, KGE001, R&D Systems), 
and total nitrite (nitrite/nitrate) (0.09-0.78 µmol·L-1 [mean = 0.25 µmol·L-1], 5.85%, and 
5.63%, respectively, KGE001, R&D Systems) were determined by following the 
respective manufacturers’ directions. 
Maximal Exercise Test Protocol 
Continuous, graded exercise tests, consisting of incremental stages, were 
performed to volitional fatigue on a motorized treadmill (WOODWAY-Desmo, 
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Waukesha, WI) to assess submaximal heart rate (HR) and oxygen uptake (V˙ O2), and 
maximal oxygen uptake (V˙ O2max). Participants warmed up by walking for 3 minutes at 
2.5 miles·h-1 and 0% grade. Stage 1 of the protocol was then initiated by the participants 
running on the treadmill at 5 miles·h-1 for 3 minutes. Stage 2 consisted of the velocity of 
the treadmill increasing to 7 miles·h-1, and was maintained at this velocity for 6 minutes. 
Beginning with stage 3, each stage consisted of running for 3 minutes at a constant 
treadmill velocity of 7 miles·h-1 and the grade increasing by 3% each stage until 
volitional fatigue. The design of stage 2 was used to assess steady-state V˙ O2 and HR over 
a prolonged, moderate intensity, submaximal exercise stage.  
Maximal exercise response was assessed through the measurement of V˙ O2 with 
the highest 30 second average of the exercise test regarded as V˙ O2max. Submaximal 
exercise response was assessed through the measurement of the submaximal, steady-state 
HR and V˙ O2 averaged over the final 60 seconds of stages 1 and 2. Expired gases were 
analyzed continuously throughout the test using open-circuit spirometry (TrueOne® 2400 
Metabolic Measurement System, Parvo Medics, Sandy, Utah) and heart rate (HR) was 
recorded by telemetry (Polar® Electro Inc., Lake Success, NY). 
Statistical Analysis 
 
All analyses were conducted with a statistical software package (SPSS® Statistics 
v. 17.0, SPSS, Inc.). Independent-sample t tests were conducted for all variables to 
determine if any differences existed for baseline measures between groups. Separate 2 × 
4 (Group × Time) factorial analysis of variance (ANOVA) with repeated measures were 
conducted to evaluate the effects of group (Echinacea and Placebo) and time (base, 2 
weeks, 4 weeks, 6 weeks) on RBC count, [Hb], Hct, MCV, MCHC, EPO, nitrite, nitrate, 
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nitrite/nitrate, V˙ O2max, submaximal V˙ O2 and submaximal HR. Post hoc means 
comparison analyses were performed with dependent and independent t-tests with a 
Bonferroni adjustment when significant main effects (group, time) or interactions (group 
× time) were found. Effect size was calculated using eta2 (η2) to estimate the 
meaningfulness of any significance or the extent to which the treatment influenced the 
effect. Statistical significance was set at p ≤ .05 (Thomas & Nelson, 2001). 
Results 
Erythropoietin and Nitric Oxide  
 
 Results of analyses of serum EPO and plasma nitrite, nitrate, and nitrite/nitrate are 
reported in Table 2. There were no significant differences in the baseline values for EPO, 
nitrite, nitrate, and nitrite/nitrate. There were no significant main effects between groups 
or across time, and there were no significant group × time interactions for any of the 
above parameters. 
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Table 2 
 
The Effect of Six Weeks of Oral Echinacea Supplementation (8,000 mg·d-1) on Serum 
Concentration of Erythropoietin and Plasma Concentration of Nitric Oxide 
 
  Measurement Point  
Variable Baseline Day 14 Day 28 Day 42 
 
EPO (mU·mL-1) 
    
Echinacea 7.92 ± 1.13 8.41 ± 1.35 8.21 ± 1.47 8.86 ± 1.54 
Placebo 9.21 ± 1.30 9.71 ± 1.23 8.31 ± 0.80 9.74 ± 1.81 
 
Nitrite (µmol·L-1) 
    
Echinacea 0.88 ± 0.07 1.04 ± 0.16 0.87 ± 0.11 0.73 ± 0.10 
Placebo 0.91 ± 0.16 1.03 ± 0.19 1.00 ± 0.21 0.96 ± 0.22 
 
Nitrate (µmol·L-1) 
    
Echinacea 17.44 ± 1.85 19.99 ± 1.92 18.75 ± 2.00 20.16 ± 2.23
Placebo 16.01 ± 1.50 15.91 ± 2.28 18.28 ± 2.40 14.77 ± 1.21
 
Nitrite/Nitrate(µmol·L-1) 
    
Echinacea 18.32 ± 1.86 21.03 ± 1.94 19.62 ± 1.99 20.89 ± 2.25
Placebo 16.92 ± 1.49 16.94 ± 2.35 19.28 ± 2.46 15.73 ± 1.22
 
Note. Values are mean ± standard error; n = 12 for Echinacea and Placebo groups, respectively. 
EPO indicates erythropoietin; Nitrite/Nitrate (total nitrite). 
 
Erythropoietic Status Measures 
 Values for erythropoietic status measures from whole blood samples are presented 
in Table 3. There were no significant differences in the baseline values for RBC, [Hb], 
Hct, MCV, or MCHC between the Echinacea and Placebo groups. There were no 
significant main effects between groups or across time, and there were no significant 
group × time interactions for RBC, [Hb], Hct, MCV, and MCHC.  
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Table 3 
 
The Effect of Six Weeks of Oral Echinacea Supplementation (8,000 mg·d-1) on Measures 
of Erythropoietic Status 
 
  Measurement Point  
Variable Baseline Day 14 Day 28 Day 42 
 
RBC (M·µL-1) 
    
Echinacea 4.76 ± 0.13 4.75 ± 0.10 4.80 ± 0.10 4.73 ± 0.10 
Placebo 4.81 ± 0.11 4.75 ± 0.10 4.80 ± 0.07 4.87 ± 0.09 
 
Hb (g·dL-1) 
    
Echinacea 14.8 ± 0.3 14.8 ± 0.3 15.0 ± 0.3 14.8 ± 0.2 
Placebo 15.0 ± 0.3 14.7 ± 0.3 14.9 ± 0.2 15.1 ± 0.2 
 
Hct (%) 
    
Echinacea 42.9 ± 0.9 43.0 ± 0.7 43.4 ± 0.6 42.7 ± 0.5 
Placebo 43.2 ± 0.9 42.7 ± 0.8 43.1 ± 0.6 43.6 ± 0.6 
 
MCV [fL(µm3)] 
    
Echinacea 90.4 ± 1.4 90.7 ± 1.3 90.6 ± 1.4 90.6 ± 1.4 
Placebo 89.9 ± 0.9 90.0 ± 0.8 89.9 ± 0.8 89.7 ± 0.9 
 
MCHC (g·dL-1) 
    
Echinacea 34.6 ± 0.3 34.5 ± 0.2 34.5 ± 0.3 34.6 ± 0.1 
Placebo 34.7 ± 0.2 34.5 ± 0.1 34.5 ± 0.2 34.6 ± 0.2 
 
Note. Values are mean ± standard error; n = 24. RBC indicates red blood cells; Hb, hemoglobin;  
Hct, hematocrit; MCV, mean corpuscular volume; MCHC, mean corpuscular hemoglobin concentration. 
 
Physiological Exercise Responses 
 
Maximal exercise response. Maximal exercise response variables of interest are 
presented in Table 4. There were no significant differences in the baseline values for  
V˙ O2max (mL·kg-1·min-1). There were no significant main effects between groups or across 
time, and there were no significant group × time interactions for V˙ O2max. 
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Table 4 
 
The Effect of Six Weeks of Oral Echinacea Supplementation (8,000 mg·d-1) on Maximal 
and Submaximal Exercise Response 
 
  Measurement Point  
Variable Baseline Day 14 Day 28 Day 42 
 
Maximal Performance 
    
V˙ O2 (mL·kg-1·min-1)     
Echinacea 52.5 ± 1.3 53.5 ± 1.1 53.6 ± 1.4 54.1 ± 1.5 
Placebo 53.3 ± 1.3 52.8 ± 1.2 53.8 ± 1.3 53.3 ± 1.4 
 
Submaximal 
Performance 
    
Stage 1a     
V˙ O2 (mL·kg-1·min-1)     
Echinacea 27.3 ± 0.9 27.5 ± 0.8 27.3 ± 0.9 27.2 ± 1.0 
Placebo 27.0 ± 0.6 26.9 ± 0.5 26.8 ± 0.6 26.8 ± 0.5 
 
HR (beats·min-1) 
    
Echinacea 133.8 ± 3.8 132.4 ± 4.3 132.1 ± 3.9 133.0 ± 4.2 
Placebo 128.3 ± 3.1 131.6 ± 3.7 131.1 ± 2.8 134.0 ± 3.9 
 
Stage 2b  
    
V˙ O2 (mL·kg-1·min-1)     
Echinacea 38.4 ± 1.2 38.2 ± 1.0 38.0 ± 0.9 38.1 ± 1.1 
Placebo 37.7 ± 0.7 38.0 ± 0.6 37.6 ± 0.6 37.4 ± 0.7 
 
HR (beats·min-1) 
    
Echinacea 168.5 ± 4.3 166.7 ± 4.3 167.2 ± 4.0 165.8 ± 4.2 
Placebo 160.3 ± 3.3 162.9 ± 4.1 163.3 ± 3.4 165.2 ± 3.9 
 
Note. Values are mean ± standard error; n = 24. V˙ O2 indicates oxygen consumption; HR, heart rate.  
Percent V˙ O2max values for Stages 1 and 2 were averaged across the four exercise tests; n= 24. 
aStage 1 was 51.0 % ± 0.05 of the V˙ O2max (53.4 ± 0.5 mL·kg-1·min-1); values are mean ± SE. 
bStage 2 was 71.0 % ± 0.07 of the V˙ O2max (53.4 ± 0.5 mL·kg-1·min-1); values are mean ± SE. 
 
Submaximal exercise response. Submaximal exercise response variables of 
interest are presented in Table 4. There were no significant differences in the baseline 
values for V˙ O2 (mL·kg-1·min-1) at Stage 1 or Stage 2. There were no significant main 
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effects between groups or across time, and there were no significant group × time 
interactions for any of these time measurement points.  
There were no significant differences in the baseline values for HR (beats·min-1) 
at Stage 1 or Stage 2. There were no significant main effects between groups or across 
time, and there were no significant group × time interactions at Stage 1. There were no 
significant main effects between groups or across time for HR at Stage 2. Significant 
group × time interactions for HR at Stage 2, F(3, 66) = 3.29, P < .03, η2 = .129, were 
observed; however, when post hoc means comparison analysis was employed with 
Bonferroni adjustment significant differences were not detected. 
Discussion 
Erythropoietin and Erythropoietic Status 
 The major observation of this study was that six weeks of Echinacea 
supplementation (Echinacea purpurea, 8,000 mg·d-1) did not induce a significant 
increase in serum EPO. This is in contrast with Whitehead et al. (2007) who reported that 
Echinacea supplementation significantly increased serum EPO at days 7 (44%), 14 
(63%), and 21 (36%) of a 28 day supplementation period (Whitehead et al., 2007). 
Consequently, the present study did not observe alterations in any measures of 
erythropoietic status (RBC count, [Hb], Hct, MCV, and MCHC).  
 The rationale for evaluating these markers was based on previous findings 
(O’Neill et al, 2002; Whitehead et al, 2007). O’Neill et al. (2002) reported that Echinacea 
supplementation for 21 days in horses significantly increased RBC count and [Hb] 
compared to placebo. The mechanism responsible for the observed Echinacea-induced 
increase in RBC count and [Hb] (O’Neill et al., 2002) was not clear as EPO was not 
103 
 
measured. However, this was followed by the investigation of Whitehead et al. (2007) 
reporting that Echinacea supplementation for 28 days in humans demonstrated a 
significant increase in serum EPO. An interesting finding by Whitehead et al. (2007) was 
that the significant increase in EPO was not accompanied with any statistically significant 
alterations in erythropoietic status, including RBC count and [Hb]. In spite of this, there 
were nonsignificant increases in the erythropoietic status towards the conclusion of the 
investigation, including percent changes in RBC count, [Hb], Hct, and MCV, suggesting 
that erythropoiesis may have been initiated during the study and possibly completed after 
the study ended. 
 An observation from the study by Whitehead et al. (2007) was that the 
Echinacea-induced peak in serum EPO levels occurred at day 14 of the 28 day study, 
permitting only 14 days to observe any significant alterations in erythropoietic status that 
would be expected with a significant increase in EPO (63%) at day 14 (20.21 mU·mL-1) 
compared to baseline (12.37 mU·mL-1). Erythropoietin acts on the mature stages of 
erythroid progenitor cell development to increase the proliferation and development into 
mature RBCs (Fisher, 2003; Gregory & Eaves, 1977; Gregory & Eaves, 1978) and 
following this, new RBCs could appear in circulation ~5 days after the peak in EPO 
production (Guyton & Hall, 2000). However, it has been suggested that it may take about 
15 days for the pluripotent hematopoietic stem cells to develop into circulating 
reticulocytes (Marieb & Hoehn, 2010) with an additional 1-2 days to develop into mature 
RBCs (Guyton & Hall, 2000; Marieb & Hoehn, 2010). Consequently, a rationale for the 
design of the present study was to expand the window of observation of the measures of 
erythropoietic status through an extended data collection time period of six weeks; two 
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weeks beyond the previous 28 day investigation (Whitehead et al., 2007). Therefore, if 
the present study observed a significant increase in EPO at day 14 then there would be 28 
days to monitor erythropoietic development compared to 14 days (Whitehead et al., 
2007) in the previous study. However, the present study was unable to replicate the 
changes in serum EPO reported previously (Whitehead et al., 2007). 
Potential Factors of Variation in Echinacea-Induced EPO Production 
 The present study did not observe any alterations in EPO levels over the course 
of six weeks. The explanation for the absence of any alteration in serum EPO in this 
study is unclear at this time; however two plausible factors that may have influenced the 
lack of an EPO response are the higher fitness levels of the subjects utilized for the 
present study compared to Whitehead et al. (2007) and/or differences in the quality of the 
Echinacea supplements. 
 Physical fitness status of participants. The baseline aerobic fitness (e.g., 
maximal oxygen uptake) of the participants in the present study (52.9 ± 0.9 mL·kg-1· 
min-1) was considerably higher than that of the previous study (42.5 ± 1.6 mL·kg-1·min-1) 
(Whitehead et al., 2007). The present study specifically utilized participants with higher 
than average aerobic fitness levels in an effort to enhance the applied value of the 
submaximal and maximal endurance exercise response data compared to previous 
research (Szołomicki et al., 2000; Whitehead et al., 2007). Based on this difference, a 
possible explanation is that the Echinacea-induced mechanisms for EPO production are 
influenced by the cardiorespiratory fitness of an individual. However, this is speculative 
at best, as no studies have evaluated the role that training status and/or physical fitness 
level may play in the erythropoietic response to Echinacea supplementation. 
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 The specific mechanism(s) for the Echinacea-induced EPO production reported 
by Whitehead et al. (2007) are unclear; however, Echinacea has been shown to stimulate 
macrophage activity (Burger et al., 1997; Goel et al., 2002a, 2002b; Mishima et al., 2004; 
Rininger et al., 2000; Roesler et al., 1991; Stimpel et al., 1984), and macrophages have 
been reported to secrete several compounds (Burger at al., 1997; Busam et al., 1991; 
Decker, 1990; Dieter et al., 1999; Duyster et al., 1993; Gallaird et al., 1992; Grewe et al., 
1994) including prostaglandin E2 (PGE2) which is reported to augment the production of 
EPO (Boer et al., 2002; Fisher et al., 1980; Gross et al., 1976; Jelkmann et al., 1985; 
Kurtz et al., 1985; Ortega et al., 1984) and granulocyte-macrophage colony-stimulating 
factor (GM-CSF) (Emond, Fortier, Murphy, & Lambert, 1998). In addition, Echinacea 
has been shown to enhance T-cell activity (Mishima et al., 2004) which is reported to 
stimulate the production of GM-CSF and the erythroid progenitor growth factor IL-3 
(Bickel et al., 1988; Cuturi et al., 1989; Davignon et al., 1988; Fitzpatrick & Kelso, 1995; 
Oster et al., 1989). Whitehead et al. (2007) stated that Echinacea supplementation caused 
a nonsignificant increase in PGE2 that preceded the significant increase in serum EPO, a 
significant increase in IL-3 that paralleled the significant increase in EPO, and a 
nonsignificant increase in GM-CSF possibly suggesting T-cell activity (Whitehead et al., 
2007). 
 The present study did not measure the potential mechanisms of an Echinacea-
induced serum EPO stimulation, such as macrophage-derived factors, T-cells, PGE2, 
GM-CSF, and IL-3 being that there was not an observed increase in EPO. It is unclear 
whether cardiorespiratory fitness or training status affects Echinacea-induced 
macrophage or T-cell activity, which in turn has been shown to stimulate PGE2, GM-
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CSF, and IL-3 production. In addition, independent of Echinacea supplementation, 
research has not provided adequate evidence comparing athletes and nonathletes in 
regards to changes in immune function (Nieman, 2001), including the immunostimulation 
of macrophage-derived factors. Research has indicated that of all the immune measures, 
elevated natural killer (NK) cell activity in athletes has been a rather consistent indicator 
differentiating immune function in athletes compared to nonathletic controls (Nieman, 
2001; Nieman et al., 1995, Nieman et al., 2000, Tvede et al. 1991). Consequently, further 
research is warranted to investigate if cardiorespiratory fitness levels or training status 
play a role in Echinacea-induced mechanisms for EPO production. 
 Echinacea. With regard to the quality of the Echinacea product, there are 
several factors that can be considered sources of variation which may influence studies 
utilizing herbal supplements such as Echinacea (Senchina et al., 2009b). These may 
include variation in the biology and ecology of the herb itself and/or chemical factors 
associated with harvesting, processing and storage. Plant-associated factors, such as 
variations in species, organ of species (i.e., root, aerial), age of plant, season of harvest, 
plant hydration status, soil composition, and sunlight likely impact the performance of the 
Echinacea extracts (Senchina et al., 2009b). The extracts among the Echinacea species 
that are most often recognized for their immunomodulatory effects are the alkamides, 
polysaccharides, and cichoric acid (Dennehy, 2001; Wagner, 1997). As well, different 
species of the Echinacea plant have been shown to elicit different immune responses 
(McCann et al., 2007; Senchina et al., 2005; Senchina, Flagel, Wendel, & Kohut, 2006a; 
Senchina et al., 2009a; Senchina et al., 2009b). The present study used Echinacea 
purpurea (aerial) which is the same species and organ used by Whitehead et al. (2007), 
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thereby accounting for any variations between plant species. However, it has been 
reported that phytochemistry can vary within the same species due to botanical 
differences (Senchina et al., 2009b). For instance, phytochemistry can vary by the age 
(Gray, Pallardy, Garrett, & Rottinghaus, 2003) and the organ of the plant, such as the 
aerial-flowerheads or roots (Binns, Livesey, Arnason, & Baum, 2002; Powell, Carrier, 
Crowe, & Bantle, 2001; Senchina et al., 2009b). In addition, hydration status of the plant 
related to the degree of drought stress, soil composition, as well as agricultural practices 
such as fertilizer treatments can influence plant phytochemistry (Gray et al., 2003; Powell 
et al., 2001; Senchina et al., 2009b).  
 The chemical factors involved in the preparation of the herbal supplement 
Echinacea, such as drying regimens and storage conditions, can also affect the 
performance of the extracts (Senchina et al., 2009b). Different methods of handling and 
storage such as variations in processing, drying, storage time, and temperature have been 
shown to impact Echinacea phytochemical composition including alkylamide and 
cichoric acid levels (Kim, Durance, Scaman, & Kitts, 2000a, 2000b; Perry, van Klink, 
Burgess, & Parmenter, 2000; Senchina et al., 2009b; Stuart and Wills, 2003; Wills and 
Stuart, 2000).  
 In order to induce a similar increase in serum EPO as Whitehead et al. (2007), 
this present study utilized the Echinacea purpurea (aerial) from the same manufacturer 
(Puritan’s Pride, Oakdale, NY). As previously indicated, it is possible that there could 
have been differences in the phytochemical concentrations (active ingredients) of the 
Echinacea supplement from batch to batch (Wolsko, Solondz, Phillips, Schachter, & 
Eisenberg, 2005). However, most supplements do not include the chemical composition 
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information on the product label (Senchina et al., 2009b). The product used in this study 
indicated the species of Echinacea, Echinacea purpurea (aerial), and the dosage per 
capsule. In spite of this, Gilroy, Steiner, Byers, Shapiro, & Georgian (2003) reported that 
Echinacea supplements have demonstrated that the content and dosage of the supplement 
have often been inconsistent with the label of the product. Therefore, there is no 
guarantee as to the content, quality, or variability in Echinacea supplements (Gilroy et al., 
2003). Consequently, some laboratories have challenged themselves to perform their own 
chemical profiling of the supplements they are studying (Senchina et al., 2009b). As a 
result, if poor quality control and the potential for high content variability exist within 
standardized supplement products, the ability to observe significant changes within well-
designed investigations may be limited (Wolsko et al., 2005).  
Nitric Oxide 
 Echinacea has been shown to stimulate macrophage activity (Burger et al., 
1997; Goel et al., 2002a, 2002b; Mishima et al., 2004; Rininger et al., 2000; Roesler et 
al., 1991; Stimpel et al., 1984), and human macrophages have been shown to stimulate 
nitric oxide (NO) production (Panaro et al., 2003). Echinacea-induced macrophage 
activity can be determined from measuring macrophage-derived factors including tumor 
necrosis factor-α (TNF-α), IL-1α, IL-1β, IL-6, IL-10, and NO (Rininger et al., 2000). 
Additionally, Whitehead et al. (2007) reported a nonsignificant increase in PGE2, which 
activated macrophages have been shown to secrete in addition to other biological 
compounds such as cytokines, NO, and oxygen radicals (Burger at al., 1997; Busam et 
al., 1991; Decker, 1990; Dieter et al., 1999; Duyster et al., 1993; Gallaird et al., 1992; 
Grewe et al., 1994). Therefore, it is plausible that Echinacea may have stimulated 
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macrophage activity (Whitehead et al., 2007). The present study did not indicate any 
changes in the measured nitric oxide metabolites, nitrite, nitrate or nitrite/nitrate 
suggesting that Echinacea supplementation did not induce macrophage activity. 
 Erythropoietin serves a primary role in erythropoieis (Beleslin-Cokic et al., 
2004; Fliser & Bahlmann, 2008); however, there is evidence that EPO also has vasculo-
protective effects (Fliser & Bahlmann, 2008). Researchers have indicated that EPO can 
stimulate the activation of endothelial nitric oxide synthase (eNOS) which is important 
for a variety of endothelial and vascular effects (Beleslin-Cokic et al., 2004; d’Uscio et 
al., 2007) such as regulation of systemic blood flow and blood pressure, endothelial 
repair and angiogenesis (Dimmeler et al., 1999). Nitric oxide functions as an essential 
signaling molecule to the endothelial cells lining the vascular walls to facilitate 
vasodilation for the regulation of blood flow and reducing vascular resistance (Joannides 
et al., 1995; Klabunde, 2005). In response to the reported Echinacea-induced increase in 
EPO (Whitehead et al., 2007), the present study hypothesized that a nonhematological 
response to the elevated EPO levels could be enhanced NO production (Gore, Clark, & 
Saunders, 2007). However, once again, the present study did not observe the Echinacea-
induced increase in EPO (Whitehead et al., 2007) necessary to warrant evaluation of this 
potential nonhematological response.  
Endurance Exercise Performance  
 In light of the fact that in the present study there was no evidence of 
erythropoiesis or NO production with Echinacea supplementation, it is not surprising that 
there were no alterations in submaximal endurance exercise performance or maximal 
oxygen uptake (V˙ O2max) following six weeks of Echinacea supplementation. These 
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findings are in conflict with the previous findings of Szołomicki et al. (2000) and 
Whitehead et al. (2007) who reported small increases in V˙ O2max and serum EPO levels, 
and the increases in NO production reported in response to elevated EPO levels (Gore, 
Clark, & Saunders, 2007). 
Conclusion 
 Results from the present study indicate that six weeks of oral Echinacea 
supplementation (Echinacea purpurea, 8,000mg·d-1) did not increase the production of 
serum EPO and consequently there were no changes in erythropoietic status observed 
over the course of the study. Additionally, Echinacea supplementation did not alter 
plasma nitrite, nitrate, or nitrite/nitrate. Consequently, in the absence of any of these 
changes, improvements in oxygen carrying capacity, submaximal endurance exercise 
performance, and maximal oxygen uptake (V˙ O2max) were not observed. These findings 
are in contrast with previous reports of Echinacea supplementation (O’Neill et al., 2002; 
Whitehead et al., 2007) and any explanation for these differences, including the role that 
training and/or physical fitness level have, are speculative at best. Nonetheless, in 
comparison to the subject population utilized by Whitehead et al. (2007), it is possible 
that individuals with average physical fitness levels may respond better to Echinacea 
supplementation compared to individuals with higher training and/or physical fitness 
levels.  
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APPENDIX N 
 
DATA COLLECTION TIMELINE 
 
Day Fam-1 Fam-2 0 
Base 
7 14 21 28 35 42 
Post 
Blood Collection   X 
 
 X 
 
 X 
 
 
 
X 
 
Exercise Test X X X 
 
 X 
 
 X  X 
Supplementation   X  X X X X X X 
Diet Recalla  X 
 
       
Physical Activity 
Questionnaireb 
 
 X 
 
       
Dietary Controlc 
 
   X 
 
 X 
 
 X 
 
 
Physical Activity 
Controld 
   X 
 
 X 
 
 X 
 
 
 
Note. Fam-1 indicates familiarization visit 14 days prior to day-0; Fam-2 indicates familiarization visit 7 
days prior to day-0; Base indicates baseline visit; Post indicates the final visit. 
aDiet Recall recorded for 3 days prior to baseline. 
bPhysical Activity Questionnaire recorded for 3 days prior to baseline. 
cDietary Control followed for 3 days leading up to day-14, -28, -42. 
dPhysical Activity Control followed for 3 days leading up to day-14, -28, -42. 
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APPENDIX O 
 
MAXIMAL EXERCISE TEST 
 
Stage Stage Duration 
(min:sec) 
Total Test Time 
(min:sec) 
Treadmill Speed 
(mph) 
Treadmill 
Grade (%) 
Warm-up 3:00 3:00 2.5 0.0 
Stage 1a 3:00 6:00 5.0 0.0 
Stage 2b 6:00 12:00 7.0 0.0 
Stage 3 3:00 15:00 7.0 3.0 
Stage 4 3:00 18:00 7.0 6.0 
Stage 5 3:00 21:00 7.0 9.0 
Stage 6 3:00 24:00 7.0 12.0 
Stage 7 3:00 27:00 7.0 15.0 
 
Note. Stage 2 of the exercise test was 6-min in duration.  
Percent V˙ O2max values for Stages 1 and 2 were averaged across the four exercise tests; n= 24. 
aStage 1 was 51.0 % ± 0.05 of the V˙ O2max (53.4 ± 0.5 mL·kg-1·min-1); values are mean ± SE. 
bStage 2 was 71.0 % ± 0.07 of the V˙ O2max (53.4 ± 0.5 mL·kg-1·min-1); values are mean ± SE.  
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APPENDIX P 
 
SUBJECT RAW DATA 
 
Descriptive Characteristics of Individual Participants 
 
Subject Group 
 
 
V˙ O2max  
(mL·kg-1·min-1) 
Weight  
(kg) 
Height  
(cm) 
Age  
(yr) 
Body fat 
(%) 
1 Echinacea 48.9 69.1 172.7 20 11.2 
2 Echinacea 56.3 71.4 170.2 20 9.8 
3 Echinacea 52.8 74.7 182.9 23 17.4 
4 Echinacea 46.5 83.9 192.5 22 8.2 
5 Echinacea 49.6 68.5 168.9 20 13.4 
6 Echinacea 59.3 70.5 177.2 33 13.1 
7 Echinacea 49.8 91.9 182.9 23 11.3 
8 Echinacea 49.8 90.7 177.8 41 22.0 
9 Echinacea 61.0 79.5 167.9 29 14.7 
10 Echinacea 50.4 73.2 181.6 24 10.2 
11 Echinacea 55.6 80.6 174.0 27 16.8 
12 Echinacea 50.0 78.2 184.8 23 10.4 
13 Placebo 50.3 97.7 190.5 32 16.8 
14 Placebo 61.5 78.5 172.7 23 9.4 
15 Placebo 49.6 79.7 180.3 44 18.4 
16 Placebo 55.7 67.5 179.1 20 6.4 
17 Placebo 51.5 72.3 183.0 21 6.5 
18 Placebo 49.2 72.6 175.3 20 17.2 
19 Placebo 56.3 73.8 184.2 33 7.2 
20 Placebo 60.4 73.2 168.9 23 8.0 
21 Placebo 49.3 82.3 181.0 22 9.4 
22 Placebo 48.9 80.3 168.3 22 13.3 
23 Placebo 51.6 76.9 172.1 20 13.4 
24 Placebo 55.4 87.6 185.4 19 19.7 
       
Mean  52.9 78.1 178.1 25.2 12.7 
± SD  4.4 7.9 7.1 6.8 4.4 
± SE  0.9 1.6 1.4 1.4 0.9 
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Descriptive Characteristics of Echinacea Group 
 
Subject V˙ O2max  
(mL·kg-1·min-1) 
Weight  
(kg) 
Height  
(cm) 
Age  
(yr) 
Body fat 
(%) 
1 48.9 69.1 172.7 20 11.2 
2 56.3 71.4 170.2 20 9.8 
3 52.8 74.7 182.9 23 17.4 
4 46.5 83.9 192.5 22 8.2 
5 49.6 68.5 168.9 20 13.4 
6 59.3 70.5 177.2 33 13.1 
7 49.8 91.9 182.9 23 11.3 
8 49.8 90.7 177.8 41 22.0 
9 61.0 79.5 167.9 29 14.7 
10 50.4 73.2 181.6 24 10.2 
11 55.6 80.6 174.0 27 16.8 
12 50.0 78.2 184.8 23 10.4 
      
Mean 52.5 77.7 177.8 25.4 13.2 
± SE 1.3 2.3 2.0 1.8 1.1 
 
 
Descriptive Characteristics of Placebo Group 
 
Subject V˙ O2max  
(mL·kg-1·min-1) 
Weight  
(kg) 
Height  
(cm) 
Age  
(yr) 
Body fat 
(%) 
13 50.3 97.7 190.5 32 16.8 
14 61.5 78.5 172.7 23 9.4 
15 49.6 79.7 180.3 44 18.4 
16 55.7 67.5 179.1 20 6.4 
17 51.5 72.3 183.0 21 6.5 
18 49.2 72.6 175.3 20 17.2 
19 56.3 73.8 184.2 33 7.2 
20 60.4 73.2 168.9 23 8.0 
21 49.3 82.3 181.0 22 9.4 
22 48.9 80.3 168.3 22 13.3 
23 51.6 76.9 172.1 20 13.4 
24 55.4 87.6 185.4 19 19.7 
      
Mean 53.3 78.5 178.4 24.9 12.1 
± SE 1.3 2.3 2.0 2.2 1.4 
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Red Blood Cells (M·µL-1) Echinacea Group 
 
Subject Baseline Day 14 Day 28 Day 42 
1 5.02 5.04 5.05 4.94 
2 4.79 4.92 4.79 4.55 
3 4.92 4.90 5.05 5.10 
4 5.01 4.81 5.25 5.09 
5 5.26 4.90 5.04 4.73 
6 5.21 4.87 5.05 5.06 
7 4.97 5.04 4.96 4.87 
8 4.93 4.88 4.62 4.84 
9 4.44 4.61 4.47 4.58 
10 4.21 4.15 4.42 4.17 
11 3.76 4.01 4.01 4.10 
12 4.55 4.84 4.92 4.69 
     
Mean 4.76 4.75 4.80 4.73 
± SE 0.13 0.10 0.10 0.10 
 
 
Red Blood Cells (M·µL-1) Placebo Group 
 
Subject Baseline Day 14 Day 28 Day 42 
13 5.24 5.20 5.17 5.24 
14 4.88 4.77 4.93 4.88 
15 4.33 4.40 4.71 4.72 
16 4.51 4.46 4.71 4.77 
17 4.68 4.55 4.51 4.69 
18 4.85 5.00 4.98 4.88 
19 4.80 4.72 4.68 4.97 
20 4.94 4.91 4.90 4.97 
21 5.05 5.02 4.90 4.87 
22 5.52 5.23 5.05 5.28 
23 4.77 4.67 4.67 5.04 
24 4.13 4.09 4.37 4.13 
     
Mean 4.81 4.75 4.80 4.87 
± SE 0.11 0.10 0.07 0.09 
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Hemoglobin (g·dL-1) Echinacea Group 
 
Subject Baseline Day 14 Day 28 Day 42 
1 14.9 15.2 15.0 15.0 
2 16.7 16.9 16.3 15.5 
3 14.4 14.6 15.0 15.1 
4 15.7 15.4 17.0 15.8 
5 15.6 14.4 15.1 14.0 
6 15.4 14.5 15.1 15.2 
7 15.3 15.6 15.4 15.0 
8 14.8 14.7 14.0 14.9 
9 13.3 13.8 13.6 14.0 
10 14.1 14.0 15.1 14.2 
11 13.6 13.7 13.5 13.8 
12 14.0 15.2 14.9 14.5 
     
Mean 14.8 14.8 15.0 14.8 
± SE 0.3 0.3 0.3 0.2 
 
 
Hemoglobin (g·dL-1) Placebo Group 
 
Subject Baseline Day 14 Day 28 Day 42 
13 16.7 16.4 16.1 16.4 
14 15.2 14.8 15.1 15.2 
15 14.6 14.1 15.3 15.3 
16 13.9 13.5 14.1 14.6 
17 14.1 13.6 13.6 14.1 
18 14.6 14.8 15.0 14.9 
19 15.1 14.8 15.0 15.8 
20 15.3 15.4 15.5 15.6 
21 16.3 16.2 15.9 15.8 
22 16.7 15.7 15.3 15.5 
23 13.9 13.7 13.4 14.7 
24 13.7 13.8 14.5 13.6 
     
Mean 15.0 14.7 14.9 15.1 
± SE 0.3 0.3 0.2 0.2 
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Hematocrit (%) Echinacea Group 
 
Subject Baseline Day 14 Day 28 Day 42 
1 44.3 44.2 44.3 42.9 
2 46.8 47.7 46.3 44.1 
3 42.2 41.8 43.5 43.9 
4 45.0 42.7 46.2 45.3 
5 45.0 42.8 42.9 40.2 
6 45.1 42.6 44.0 43.9 
7 45.3 45.9 45.0 44.1 
8 43.6 43.0 40.4 43.6 
9 39.1 41.4 40.3 41.1 
10 40.9 40.0 43.3 40.3 
11 37.0 39.7 39.9 40.9 
12 40.3 44.0 44.6 41.9 
     
Mean 42.9 43.0 43.4 42.7 
± SE 0.9 0.7 0.6 0.5 
 
 
Hematocrit (%) Placebo Group 
 
Subject Baseline Day 14 Day 28 Day 42 
13 47.1 46.6 46.4 46.3 
14 44.1 42.1 43.9 42.9 
15 40.1 41.0 43.1 43.6 
16 40.0 39.5 41.4 42.1 
17 40.7 39.8 40.0 41.5 
18 41.3 43.8 43.9 41.9 
19 43.5 42.8 42.7 44.8 
20 45.1 45.3 44.3 45.4 
21 47.4 46.4 45.9 45.2 
22 47.7 45.9 43.9 46.6 
23 41.6 40.2 40.3 43.6 
24 39.4 39.2 41.6 39.8 
     
Mean 43.2 42.7 43.1 43.6 
± SE 0.9 0.8 0.6 0.6 
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Mean Corpuscular Volume [fL(µm3)] Echinacea Group 
 
Subject Baseline Day 14 Day 28 Day 42 
1 88.2 87.8 87.7 87.0 
2 97.7 97.1 96.8 96.9 
3 85.7 85.3 86.1 86.1 
4 89.7 88.7 88.1 89.0 
5 85.5 87.4 85.2 85.0 
6 86.6 87.6 87.1 86.9 
7 91.1 91.1 90.8 90.6 
8 88.4 88.1 87.6 90.1 
9 88.1 89.6 90.1 89.7 
10 97.1 96.5 97.9 96.6 
11 98.5 98.9 99.5 99.8 
12 88.5 90.8 90.7 89.4 
     
Mean 90.4 90.7 90.6 90.6 
± SE 1.4 1.3 1.4 1.4 
 
 
Mean Corpuscular Volume [fL(µm3)] Placebo Group 
 
Subject Baseline Day 14 Day 28 Day 42 
13 89.8 89.5 89.8 88.3 
14 90.3 88.3 89.0 87.9 
15 92.8 93.2 91.6 92.4 
16 88.8 88.6 87.9 88.3 
17 87.0 87.4 88.6 88.5 
18 85.1 87.7 88.1 85.8 
19 90.6 90.7 91.2 90.2 
20 91.4 92.1 90.5 91.2 
21 93.8 92.3 93.7 92.8 
22 86.4 87.8 86.9 88.3 
23 87.2 86.0 86.4 86.6 
24 95.6 95.8 95.2 96.2 
     
Mean 89.9 90.0 89.9 89.7 
± SE 0.9 0.8 0.8 0.9 
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Mean Corpuscular Hemoglobin Concentration (g·dL-1) Echinacea Group 
 
Subject Baseline Day 14 Day 28 Day 42 
1 33.7 34.3 33.8 34.9 
2 35.8 35.4 35.1 35.3 
3 34.1 35.0 34.4 34.4 
4 34.9 36.2 36.7 34.8 
5 34.6 33.7 35.1 34.9 
6 34.1 34.1 34.4 34.7 
7 33.8 33.9 34.2 34.1 
8 33.9 34.3 34.7 34.2 
9 33.9 33.4 33.8 34.1 
10 34.4 35.1 34.8 35.4 
11 36.6 34.5 34.0 33.8 
12 34.8 34.5 33.3 34.5 
     
Mean 34.6 34.5 34.5 34.6 
± SE 0.3 0.2 0.3 0.1 
 
 
Mean Corpuscular Hemoglobin Concentration (g·dL-1) Placebo Group 
 
Subject Baseline Day 14 Day 28 Day 42 
13 35.5 35.2 34.7 35.4 
14 34.5 35.1 34.5 35.4 
15 36.4 34.4 35.5 35.0 
16 34.6 34.2 34.1 34.6 
17 34.5 34.3 34.0 34.0 
18 35.3 33.8 34.1 35.6 
19 34.6 34.6 35.0 35.3 
20 33.8 33.9 34.9 34.3 
21 34.3 35.0 34.7 34.8 
22 34.9 34.2 34.8 33.3 
23 33.4 34.2 33.3 33.7 
24 34.7 35.2 34.9 34.3 
     
Mean 34.7 34.5 34.5 34.6 
± SE 0.2 0.1 0.2 0.2 
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Erythropoietin (mU·mL-1) Echinacea Group 
 
Subject Baseline Day 14 Day 28 Day 42 
1 4.81 3.97 3.88 4.12 
2 15.04 12.10 17.79 17.94 
3 5.14 5.98 6.07 4.39 
4 7.86 12.87 9.82 18.44 
5 7.23 7.38 6.31 7.29 
6 4.39 3.30 2.02 7.65 
7 7.47 6.70 8.01 7.11 
8 5.50 4.51 4.00 3.79 
9 14.15 18.63 14.15 13.70 
10 8.24 11.15 9.52 5.59 
11 12.19 10.35 14.42 11.99 
12 3.05 4.04 2.51 4.35 
     
Mean 7.92 8.41 8.21 8.86 
± SE 1.13 1.35 1.47 1.54 
 
 
Erythropoietin (mU·mL-1) Placebo Group 
 
Subject Baseline Day 14 Day 28 Day 42 
13 5.95 7.11 4.99 3.57 
14 8.18 7.89 7.29 9.55 
15 14.59 17.41 12.61 9.58 
16 7.98 10.98 7.77 8.93 
17 19.86 12.70 9.88 8.36 
18 6.10 4.87 6.16 5.02 
19 7.71 6.99 5.32 27.76 
20 5.56 6.16 5.71 6.87 
21 6.49 6.43 6.72 9.40 
22 5.95 8.45 9.51 12.24 
23 8.19 17.64 12.87 4.49 
24 14.02 9.89 10.85 11.10 
     
Mean 9.21 9.71 8.31 9.74 
± SE 1.30 1.23 0.80 1.81 
 
 
 
 
 
 
 
175 
 
Nitrite (µmol·L-1) Echinacea Group 
 
Subject Baseline Day 14 Day 28 Day 42 
1 1.06 1.68 1.06 0.90 
2 0.90 0.74 1.21 0.74 
3 1.06 1.37 0.42 1.06 
4 0.90 1.37 0.42 0.74 
5 0.74 0.42 0.58 1.21 
6 1.06 0.90 0.74 0.42 
7 1.21 1.37 1.37 1.06 
8 1.06 1.06 1.37 0.42 
9 0.74 1.06 0.74 1.21 
10 0.90 1.99 0.74 0.26 
11 0.42 0.42 0.42 0.42 
12 0.58 0.10 1.37 0.26 
     
Mean 0.88 1.04 0.87 0.73 
± SE 0.07 0.16 0.11 0.10 
 
 
Nitrite (µmol·L-1) Placebo Group 
 
Subject Baseline Day 14 Day 28 Day 42 
13 0.26 1.06 0.42 1.52 
14 0.42 0.42 0.90 0.58 
15 0.90 1.21 0.26 1.21 
16 1.06 0.42 1.52 1.06 
17 1.06 0.74 0.58 1.37 
18 1.21 1.06 0.42 0.90 
19 1.06 1.06 0.58 0.58 
20 1.06 1.68 1.37 0.74 
21 0.74 0.90 0.74 0.26 
22 0.42 0.58 2.44 2.90 
23 0.42 0.42 0.58 0.10 
24 2.29 2.75 2.14 0.26 
     
Mean 0.91 1.03 1.00 0.96 
± SE 0.16 0.19 0.21 0.22 
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Nitrate (µmol·L-1) Echinacea Group 
 
Subject Baseline Day 14 Day 28 Day 42 
1 24.15 25.17 33.78 38.63 
2 18.74 19.31 27.48 19.93 
3 16.72 17.45 15.90 15.69 
4 24.31 28.97 23.96 26.72 
5 13.71 19.63 13.88 12.41 
6 15.69 16.67 17.87 24.78 
7 8.86 21.57 12.05 24.97 
8 28.05 11.11 10.38 20.46 
9 12.26 31.53 18.07 17.39 
10 21.42 10.81 15.38 16.48 
11 18.39 24.37 22.52 12.16 
12 6.97 13.32 13.71 12.32 
     
Mean 17.44 19.99 18.75 20.16 
± SE 1.85 1.92 2.00 2.23 
 
 
Nitrate (µmol·L-1) Placebo Group 
 
Subject Baseline Day 14 Day 28 Day 42 
13 13.37 10.69 17.98 11.48 
14 20.25 12.99 16.67 23.18 
15 13.98 14.91 20.83 19.67 
16 15.89 20.25 12.31 7.34 
17 11.32 12.47 13.67 11.22 
18 27.89 17.55 26.84 13.77 
19 16.08 11.53 20.71 16.37 
20 18.17 39.28 19.10 16.21 
21 8.07 10.85 9.54 13.16 
22 20.25 11.17 13.88 16.53 
23 14.87 14.03 8.86 16.02 
24 11.96 15.24 39.02 12.32 
     
Mean 16.01 15.91 18.28 14.77 
± SE 1.50 2.28 2.40 1.21 
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Total Nitrite: Nitrite/Nitrate (µmol·L-1) Echinacea Group 
 
Subject Baseline Day 14 Day 28 Day 42 
1 25.21 26.85 34.84 39.53 
2 19.64 20.05 28.70 20.67 
3 17.78 18.81 16.33 16.74 
4 25.21 30.34 24.38 27.47 
5 14.46 20.05 14.46 13.63 
6 16.74 17.57 18.61 25.21 
7 10.07 22.94 13.42 26.03 
8 29.11 12.17 11.75 20.88 
9 13.00 32.59 18.81 18.61 
10 22.32 12.79 16.12 16.74 
11 18.81 24.79 22.94 12.58 
12 7.55 13.42 15.08 12.58 
     
Mean 18.32 21.03 19.62 20.89 
± SE 1.86 1.94 1.99 2.25 
 
 
Total Nitrite: Nitrite/Nitrate (µmol·L-1) Placebo Group 
 
Subject Baseline Day 14 Day 28 Day 42 
13 13.63 11.75 18.40 13.00 
14 20.67 13.42 17.57 23.77 
15 14.87 16.12 21.09 20.88 
16 16.95 20.67 13.83 8.39 
17 12.37 13.21 14.25 12.58 
18 29.11 18.60 27.26 14.67 
19 17.13 12.58 21.29 16.95 
20 19.23 40.96 20.47 16.95 
21 8.82 11.75 10.28 13.42 
22 20.67 11.75 16.33 19.43 
23 15.29 14.46 9.45 16.12 
24 14.25 17.99 41.16 12.58 
     
Mean 16.92 16.94 19.28 15.73 
± SE 1.49 2.35 2.46 1.22 
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V˙ O2max (mL·kg-1·min-1) Echinacea Group 
 
Subject Fam-1 Fam-2 Baseline Day 14 Day 28 Day 42 
1 52.0 52.6 48.9 53.6 52.7 50.4 
2 55.0 51.4 56.3 55.9 57.8 57.0 
3 51.6 54.8 52.8 54.0 55.2 55.5 
4 47.0 46.7 46.5 46.5 46.4   43.3a 
5 54.0 51.9 49.6 55.7 52.2 52.4 
6 55.8 58.4 59.3 59.1 61.9 62.5 
7 47.9 47.5 49.8 48.6 48.4 51.4 
8 50.7 46.6 49.8 51.2 51.2 52.7 
9 56.9 60.4 61.0 58.2 61.3 62.4 
10 49.1 48.4 50.4 52.0 51.4 52.5 
11 52.4 55.9 55.6 54.6 56.1 57.0 
12 49.3 51.3 50.0 52.0 49.0 52.1 
       
Mean 51.8 52.2 52.5 53.5 53.6 54.1 
± SE 0.9 1.3 1.3 1.1 1.4 1.5 
 
aTechnical difficulties with nose clip during final stage of exercise test. 
 
 
V˙ O2max (mL·kg-1·min-1) Placebo Group 
 
Subject Fam-1 Fam-2 Baseline Day 14 Day 28 Day 42 
13 51.1 48.8 50.3 49.0 50.7 50.4 
14 62.8 61.0 61.5 57.1 62.0 62.3 
15 49.4 48.4 49.6 49.3 50.0 50.1 
16 56.0 56.4 55.7 56.7 56.5 58.7 
17 48.2 53.3 51.5 50.5 51.2 50.5 
18 47.8 48.2 49.2 49.7 48.8 49.5 
19 54.4 55.6 56.3 57.2 55.7 55.4 
20 59.2 56.9 60.4 60.6 60.3 60.1 
21 52.1 52.9 49.3 49.6 47.3 47.2 
22 48.3 48.7 48.9 49.5 53.7 49.7 
23 48.6 52.0 51.6 48.9 54.6 50.1 
24 54.7 54.3 55.4 55.4 55.2 56.1 
       
Mean 52.7 53.0 53.3 52.8 53.8 53.3 
± SE 1.4 1.2 1.3 1.2 1.3 1.4 
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V˙ O2 (mL·kg-1·min-1) for Stage 1 Echinacea Group 
 
Subject Fam-1 Fam-2 Baseline Day 14 Day 28 Day 42 
1 26.1 25.6 24.7 24.0 24.2 24.5 
2 30.9 31.9 31.1 28.9 31.3 31.9 
3 28.7 28.7 26.5 27.4 26.2 25.8 
4 25.8 24.2 23.1 24.7 23.9 23.1 
5 30.1 29.8 29.0 31.0 29.6 29.2 
6 33.2 30.2 27.7 28.2 28.2 27.4 
7 34.2 35.3 33.3 33.7 32.7 34.1 
8 25.4 25.9 24.9 25.6 24.7 26.3 
9 29.7 30.7 29.0 27.9 29.5 28.0 
10 28.3 27.5 26.7 27.6 27.0 27.0 
11 23.0 25.1 24.1 23.7 23.2 22.1 
12 27.2 27.7 27.2 26.9 26.5 27.1 
       
Mean 28.6 28.6 27.3 27.5 27.3 27.2 
± SE 0.9 0.9 0.9 0.8 0.9 1.0 
 
 
V˙ O2 (mL·kg-1·min-1) for Stage 1 Placebo Group 
 
Subject Fam-1 Fam-2 Baseline Day 14 Day 28 Day 42 
13 27.2 27.4 26.3 25.4 25.6 25.7 
14 28.0 28.5 26.4 29.3 24.3 27.9 
15 23.5 23.2 24.5 23.5 23.6 23.4 
16 30.2 30.6 29.7 28.5 30.2 29.1 
17 27.7 26.6 28.0 27.7 29.2 26.6 
18 27.8 27.3 28.7 26.6 27.1 27.6 
19 27.0 27.3 26.7 26.6 26.6 27.3 
20 28.4 28.4 27.6 28.3 28.8 28.8 
21 25.6 26.1 23.3 25.8 24.4 26.0 
22 27.0 26.8 25.5 26.8 25.3 27.0 
23 26.5 27.2 26.1 26.1 27.2 26.9 
24 30.6 28.1 31.2 28.7 29.0 25.3 
       
Mean 27.5 27.3 27.0 26.9 26.8 26.8 
± SE 0.5 0.5 0.6 0.5 0.6 0.5 
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Heart Rate (beats·min-1) for Stage 1 Echinacea Group 
 
Subject Fam-1 Fam-2 Baseline Day 14 Day 28 Day 42 
1 143 137 131 131 129 136 
2 135 130 155 131 136 151 
3 146 143 125 162 115 120 
4 136 139 127 125 128 127 
5 144 132 150 149 140 137 
6 136 - 128 122 125 120 
7 167 145 158 157 157 168 
8 126 127 128 125 125 130 
9 139 132 122 123 154 125 
10 136 122 137 125 133 138 
11 111 115 118 115 112 117 
12 139 159 126 124 131 127 
       
Mean 138.2 134.6 133.8 132.4 132.1 133.0 
± SE 3.8 3.6 3.8 4.3 3.9 4.2 
 
Note. No data point is a result of technical difficulties with heart rate monitor. 
  
 
Heart Rate (beats·min-1) for Stage 1 Placebo Group 
 
Subject Fam-1 Fam-2 Baseline Day 14 Day 28 Day 42 
13 134 133 125 128 125 121 
14 149 151 136 144 132 136 
15 154 111 108 107 108 113 
16 136 134 129 123 127 132 
17 144 148 136 146 139 154 
18 152 149 144 135 137 143 
19 122 118 117 112 125 115 
20 145 142 128 140 145 147 
21 125 121 115 127 130 138 
22 155 146 139 148 140 144 
23 137 126 127 133 135 143 
24 152 135 136 136 130 122 
       
Mean 142.1 134.5 128.3 131.6 131.1 134.0 
± SE 3.2 3.8 3.1 3.7 2.8 3.9 
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V˙ O2 (mL·kg-1·min-1) for Stage 2 Echinacea Group 
 
Subject Fam-1 Fam-2 Baseline Day 14 Day 28 Day 42 
1 37.1 37.3 33.7 36.1 34.5 35.7 
2 41.7 41.2 43.7 43.1 43.2 44.0 
3 36.9 38.0 35.8 36.5 35.2 34.9 
4 36.6 35.5 34.0 33.3 33.7 33.2 
5 40.7 41.7 43.0 42.2 41.2 40.0 
6 38.5 39.1 36.5 36.8 37.1 36.8 
7 45.7 45.6 45.2 43.5 43.0 46.2 
8 35.8 36.2 35.5 36.8 36.9 37.2 
9 42.1 41.2 42.7 40.2 40.0 40.8 
10 38.0 38.1 38.3 38.9 39.2 37.1 
11 32.5 37.9 36.3 35.8 35.7 35.1 
12 36.0 36.1 36.0 35.7 36.0 36.2 
       
Mean 38.5 39.0 38.4 38.2 38.0 38.1 
± SE 1.0 0.8 1.2 1.0 0.9 1.1 
 
 
V˙ O2 (mL·kg-1·min-1) for Stage 2 Placebo Group 
 
Subject Fam-1 Fam-2 Baseline Day 14 Day 28 Day 42 
13 38.4 36.0 37.7 36.4 36.8 36.2 
14 37.8 36.5 35.7 36.7 36.2 37.2 
15 34.8 34.4 34.2 34.4 34.7 33.1 
16 39.0 40.8 41.2 40.0 39.6 39.6 
17 41.5 40.8 39.7 42.0 41.5 41.5 
18 38.8 38.0 39.1 38.2 37.1 36.7 
19 37.0 37.2 37.3 36.1 36.1 37.1 
20 40.9 38.2 39.3 40.2 39.8 40.6 
21 37.1 37.9 33.9 37.2 35.4 36.0 
22 36.2 34.5 35.1 36.2 36.3 35.6 
23 37.2 39.0 38.2 38.7 37.8 38.6 
24 41.6 39.4 40.9 39.7 40.0 36.9 
       
Mean 38.4 37.7 37.7 38.0 37.6 37.4 
± SE 0.6 0.6 0.7 0.6 0.6 0.7 
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Heart Rate (beats·min-1) for Stage 2 Echinacea Group 
 
Subject Fam-1 Fam-2 Baseline Day 14 Day 28 Day 42 
1 176 180 178 179 175 176 
2 165 175 181 176 172 174 
3 169 164 155 155 151 155 
4 176 169 166 162 166 165 
5 174 176 190 186 184 176 
6 166 171 161 159 160 155 
7 193 190 189 188 188 194 
8 152 154 154 154 154 162 
9 158 154 151 146 149 153 
10 180 171 183 178 180 179 
11 145 149 149 147 151 140 
12 181 180 165 170 176 160 
       
Mean 169.6 169.4 168.5 166.7 167.2 165.8 
± SE 3.9 3.5 4.3 4.3 4.0 4.2 
 
 
Heart Rate (beats·min-1) for Stage 2 Placebo Group 
 
Subject Fam-1 Fam-2 Baseline Day 14 Day 28 Day 42 
13 161 157 151 154 150 154 
14 171 172 159 159 163 163 
15 134 142 138 137 141 144 
16 159 163 164 154 157 158 
17 176 176 172 175 177 173 
18 186 186 180 179 177 180 
19 148 149 149 141 149 146 
20 170 165 155 164 168 169 
21 168 161 158 168 170 171 
22 187 180 167 182 174 182 
23 174 169 163 173 169 183 
24 176 170 168 169 165 159 
       
Mean 167.5 165.8 160.3 162.9 163.3 165.2 
± SE 4.4 3.6 3.3 4.1 3.4 3.9 
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